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ABSTRACT 
Some recombinant bacterial strains have been shown to be very efficient in 
experimental therapies against cancer in rodent models. Amongst them is an E. coli 
that expresses the Listeriolysin-O protein (LLO) and a model tumour antigen 
ovalbumin (OVA). I have demonstrated the efficacy of E. coli-LLO/OVA in preventive 
or therapeutic models against OVA-expressing tumours. This effect is mediated by 
specific cytotoxic T-lymphocytes (CTL) against OVA antigen and inhibition of the 
suppressive function of Foxp3+ T-regulatory (Treg) cells. When applying a “real” and 
clinically-relevant tumour antigen, Wilms’ tumour-1 antigen (WT1), this vaccine (E. 
coli-LLO/WT1) is capable of inducing an anti-tumour effect. Furthermore, we have 
characterised the immunodominant epitope involved in E. coli-LLO/WT1-
immunisation (pWT130-138, NAPYLPSCL) through screening of a peptide library of the 
WT1 protein by cytokine ELISpot, lymphocyte stimulation effects, MHC stability, and 
specific cytotoxicity. Also, the effect on Treg when applying a real tumour antigen is 
still preserved. Co-injection of pWT130-138 with E. coli-LLO resulted in an anti-tumour 
effect equivalent to that obtained with E. coli-LLO/WT1, demonstrating that the 
adjuvant properties of the E. coli-LLO vaccine can be exploited in conjunction with 
peptides.  
Treg are recognised as playing important roles in immunotherapy. An ideal 
vaccine for cancer would stimulate specific cytotoxic responses and suppress Treg 
function. This study showed that E. coli-LLO vaccine suppresses Treg cell function 
and the Treg RNA microarray analysis revealed expression differences of some 
cytokine/chemokine genes which could be relevant to the reversal of Treg 
suppression. This may have important implications for developing anti-tumour 
vaccine strategies in humans. Overall, this study demonstrated that an E. coli-LLO 
vaccine is effective in cancer immunotherapy, either co-expressed with a real tumour 
antigen or co-injected with a peptide. The efficacy of this vaccine was due to its 
ability to dampen Treg suppressive function. 
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CHAPTER 1.  INTRODUCTION 
 
1.1 CANCER IMMUNOTHERAPY 
1.1.1 Emergence of immunotherapy in cancer  
 
Cancer is the second leading cause of death in the industrialised world and the first 
in Taiwan. It is thought to be the result of several events, including genetic 
predisposition, transformation by viruses or environmental mutagens such as 
radiation and chemicals, and tumour promoters leading to abnormal and uncontrolled 
cell growth. Conventional cancer treatment comprises surgery, radiation, and 
chemotherapy. The primary tumour can, when diagnosed at early stages, be 
efficiently treated by a combination of these modalities, preventing the subsequent 
metastatic spread of the disease. However, these tumours can relapse and tumour-
free survival is not always obtained. Despite enormous advances in the development 
of new chemotherapeutic drugs and improvements in radiotherapy, conventional 
cancer therapy often falls short of the goal of controlling tumour progression. The 
development of tumour cell resistance to chemotherapy and to radiation therapy, as 
well as the toxicity of these treatment modalities, limit the success of the treatment 
and necessitate the search for better treatment options or new combinations.  
The potential of cancer immunotherapy was first introduced by William Coley in 
1890, when bacterial products (Coley's toxins) were administered for advanced 
inoperable cancers, with sometimes dramatic responses (Figure 1) (Nauts, Fowler et 
al. 1953). After the successful application of Bacillus Calmette-Guérin (BCG) vaccine 
to prevent  Mycobacterium tuberculosis infection in 1924 (Levine 1947), the possible 
use of BCG as cancer therapy began from the late 1950s (Old, Clarke et al. 1959). 
However, the potential of cancer immunotherapy was generally ignored until the latter 
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part of the 20th century, when studies of chemically-induced tumours of inbred mice 
demonstrated transplantation resistance (Nathanson 1976), and spontaneous 
regression of melanoma fuelled speculation that immunologic responses contributed 
to tumour regression. In the 1980s, lymphocytes activated with lectins or interleukin-2 
(IL-2) were demonstrated to target tumour cells in vitro (Grimm, Mazumder et al. 
1982) and exogenous cytokines were investigated in large-scale clinical trials for 
metastatic melanoma (Kirkwood, Ernstoff et al. 1985).  
 
 
Figure 1. Key events in the history of cancer immunotherapy.  BCG, Bacillus Calmette-
Guérin; IFN-α, interferon alfa; IL-2, interleukin-2.   (Kirkwood, Ernstoff et al. 1985) 
  
The immune system continually recognises and eliminates tumour cells. 
Tumour-specific lymphocytes can be found in the blood, draining lymph nodes, and 
the tissues surrounding tumours in patients with actively growing tumours. However, 
this interaction between tumour and immunity appeared to be considerably more 
complicated than the early “immune surveillance” theories suggested, mainly 
because of the need for the immune system to avoid aberrant responses directed at 
the normal tissues (Pardoll 1998). Cancer recurrence or metastatic spreading usually 
results from tumour evading immune surveillance and growing too large for the 
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immune system to eradicate (Dunn, Old et al. 2004). Tumours vary greatly in their 
immunogenicity and can evade immune elimination even if tumours can be 
recognised by the host immune system. Therefore, cancer immunotherapy is a 
promising approach, due to its potential for the eradication of disseminated tumour 
cells present in the blood circulation, residual cancer cells from primary treatment 
and micro-metastases in distant organs. The main strategies of cancer 
immunotherapy, either actively or passively, aim to exploit the therapeutic potential of 
tumour-specific antibodies and cellular immune effector mechanisms. A better 
understanding of both the molecular mechanisms that govern the generation of an 
effective immune response, and the biology of a tumour, has contributed to 
substantial progress in the field. 
 
1.1.2 Targeting Tumour Antigens 
 
From the earliest days in the field of tumour immunology, researchers are 
continuously attempting to discover tumour antigens, which can be targets of 
immunotherapy, in various kinds of cancer. Tumour antigens can broadly be 
separated into two groups: tumour-specific antigens (TSA) and tumour-associated 
antigens (TAA).  
TSA, which are usually mutant proteins, are expressed exclusively by cancer cells 
and are often crucial for tumourigenicity. For example, Ras mutations are prevalent in 
many types of adenocarcinomas including pancreatic (∼90%), colorectal (∼50%), lung 
(∼30%), and thyroid cancers (∼50%) (Hruban, van Mansfeld et al. 1993), and three 
Ki-RAS point mutations (single amino acid substitutions) are found in about 95% of 
all patients with pancreatic cancers. They are ideal targets for anti-cancer therapy. 
TSAs are ideal targets for cancer immunotherapy because they are exclusively 
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expressed by the cancer cell and not in non-malignant tissues, minimising the risk of 
autoimmune destruction. In addition, because the immune system has not been 
previously exposed to these antigens, there is no neonatal or peripheral tolerance to 
these antigens prior to tumour development. During tumour development, the 
immune system can recognise these determinants as non-self and generate specific, 
high-affinity antibodies and T cells against them. Another major advantage of tumour-
specific antigens is that many of the mutant proteins that result in tumour-specific 
antigens are themselves essential for tumourigenesis. Several studies have 
reinforced the importance of targeting such essential proteins with cancer 
immunotherapy (Lennerz, Fatho et al. 2005). Experimental and clinical observations 
suggest that those proteins required for the maintenance of the malignant phenotype 
are less likely to be lost during tumour progression, even under the selective 
pressure of anti-cancer treatments such as immunotherapy (Sensi, Nicolini et al. 
2005). However, targeting TSA would require therapeutic strategies to be tailored to 
individual patients or small subgroups of patients, making the targeting of TSA more 
technically challenging and labour-intensive. As a result, the focus of targeting 
peptides has been gradually moved toward normal molecules that are not tumour-
specific but expressed on large groups of cancers, TAA.  
TAA represent a group of normal non-mutant molecules that can be subdivided into 
four major categories according to expression pattern (Novellino, Castelli et al. 2005; 
Schietinger, Philip et al. 2008):  
 Oncospermatogonal antigens (cancer-testis antigens) are expressed by 
cancer cells but are normally found on spermatocytes/spermatogonia 
(MAGE, GAGE, BAGE and NY-ESO-1) (Fijak and Meinhardt 2006). These 
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antigens, like all other tumour-associated antigens, also induce some level of 
central or peripheral tolerance. 
 Differentiation antigens are molecules expressed on non-malignant cells of 
the same cell lineage as the tumour (TRP-1, gp100, MART-1, tyrosinase, 
CD20 and EpCAM) (Kawakami, Robbins et al. 1998; Armstrong and Eck 
2003).  
 Oncofetal antigens are antigens found in embryonic and fetal tissues as well 
as certain cancers (alpha fetoprotein, carcinoembryonic antigen, Wilms’ 
tumour-1, and 5T4) (Coggin, Barsoum et al. 2005). 
 Over-expressed antigens are normal proteins whose expression is up-
regulated in cancer cells (PSA, wild-type p53, Her2/Neu, Telomerase, and 
EGFR) (Novellino, Castelli et al. 2005).   
Because of their expression in normal, non-malignant tissue, TAA are more likely to 
have induced immunologic tolerance and are less likely to stimulate effective immune 
responses (Cloosen, Arnold et al. 2007). Self-reactive T cells are readily deleted 
and/or functionally inactivated, and when not deleted, have a reduced capacity to 
recognise target antigens (Yu, Theoret et al. 2004). If a cancer vaccine does break 
tolerance to a tumour-associated, shared antigen, with emergence of self-reactive T 
cells, destruction of normal tissue or even fatal autoimmune damage can result 
(Ludewig, Ochsenbein et al. 2000; Gilboa 2001). Although T cells can be engineered 
to express receptors with high (nanomolar) affinity for self-antigens that are highly 
expressed in cancers, there is concern that such T cells could cause significant 
autoimmune damage if used therapeutically. Such autoimmune damage may be 
tolerable if the self-antigen is expressed only in non-essential, normal tissue. It is 
unclear, however, whether T cells that target self-antigens in tumours could be 
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similarly effective, even if normal cells expressing those antigens were dispensable. 
Another concern is that targeting of TAA that are non-essential can lead to the 
emergence of antigen loss variants (Lozupone, Rivoltini et al. 2003). In summary, 
selection of TSA or TAA should be judged according to the biologic nature of the 
target tumour, the immunotherapeutic strategies undertaken, and of course the 
risks/benefits. 
 
1.1.3 T cells and Antigen Recognition 
 
The immune response is broadly classified into either the innate, antigen-nonspecific 
response, or the adaptive, antigen-specific response. Leukocytes of the innate 
immune system reside in peripheral tissues and circulate through the blood and 
secondary lymphoid tissues (the spleen and the lymph nodes), acting as 
immunologic sentinels for detecting external pathogens. Similarly, B and T 
lymphocytes traverse the body to mediate the adaptive immune response. These 
cells express a comprehensive repertoire of antigen-specific receptors (cell surface 
immunoglobulin receptors for B cells, and cell surface T cell receptors (TCR) for T 
cells) that can recognise over one million distinct antigens (Oltz 2001). Whereas the 
B cell antigen receptor directly binds to antigenic determinants present on soluble 
proteins, carbohydrates, or nucleic acids, the T cell antigen receptor binds most 
commonly to short fragments of antigens that have been broken down and loaded 
onto Major Histocompatibility Complex (MHC) molecules. Thus, B cells can see 
antigen directly, and respond by differentiating into immunoglobulin-secreting plasma 
cells. In contrast, T cells detect processed antigen in the context of self MHC 
molecules, thereby providing a basis for self-nonself discrimination (Germain 1995). 
Two major subsets of T cells collaborate to mediate an effective immune response. 
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CD4+ helper T cells are activated after binding peptide antigen presented by MHC 
Class II molecules, and provide cytokine-mediated “help” both to shape the B cell-
mediated humoral response, and to maximise the quality and durability of the CD8+ T 
cell-mediated cytotoxic T lymphocyte (CTL) response (Pulendran 2004). CD4+ T cells 
can be further divided into T helper type 1 cells, which secrete interleukin-2 (IL-2) and 
interferon-γ (IFN-γ) to promote CTL activity, and T helper type 2 cells, which secrete 
interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-6 (IL-6), and promote humoral 
and allergic immune responses. Of these two T helper phenotypes, the T helper type 
1 phenotype is generally considered to contribute more to antitumour immunity (Kidd 
2003). CTLs are activated after TCR binding antigen presented by MHC Class I 
molecules, deploying a payload of cytokines and enzymes that can effectively lyse 
diseased cellular targets. Thus, it is CD8+ effector T cells that are critical for 
destroying host cells altered by either viral infection or oncogenic transformation.  In 
order for CD8+ CTL to recognise and destroy diseased cellular targets, they must 
migrate throughout the body to interact with professional antigen presenting cells 
(APCs) (usually DCs, B cells, macrophages, and γδT cells)  (Trombetta and Mellman 
2005). After the priming APC-T cell interaction, CD8+ CTL subsequently engage 
target cells that have been altered by pathogens or neoplastic transformation.  
T cell activation is initiated at the molecular level by the TCR-mediated recognition of 
antigenic epitopes bound to MHC molecules. The specificity of most T cell responses 
is conferred by the αβ  TCR. These TCRs are formed by two transmembrance 
glycoproteins, each composed of one extracellular variable, which determines the 
diversity of TCR, and constatnt domain joined by a hinge region to the 
transmembrane domain. The presence of MHC diversity also impacts antigen 
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recognition by T cells indirectly by controlling peptide binding to MHC, and directly by 
physical contacs between the TCR and MHC molecule (Davis, Boniface et al. 1998). 
The cellular interactions during the priming and effector cross-talk will affect the 
ultimate quality and character of the immune response, reflected by the size, 
phenotype (effector, tolerogenic, or memory), and functional status (cytokine 
secreting, cytotoxic) of the activated T cell repertoire. Due both to their delicate 
antigenic specificity and their capacity for vigorous secondary response, the use of T 
cells for the immune-mediated therapy of cancer has attracted great interest. With 
the advances in understanding how T cells see antigen at the molecular and cellular 
level, many preclinical and clinical studies in T cell-based immunotherapy are 
undergoing. Future scientific progress elucidating the mechanisms controlling 
antitumour T cell activity will provide the foundation for developing cancer 
immunotherapy strategies that harness the power of the antitumour T cell response.  
 
1.1.4 Different strategies of cancer immunotherapy 
 
The first cancer vaccines were composed of irradiated or otherwise inactivated whole 
tumour cells (Ward, Casey et al. 2002), based on the success of using attenuated 
pathogen vaccines in infectious diseases. This immunisation strategy was successful 
in mouse models and produced tumour-specific immune responses and rejection of a 
tumour-challenge. Concerning the safety and immunogenicity of whole tumour cells, 
and also after deciphering the exact mechanism of antigen presentation and T-cell 
activation by the immunologists, several different immunisation strategies, aimed at 
specific target protein/gene in tumour or using different adjuvant to enhance immune 
reactions or modify antigen presentation, have been introduced in past ten years.   
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1.1.4.1 BCG vaccine  
 
The possible use of BCG as cancer therapy began with landmark studies in the late 
1950s by Lloyd Old at the Sloan-Kettering Institute in New York (Old, Clarke et al. 
1959). In a series of elegant experiments Old demonstrated that mice infected with 
BCG showed increased resistance to challenge with transplantable tumours. The 
action of BCG was attributed to the general augmentation of immunological reactivity. 
BCG was found to activate macrophages, which can inhibit or destroy cancer cells 
and induce necrosis of mouse tumours, providing the first direct evidence that BCG 
had anti-tumour effects.  
In the 1970s Burton et al further demonstrated the tumour inhibitory properties of 
BCG injected into animals (Zbar, Bernstein et al. 1971). Animals that rejected tumour 
cells at the site of an infection with BCG showed suppressed tumour growth and 
delayed hypersensitivity reactions to a subsequent challenge of tumour cells. The 
clinical use of BCG as cancer therapy began in 1969 when Mathe in France reported 
encouraging results with BCG as adjuvant therapy for acute lymphoblastic leukaemia, 
and in 1970 Morton in the United States observed regression of malignant melanoma 
treated with intralesional BCG. In 1975 deKernion et al reported that isolated 
melanoma in the bladder was successfully treated with cystoscopic injection of BCG 
vaccine (deKernion, Golub et al. 1975) . These reports created enormous interest in 
BCG, hailed as an effective anticancer agent, and clinical trials flourished using BCG 
against lung, prostate, colon and kidney cancers. Their promise was not fulfilled, 
however, and BCG was soon replaced by more effective therapies. The only notable 
exception is bladder cancer, for which remains a standard intravesical therapy 
against high-grade non-invasive disease. Nowadays, BCG is frequently used as 
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vaccine adjuvant to enhance immune responses in experimental models (Cox and 
Coulter 1999; Suttmann, Jacobsen et al. 2004).  
 
1.1.4.2 Recombinant Cytokines  
 
 
Interferon alpha (IFN-α) was the first exogenous cytokine to demonstrate anti-tumour 
activity in advanced melanoma. IFN-2β (Intron A; Schering Corporation), a type I IFN, 
is a highly pleiotropic cytokine with immunoregulatory, antiproliferative, differentiation-
inducing, apoptotic, and antiangiogenic properties in multiple malignancies, and 
objective tumour response rates of approximately 20% were observed in phase I/II 
trials for metastatic disease (Kirkwood 2002). However, tolerability is an issue with 
this regimen, because of flu-like symptoms, anorexia, fatigue, and depression related 
to its systemic effect. Interleukin-2 (IL-2, Aldesleukin, Proleukin; Novartis) was the 
second exogenous cytokine to demonstrate anti-tumour activity against melanoma. 
High-dose bolus intravenous IL-2 was shown to have anti-tumour effects with or 
without lymphokine-activated killer cells in eight clinical trials conducted between 
1985 and 1993, involving 270 patients with advanced metastatic melanoma (Atkins, 
Lotze et al. 1999). There was an objective response rate of 16% (median response 
duration, 8.9 months) with a durable response rate of 4%, suggesting that a memory 
T-cell response was established. This provided a solid basis for the approval by the 
US FDA in 1998 for the treatment of adults with advanced metastatic melanoma and 
renal cell carcinoma. The majority of toxicities associated with high-dose IL-2 are 
severe but reversible, including hemodynamic complications, autoimmunity and 
thyroid dysfunction. These cytokines were also exploited in co-expressing- (Dummer, 
Rochlitz et al. 2008), combination- (Yockman, Kim et al. 2007; Rodriguez, Ryu et al. 
2008), or adoptive-cell therapy (Heemskerk, Liu et al. 2008).  
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1.1.4.3 Peptide vaccines 
 
Since the discovery of the tumour-derived peptide, the immunogenic motif in 
cytotoxic T-cell (CTL) stimulation, many studies have used peptides derived from 
documented tumour-associated antigens, specifically designed to associate with T 
cells in the context of specific MHC class I or II molecules (Brinkman, Fausch et al. 
2004). Several clinical trials in different tumour types have been conducted utilising 
this vaccination strategy. The majority of these trials indicated that peptide 
vaccination has few toxicities associated with its administration, but disparities exist 
between in-vitro and clinical responses. A clinical study in patients with melanoma 
was disappointing despite 91% of patients demonstrating CTL responses after 
gp100209–217 peptide vaccination with incomplete Freund's adjuvant (Rosenberg, 
Yang et al. 1998). Compared with chemotherapy in randomised phase III studies, 
complex melanoma vaccines, such as Allovectin-7 (Vical Inc, San Diego, CA), 
Canvaxin, and Melacine (Corixa Corp, Seattle, WA), failed to meet primary end 
points of improved response or survival (Mitchell 1998). Various strategies in 
attempts to improve the efficacy of peptide vaccination have been proposed, such as: 
use of adjuvant cytokines (Jager, Ringhoffer et al. 1996; Rosenberg, Yang et al. 
1998),  improving immunogenicity by peptide sequence alteration (Oka, Tsuboi et al. 
2004), use of tumour antigen or tetanus toxoid sub-epitope fusion DNA sequences 
(Rice, Elliott et al. 2001), or the incorporation of bacterial proteins as adjuvants  
(Miconnet, Coste et al. 2001). These strategies have been carried out to augment the 
immune responses or minimise tumour escape in preclinical and clinical work using 
peptide vaccination.  
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Some limitations and uncertainties concerning the mechanism of action and 
unexplained observations were made when applying TSA-derived peptides as 
targets. For example, the clinical effects or in-vivo immune responses in patients 
receiving peptide vaccination are not universally proportional to the regression, 
persistence or upregulation of targeted tumour antigen expression (Ohnmacht, Wang 
et al. 2001). In addition, the efficacy of the peptides developed for immunotherapy 
could be restricted by their low immunogenicity or low affinity for cell-surface HLA 
antigen molecules (Ohnmacht, Wang et al. 2001). Also, peptide vaccination can be 
used only in the context of appropriate HLA antigen restriction. Peptides can undergo 
rapid clearance and are dependent on intact antigen-presenting and effector-cell 
populations to induce a response. Therefore, the clinical effect might be 
unsatisfactory due to a compromised host immune system. Finally, tumour cells can 
evade recognition through the downregulation or alteration of a single gene product 
that is not essential for maintaining the malignant phenotype. 
 
1.1.4.4 Plasmid DNA and recombinant viral vaccines  
 
Since most types of cancer have a genetic predisposition, and as a result of the 
identification of various tumour suppressor genes or oncogenes and advances in 
recombinant gene technology, cancer gene therapy offers a number of exciting 
potential treatments. Gene therapy encompasses a wide range of treatment types, all 
of which use genetic material to modify cells (either in vitro or in vivo) to augment 
anti-tumour response or to promote apoptosis of tumour cells. Naked DNA, viral or 
non-viral vectors engineered to express the desired gene are frequently used for this 
purpose. Vaccination can ultimately result in the incorporation of transgenes into host  
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antigen-presenting cell (APC) for endogenous processing and presentation. However, 
the responses from naked DNA vaccination were weak and not reproducible (Vollmer, 
Eilber et al. 1999). Addition of cytokine genes to the DNA vaccine has led to 
enhanced tumour protection (Sedegah, Weiss et al. 2000; Fernandez, Zeiser et al. 
2007). Recently a diversified prime or boost strategy, boosting by a different vector 
encoding the same tumour gene, was demonstrated to be more potent than using 
repetitive vaccinations with the same vector alone. Combining DNA plasmids 
expressing AFP and GM-CSF with subsequent boost vaccination with a non-
replicating adenoviral vector encoding the same tumour antigen has also enhanced 
antigen-specific tumour protection (Meng, Butterfield et al. 2001). 
The field of cancer gene therapy is maturing rapidly and several cancer vaccine 
treatments have entered late stage clinical trials. In addition, gene transfer technology 
for cancer treatment holds great promise for increasing the effectiveness of current 
chemotherapeutic treatment regimens. Significant advances have been made in the 
field of oncolytic virotherapy, and trials are in progress that incorporate this technique 
for precancerous, as well as cancerous, treatment (Collison, Workman et al. 2007). 
 
1.1.4.5 Dendritic cell-based vaccines 
 
Dendritic-cell (DC)-based vaccines are the newest development in cancer vaccine 
design. DCs can be loaded with autologous or allogeneic tumours, apoptotic bodies, 
tumour lysates (Morgan, Dudley et al. 2006), tumour RNA or DNA (Nestle, 
Banchereau et al. 2001). Initial preclinical studies involved pulsing of DC with tumour-
specific peptides to induce antigen-specific responses (Mayordomo, Zorina et al. 
1995). A phase I study of a vaccine composed of DCs that were loaded with mRNA 
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encoding prostate-specific antigen (PSA) induced T-cell responses against PSA in 
most patients and the log slope of PSA was temporarily decreased, indicating 
perhaps that tumour growth was reduced (Heiser, Coleman et al. 2002). Although 
evidence for the safety and in-vivo bioactivity of RNA-loaded DCs in patients with 
metastatic prostate cancer was suggested, proof of clinical benefit remains to be 
established in future clinical trials. A strategy for prolonged presentation of an MHC 
class I-restricted self-peptide on DCs, through its linkage to a cell penetrating peptide, 
(CPP) was introduced (Wang and Wang 2002).  Another strategy involves the 
loading of DC with whole tumour proteins (Timmerman, Czerwinski et al. 2002). 
Gene transfer methods offer an alterative means of introducing tumour antigens into 
DC using plasmid DNA, RNA, and viral vectors (Nair, Boczkowski et al. 2007). A 
study from Zhu et al demonstrated that a vector simultaneously over-expressing 
three costimulatory molecules could be used efficiently to infect human DCs, leading 
to enhanced peptide-specific T-cell activation (Zhu, Terasawa et al. 2001).  
     Peptide vaccination depends on the loading of empty MHC molecules on APCs in 
vivo. However, single administration of peptide without a means of targeting activated 
APCs can potentially lead to loading of MHC class I molecules on nonprofessional 
APCs, which could result in tolerance (Toes, van der Voort et al. 1998; Diehl, den 
Boer et al. 1999). In this case, vaccination with antigen-pulsed DCs is superior to 
peptide-based vaccination protocols.  
 
1.1.4.6 Adoptive T cell therapy 
 
 
The discovery that human tumour-infiltrating lymphocytes (TILs) derived from 
patients with a variety of types of cancer (including metastatic melanoma, breast 
cancer, colon cancer and ovarian cancer) can exhibit specific tumour lysis or cytokine 
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release in vitro led to a new therapeutic approach. Adoptive transfer of TILs, after in-
vitro expansion in a way that preserved their anti-tumour activity, was shown to treat 
murine malignancies effectively, leading to early trials of adoptive transfer of TILs 
plus IL-2 in humans (Rosenberg, Yannelli et al. 1994). In 1994, Rosenberg et al 
reported a 34% objective response rate among patients with metastatic melanoma 
who were treated with adoptive cell therapy (Rosenberg, Yannelli et al. 1994). These 
results have steadily improved. Adding lymphocyte-depleting chemotherapy before 
adoptive cell therapy increased the objective-response rate to 49% (Dudley, 
Wunderlich et al. 2002), and adding radiotherapy increased the objective-response 
rate to 72% (unpublished data by Rosenberg et al (Rosenberg, Dudley et al. 2008)). 
With the use of cancer vaccines, the objective-response rate ranges from 3 to 7% 
(Rosenberg, Yang et al. 2004). Apart from the convincing evidence of adoptive CD8+ 
cell transfer in anti-tumour effect, ex-vivo expanded tumour antigen-specific 
autologous CD4+ cell therapy also lead to durable tumour remission (Hunder, Wallen 
et al. 2008). Qiao et al recently demonstrated the possibility of combining adoptive T-
cell therapy with oncolytic viral delivery. In mouse models, they showed that antigen-
nonspecific T cells loaded with oncolytic vesicular stomatitis virus efficiently delivered 
the virus to metastatic lymph nodes and lead to tumour clearance associated with 
anti-tumour immune priming (Qiao, Kottke et al. 2008).  
 
1.1.4.7 Monoclonal antibodies and small molecule inhibitors 
 
With the advances in understanding of aberrant signalling pathways in various types 
of cancer cells, many pivotal regulators of malignant behaviour in cancer cells have 
emerged as candidates for molecular target-based cancer therapy. Such strategies 
have improved the management of cancers and many of them have been approved 
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by FDA. The two main approaches include monoclonal antibodies (mAbs) and small 
molecule inhibitors (Imai and Takaoka 2006). Key signalling molecules, such as 
protein tyrosine kinases, have proven to be good targets with clinically-effective 
responses in chronic myeloid leukaemia (CML), gastrointestinal stromal tumours 
(GISTs) and non-small-cell lung cancer (NSCLC). Another group of targets is 
represented by tumour-selective cell-surface proteins, which can be recognised by 
mAbs, such as CD20 (Rituximab) (Coiffier 2006), Gemtuzumab (CD33) and 
HER2/Neu (trastuzumab) (Vogel, Cobleigh et al. 2002). Many of these mAbs have 
been recommended as standard therapies singly, or combination, to traditional 
cytotoxic chemotherapy. Interestingly, they are specific receptor inhibitors or B-cell 
derived mAbs, instead of therapeutic vaccines to activate CTLs, and have passed the 
acid test of clinical trials and become standard anti-cancer regimens.  
Thanks to the advances in unraveling the molecular interactions between tumours 
and the immune system, many immune-based cancer targeting approaches in 
enhancing APC/T-cell responses or antagonising regulatory pathways, so-called the 
immune checkpoint blockade that induce immune tolerance or suppressor circuits, 
have been developed (Cheever 2008). Anti-CD40 and CD40L are potent agonists for 
increasing APC function. Preclinical studies have demonstrated that agonist CD40 
monoclonal antibody (mAb) can mimic the signal of CD40L, substitute for the function 
of CD4+ lymphocytes, overcome T-cell tolerance, and direct tumour inhibition 
(Vonderheide, Flaherty et al. 2007).  Anti-CD137 (anti-4-1BB), which against a 
member of the TNF superfamily of receptors 4-1BB, has been shown its potent T-cell 
stimulation and enhance CTLs responses to vaccine by agonistic mAb (Melero, 
Shuford et al. 1997; Wilcox, Flies et al. 2002). Programmed death-1 (PD-1) is a 
negative regulator of T-cell function and blocking PD-1 can increase anti-tumour T-
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cell immunity and induce long-lasting tumour regression (Hirano, Kaneko et al. 2005). 
1-Methyl tryptophan (1MT) is also one of the small molecule inhibitors in overcoming 
tumour-related immunosuppression by enzyme indoleamine 2,3-dioxygenase (IDO) 
(Uyttenhove, Pilotte et al. 2003). These agents are being studied in combination with 
convention chemotherapies or other immunotherapy strategies.  
 
1.1.5 Obstacles in cancer vaccine development 
 
There are many factors that influence tumour response to immunotherapy. 
Neoplastic cells survive and proliferate in an often hostile environment. Under 
constant selection pressure, cells with a survival privilege ensure that the tumour 
‘‘evolves’’ to suit its environment. The concept of tumour cells developing 
mechanisms to evade the immune system and becoming immunoresistant is referred 
to as cancer immunoediting (Dunn, Bruce et al. 2002; Dunn, Old et al. 2004). Within 
this context, the ability of immune system to attack cancer cells is limited.  
    Although great progress has been made in the development of cancer vaccines in 
the past few years, many challenges remain when transferring from experimental 
results to clinical practice and to curing cancer (Ostrand-Rosenberg 2004). In testing 
in mice, effective immunity can often be elicited, with a successful inhibition of tumour 
growth following immunisation. Also, minimal toxicity and evidence of immunologic 
response have been demonstrated but only anecdotal responses to several different 
vaccine strategies in clinical trials have been reported. A clear correlation between 
immunologic and clinical response has not been consistently observed (Borges, Kufe 
et al. 2002). In Rosenberg et al’s review, an overall tumour response rate was only 
2.6% from hundreds of vaccine clinical trials (Rosenberg, Yang et al. 2004). This 
poor efficacy is due to a large number of parameters or mechanisms that prevent 
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tumour destruction by immune cells (Rosenberg 2008). These parameters are: 
inadequate numbers or avidity of the immune effector cells, the inability of the tumour 
to activate quiescent or precursor lymphocytes, tolerance mechanisms including 
anergy, and suppressor influences produced by the tumour or the immune system 
itself (Marincola, Jaffee et al. 2000; Rosenberg 2008).  
    One of the numerous peptide vaccines focusing on metastatic melanoma 
developed by Corixa Corp. (Melacine®) could delay the tumour growth in vaccinated 
patients but was restricted to a particular HLA antigen (MHC-A2 or C3) (Sosman and 
Sondak 2003). The use of cellular-based therapies (e.g., DC-based vaccines) 
appears promising, but involves technical challenges and requires sophisticated cell 
manipulation. Although DC pulsed with peptides appear to be good candidates for a 
clinical use in human tolerisation (Dallal and Lotze 2000), ex-vivo approaches suffer 
from two problems, one related to the generation of high numbers of clinically 
exploitable DCs, and the other one resulting from multiple rounds of immunisation at 
fairly short intervals that can at times lead to the emergence of Th1/Th2 cells 
imbalance and non-cytolytic CD4+ cells. Gene therapy with viral vectors expressing 
tumour antigen is potentially limited by the generation of the host-immune response 
to the vector itself, although a higher level of immune stimulation, as compared with 
naked DNA, can be achieved. In addition, antiviral response leads to rapid clearance 
of the vector in subsequent vaccinations and, thereby, prevents augmentation of the 
immune response. 
    These obstacles need to be overcome in future vaccine development and, 
additionally, vaccination schedule, mode of delivery, adjuvants, and cofactor 
molecules should be optimised. Meanwhile, all the immunologic endpoints should 
also be carefully documented (Simon, Steinberg et al. 2001). 
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1.1.6 Regulating the immune responses to tumours 
 
A major impediment to cancer immunotherapy is tumour-induced immune 
suppression and tumour evasion of anti-tumour immune responses, which ultimately 
render the host tolerant to tumour-associated antigens. Several limiting factors will 
affect the efficacy of immunotherapeutic strategies such as DC activation, antigen 
presentation, and cancer cell recognition. In addition, local immunosuppressive 
factors within the tumour milieu include secreted molecules, such as TGF-β, IL-10, 
prostaglandin E2, and vascular endothelial growth factor (VEGF). These factors are 
produced either by the tumour cells themselves or by surrounding host stromal cells 
on tumour cell signalling. The suppressive tumour environment is further maintained 
by immunosuppressive cells, such as T regulatory cells (Treg), and indolamine 2,3-
dioxygenase (IDO)-producing plasmacytoid DC (Munn and Mellor 2004). These are 
professional immune suppressor cells that are frequently found inside tumours and 
provide means for tumour escape from activated effectors. 
Current strategies for cancer immunotherapy focus mainly on enhancing T-cell 
mediated tumour lysis; however, a variety of active mechanisms may limit the 
effectiveness of this approach. The past 10 years have witnessed a renaissance in 
the field of active mechanisms of immune regulation, and much of this points to a 
particular group of T cells, currently described as CD4+CD25+Foxp3+ Treg cells 
which play a suppressive role in anti-tumour vaccinations (Kronenberg and Rudensky 
2005). Liyanage et al and others have shown that an increased prevalence of 
suppressor T cells in the tumour microenvironment of patients with invasive cancers 
can suppress a tumour-specific immune response (Liyanage, Moore et al. 2002). 
Many mouse studies have shown that using monoclonal antibodies (PC-61) depleting 
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CD25+ cells promotes immune responses induced by tumour cells or antigen-pulsed 
dendritic cells as well as immune-mediated rejection of tumour cell-lines (Onizuka, 
Tawara et al. 1999; Prasad, Farrand et al. 2005). More impressively, intra-tumoural 
injection of CD4-specific antibodies promoted regression of established tumours (Yu, 
Lee et al. 2005) indicated that tumour infiltrated CD4+CD25+ cells dampened local 
immune anti-tumour responses. In a separate study using a different tumour cell line, 
intra-tumour depletion of CD25+ cells was shown to inhibit tumour growth and the 
delay of tumour growth was extended by multiple rounds of depletion (Needham, Lee 
et al. 2006). Another effective approach tested in rodent models, the use of 
cyclophosphamide to deplete CD4+CD25+ cells in combination with tumour cell 
vaccination, led to regression of established tumours in rats (Ghiringhelli, Larmonier 
et al. 2004). Blocking antibodies to CTLA-4 are in clinical development and have 
shown durable immune-mediated response rates in the order 5% to 20% in patients 
with metastatic melanoma (Downey, Klapper et al. 2007; Ribas, Hanson et al. 2007). 
The increasing number of studies of Treg cells in patients with cancer also point 
to a role for these cells in promoting cancer progression (Betts, Clarke et al. 2006). 
There is, therefore, a clear rationale for developing clinical strategies to manipulate 
these regulatory influences, with the ultimate goal of augmenting anti-tumour 
immunity (Lizee, Radvanyi et al. 2006). 
 
 1.1.7 Potential of combined immunotherapy and chemotherapy 
 
The integration of immunotherapies with conventional treatments for cancer is a 
challenge, especially for cancer vaccines, because of the immunosuppressive effects 
of most standard treatments. However, the exploration of combined treatments is 
revealing unexpected results. The synergistic activity of the combinations is 
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supported by recent clinical and pre-clinical studies (Chong and Morse 2005). 
Although the combination would at first seem to be counterproductive, supportive 
data have revealed that cyclophosphamide, gemcitabine and doxorubicin enhance 
the efficacy of vaccines when used as a form of 'pretreatment'. In a review of three 
prostate cancer vaccine trials, researchers from the National Cancer Institute (NCI) 
offered evidence that prior immunotherapies can sensitise the tumour to subsequent 
chemotherapy  (Wheeler, Das et al. 2004; Schlom, Arlen et al. 2007). Another study 
demonstrated an apparent survival advantage for patients treated with the vaccine 
followed by chemotherapy as compared to chemotherapy alone (Antonia, Mirza et al. 
2006; Inoges, Rodriguez-Calvillo et al. 2006). All of these reports support the concept 
that a properly “conditioned” host’s immune system might be achieved by the 
combination.  
The mechanisms responsible for this observed improvement in immunotherapy 
with chemotherapy remain mostly unknown and need to be explored. The elimination 
of cells with immunosuppressive activity, especially Treg, non-specific activation of 
APC, improved cross-presentation of tumour antigens, lymphodepletion, and 
resultant homeostatic T cell proliferation have been proposed. In addition, other local 
effects have been speculated: disruption of tumour stroma that results in improved 
penetration of CTLs into the tumour site, decreased local suppressive activity of 
tumour cells, increased permeability of tumour cells to CTL-derived granzymes, 
increased expression of tumour associated antigens by tumour cells, and up-
regulation of death receptors (such as Fas) on tumour cells (or FasL on CTLs) 
(Ramakrishnan, Antonia et al. 2008). This combination may provide substantial 
clinical benefits for patients with advanced disease, since active or adoptive 
immunotherapies seem to be incapable of controlling large tumour masses. Further 
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clinical trials will attempt to optimise combinations through the selection of treatment 
modalities, the dosage of drugs, and the time-scheme of combination therapies.  
 
1.1.8 Perspective 
 
One of the hallmarks of cancer responses to cellular immunotherapy is that they are 
extremely long lived, frequently measured in years. However, objective responses 
(as opposed to the more common claim of mixed responses or disease stabilisation 
with immunotherapy) are rare, usually noted in a minority of patients, in the range of 
5% to 10% (Rosenberg, Yang et al. 2004). In a review of randomised phase III 
studies with active cancer immunotherapies, most have failed to show a significant 
benefit with respect to predetermined end points (Finke, Wentworth et al. 2007). New 
strategies are being explored (Finn 2003; Rosenberg, Yang et al. 2004), including 
vaccines based on engineered viral vectors, various approaches with dendritic cells, 
and strategies that are aimed at inhibiting immunosuppressive cells of lymphoid or 
myeloid origin.  
Based on previous experiences in developing cancer vaccines, future approaches of 
cancer immunotherapy should focus on the development of the following strategies:  
 Choose the right target: to stimulate specific CTLs, increase the number of 
antigen-expressing DCs, enhance MHC class I presentation of the encoded 
antigen. 
 Use appropriate adjuvant/vehicle to safely, easily and powerfully boost the 
frequency and magnitude of immune responses in immuno-compromised patients.  
 Immune responses, tailored to aging immune system and inhibition of Treg cells 
function-allowing to overcome tumour-induced, therapy-induced, or age-induced 
immunosuppression. 
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 Optimal immunisation schedule to induce appropriate antigen presentation in a 
short priming phase (den Boer, Diehl et al. 2001), avoid overstimulation which 
results in Treg cells activation (Darji, Guzman et al. 1997) and elicitation of long-
term memory.  
 Combination approaches to yield synergistic or additive results (Cuadros, 
Dominguez et al. 2003; Mihich 2003; Morgan, Dudley et al. 2006; Offringa 2006).  
 Strategy to modulate apoptotic pathways in cancer cells, such TRAIL receptor or 
Fas, to synergise with immunotherapy and other targeted therapy approaches. A 
soluble TRAIL ligand construct and TRAIL receptor-activating antibodies are in 
clinical development for the treatment of cancer. These approaches may be 
viewed as bypassing the need for immune effector cells. 
 
1.2 BACTERIA AND GENE THERAPY 
 
1.2.1 Bacteria and cancer 
  
Certain bacteria are associated with human cancers, for example, H. pylori and 
gastric cancer or MALT lymphoma, Salmonella typhi and gallbladder cancer 
(Lazcano-Ponce, Miquel et al. 2001), Chlamydophila pneumoniae and lung cancer 
(Littman, Thornquist et al. 2004), Streptococcus bovis and colorectal cancer (Biarc, 
Nguyen et al. 2004). Their roles in carcinogenesis, however, are still unclear. 
Convincing evidence links some species to carcinogenesis while others appear 
promising in the diagnosis, prevention or treatment of cancers. Research has shown 
that exposure to H. pylori appears to reduce the risk of oesophageal cancer; however 
S. typhi is a promising carrier of therapeutic agents for melanoma, colon and bladder 
cancers (Niethammer, Xiang et al. 2001; Mager 2006). Spontaneous tumour 
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regression has followed severe bacterial, fungal, viral and protozoal infections and 
thereby inspired the development of the earliest cancer therapies (Richardson, 
Ramirez et al. 1999). 
 
1.2.2 Use of bacteria as gene-delivery vectors 
 
In the past, direct injection of naked DNA has been shown to allow transgene 
expression in muscle (Wolff, Malone et al. 1990). However, for most gene therapy 
applications, the need for an efficient and relevant vector for gene transfer is now 
widely acknowledged. Classically, these vectors are classified into non-viral and viral 
vectors. The non-viral vectors are usually chemically defined compounds such as 
liposomes that complex the genetic material and mediate gene transfer (Glover, 
Lipps et al. 2005). Viral vectors, replicating or not, are recombinant viruses in which 
all or part of the viral genome has been replaced by the expression cassette 
encoding the therapeutic transgene. Retroviruses, adenoviruses, poxviruses, 
parvoviruses and herpesviruses belong to the most frequently used viral factors 
(Celec, Gardlik et al. 2005). Gene transfer can also occur from bacteria to a very 
broad range of recipients that include yeast (Heinemann and Sprague 1989) and 
plants (Lessl and Lanka 1994) and several laboratories have reported a relatively 
high frequency of functional gene transfer from bacteria to mammalian cells 
(Sizemore, Branstrom et al. 1995; Darji, Guzman et al. 1997; Dietrich, Bubert et al. 
1998; Grillot-Courvalin, Goussard et al. 1998; Paglia, Medina et al. 1998; Loessner 
and Weiss 2004).  
Bactofection, using bacteria for direct gene transfer into the target organism, 
organ or tissue, is a novel approach which exploits intracellular bacteria as delivery 
vectors for plasmid DNA. Distinct advantages of such carrier-based DNA vaccines 
 40 
are that: (1) these carriers specifically target APCs at the inductive sites (i.e. the most 
effective target) (2) live attenuated vaccines induce the secretion of several cytokines 
and proinflammatory mediators that enhance early innate immunity and create a local 
environment conductive to antigen presentation and (3) bacterial cell components 
and unmethylated DNA as so-called pathogen-associated molecular patterns 
(PAMPs) provide a strong “danger signal” through the activation of pattern 
recognition receptors on APCs. 
Stimulation of APC with PAMPs will trigger an innate immune response in the 
form of the production of reactive oxygen, pro-inflammatory cytokines, and nitrogen 
species, as well as up-regulation of co-stimulatory molecules. These responses 
promote the maturation and migration of DCs to secondary lymph nodes 
(Banchereau and Steinman 1998) and, in this way, PAMPs amplify the immune 
response against the antigen and act as adjuvants. PAMPs exert their action through 
binding to receptors of the Toll-like receptor (TLR) family (Banchereau and Steinman 
1998). PAMPs include compounds such as lipopolysaccharide (LPS) (Poltorak, He et 
al. 1998; Poltorak, Ricciardi-Castagnoli et al. 2000), bacterial DNA-containing 
unmethylated cytosine-phosphate-guanine (CpG) dinucleotides (Hemmi, Takeuchi et 
al. 2000; Stetson and Medzhitov 2006), flagellin (Gewirtz, Navas et al. 2001) or 
bacterial lipoproteins (Aliprantis, Yang et al. 1999).  
 
1.2.3 Mechanisms of “cargo” delivery by bacterial vectors 
 
The first step of gene transfer by bacterial vectors lies in the entry of the delivery 
vehicle uptake by host target cells. The bacterial cell is typically confined to spherical 
or cylindrical shapes between 1 and 5 μm which can innately target the phagocytic 
cells. When professional phagocytic cells such as macrophages or dendritic cells are 
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targeted, this entry is likely to happen through phagocytosis. This contact will activate 
these phagocytic cells, i.e. the APCs. Gram negative cells contain LPS, whereas 
Gram-positive cells posses lipoteichoic acid. These and other PAMPs naturally 
influence bacterial uptake and act as natural adjuvants to improve APCs activation 
through binding to TLR (Hemmi, Takeuchi et al. 2000; Poltorak, Ricciardi-Castagnoli 
et al. 2000). In the case of non-phagocytic cells, such as those of the intestinal 
epithelium, there are two major strategies for bacteria to gain entry into a eukaryotic 
cell (Marra and Isberg 1996; Poltorak, He et al. 1998). For certain genera such as 
Salmonella or Shigella, contact between the bacteria and the host results in the 
secretion by the bacteria of a set of invasion proteins that triggers intracellular 
signalling events. For example, contact of S. typhimurium with host cells results in 
activation of a specialised protein secretion system (type III) which leads to 
cytoskeletal rearrangement, membrane ruffling, and bacterial uptake by pinocytosis 
(Poltorak, He et al. 1998). For other genera such as Yersinia or Listeria, binding of a 
single bacterial protein to a particular ligand on the host cell surface is necessary and 
sufficient to trigger entry by a zipper-like mechanism. After internalisation, the 
bacteria are localised in the phagosomal vacuoles and are targeted for degradation. 
Therefore, escaping from the vacuolar compartment is essential to the delivery of 
DNA vaccines (Figure 2 (1)). 
Shigella spp. and L. monocytogenes can disrupt the endosomal/lysosomal 
membrane, escape into the host cell’s cytoplasm and spread from one infected cell to 
an adjacent one by exploiting the cell´s actin polymerisation for intracellular motility 
(Dietrich, Bubert et al. 1998; Ogawa and Sasakawa 2006). This process of 
phagosomal escape is particularly well understood and exploited in vectors based on 
bacteria replicating in the cytosol (Dietrich, Bubert et al. 1998; Grillot-Courvalin, 
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Goussard et al. 2002; Birmingham, Canadien et al. 2008). In L. monocytogenes, the 
pore-forming cytolysin listeriolysin-O (LLO), which is encoded by hly, plays an 
essential role in the escaping step. Strains with mutations in hly that inactivate the 
pore-forming activity of LLO are unable to escape from the primary phagosome 
(Gaillard, Berche et al. 1987; Michel, Reich et al. 1990). Once spread into the cytosol, 
wild-type L. monocytogenes will replicate (Portnoy, Chakraborty et al. 1992). An 
attenuated L. monocytogenes strain has been engineered to undergo self-destruction 
in the cell cytosol by production of a phage lysine under the control of the promoter of 
actA, which is preferentially activated when the bacteria are in the cytosol (Dietrich, 
Bubert et al. 1998; Brockstedt, Bahjat et al. 2005). In the case of bacterial delivery 
vectors that remain in the lysosome/phagosome, such as Salmonella, the 
mechanism of delivery remains unclear (Grillot-Courvalin, Goussard et al. 1999). 
Another interesting approach might be used in bacterial delivery systems (Palffy, 
Gardlik et al. 2006). Bacteria are not used for the gene transfer but the proteins 
secreted by bacteria persist in the target tissues (Figure 2 (2)). More recently, the 
utilisation of double-stranded RNA (dsRNA or RNA interference, so-called RNAi) to 
silence target genes has potential therapeutic applications that are widely 
acknowledged (Karagiannis and El-Osta 2005; Vassaux, Nitcheu et al. 2006). Recent 
progress in this strategy was made using nonpathogenic bacteria to induce gene 
silencing in target cells, both in vitro and in vivo. Bacteria-mediated induction of RNAi 
was established by demonstrating target-specific gene silencing after transfer of 
double-stranded RNA from E. coli in the nematode Caenorhabditis elegans 
(Timmons and Fire 1998; Timmons, Court et al. 2001). Another example of bacteria-
mediated RNAi transfer for functional genomics is postulated by Xiang et al who 
developed an siRNA delivering system using nonpathogenic E. coli engineered to 
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transcribe shRNAs from a plasmid containing the invasin gene inv and the LLO gene 
hly, which encode two bacterial factors needed for successful transfer of the shRNAs 
into mammalian cells. Upon oral or intravenous administration, E. coli encoding 
shRNA against catenin β-1 (CTNNB1) induce significant gene silencing in the 
intestinal epithelium and in human colon cancer xenografts in mice (Li, Parker et al. 
2006; Xiang, Fruehauf et al. 2006).  In another in-vivo study carried out by Zhang et 
al, using attenuated S. typhimurium to deliver STAT3-specific RNAi, bacterial vector 
could preferentially home to tumour tissues, inhibit tumour growth, and extend 
survival time in experimental mice (May, Dao et al. 2007). In the light of these results 
obtained previously, the delivery of dsRNA or eukaryotic expression plasmids 
encoding siRNAs into mammalian cells can be envisaged in the near future. 
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Figure 2.  Different strategies are undertaken by the bacterial vectors in delivering the 
DNA vaccines.  (1) After bacterial vectors penetrate into the mammalian cells, the vectors 
are destroyed or undergo lysis in the cytoplasm of target cells. The plasmid carrying the 
therapeutic gene ( ) is released, enters the nucleus and is expressed by the eukaryotic 
transcription and translation machinery ( ). (2) The passenger antigen ( ) is expressed 
within the bacterial compartment and delivered into the target cells. These non-secretory 
antigens can only be released into the cytoplasm of the target cell upon phagosomal lysis of 
the vector. Further antigen processing and presentation will happen essentially in antigen-
presenting cells (APC). (3) Bacterial vectors do not enter the eukaryotic cell, but express and 
secret the therapeutical transgene in the intercellular space. (4) The bacterial vector can 
escape from lysosomal/phagosomal lysis. The transgene is expressed by the prokaryotic 
transcription and translation machinery after penetrating into the cytoplasm of the target cell, 
and the expressed antigenic protein is secreted into the cytoplasm. 
 
 
1.2.4 Protein vs. Gene therapy 
 
Another approach that might be used in gene therapy is the so-called alternative 
gene therapy (AGT) (Celec, Gardlik et al. 2005; Palffy, Gardlik et al. 2006). Bacteria 
are not used for the gene transfer but persist in the target tissues. Persisting bacteria 
maintain the therapeutic polypeptide in situ, thus, this technique resembles bacterial 
protein delivery (Figure 2 (4)). In comparison to classic gene therapy using gene 
transfer into the mammalian cells, AGT offers the possibility of regulation of gene 
expression using low molecular weight inducers of expression dependent on the 
expression system used. Celec et al demonstrated that the transformed E. coli 
expressing VEGF (in the T7 expression system) could induce blood vessel formation 
in mice after intraperitoneal injection (Celec, Gardlik et al. 2005). If needed, the 
therapy can always be stopped. Bacteria can be eliminated using antibiotics as their 
resistance spectrum is defined. This negative regulation cannot be performed in 
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classic gene therapy or bactofection. The use of antibiotics in bactofection or suicide 
genes (e.g. thymidine kinase) in viral vectors can increase the safety of delivery, but 
does not affect the expression of therapeutic genes. AGT can be improved using 
experience from bactofection experiments since the transport of bacteria in the 
organism does not differ significantly between these two methods. Although 
bactofection and AGT share some characteristics such as their side effects and other 
similarities, the key difference lies in the expression of the desired gene. In 
bactofection, the transgene is expressed in the eukaryotic host cell; in AGT bacteria 
are the producer of the therapeutic peptide. 
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1.2.5 Application of bacterial vectors in cancer immunotherapy 
 
Anecdotal case reports from more than 200 years ago describe tumour 
regression in patients with severe bacterial infections (Hall 1998). Application of 
bacteria in cancer therapy was pioneered independently by Friedrich Fehleisen and 
William B Coley in the late 1800s and early 1900s (Coley 1893), leading eventually to 
immunomodulation for the treatment of cancer. Many more recent studies have 
shown the potential of genetically engineered bacteria as tumour-targeting vectors in 
human cancer therapy (Table 1). Among the bacterial vectors designed for cancer 
vaccines, Salmonella strains have essentially been used to deliver DNA for 
therapeutic applications in oncology. In the first instance, ‘model’ tumour antigens 
such as β-galactosidase were encoded in eukaryotic expression vectors carried by 
strains of Salmonella (Paglia, Medina et al. 1998; Weth, Christ et al. 2001). Oral 
administration of these bacterial strains to deliver DNA vaccines encoding the model 
tumour antigens protected the mice against challenges with fibrosarcoma (Paglia, 
Medina et al. 1998) or  renal carcinoma (Weth, Christ et al. 2001). In addition, when 
real murine/human tumour antigens/epitopes were expressed in Salmonella vector, 
the tumour protective effect could still be demonstrated in neuroblastoma (Xiang, 
Lode et al. 2000; Huebener, Lange et al. 2003; Pertl, Wodrich et al. 2003), melanoma 
(Weth, Christ et al. 2001; Cochlovius, Stassar et al. 2002) and adenocarcinoma 
(Niethammer, Primus et al. 2001; Zhou, Luo et al. 2004).  
Attacking the tumour’s vasculature has been documented as an effective 
strategy to inhibit tumour growth/metastasis. This antiangiogenic intervention has 
been demonstrated in Salmonella expressing vascular endothelial growth factor 
receptor (FLK-1 or Fra-1) (Niethammer, Xiang et al. 2002; Reisfeld, Niethammer et al. 
2004; Reisfeld, Niethammer et al. 2004; Zhou, Luo et al. 2005; Luo, Markowitz et al. 
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2007). Recently, Endoglin (CD105), a co-receptor in the TGF-β receptor complex that 
is overexpressed on proliferating endothelial cells in the breast tumour 
neovasculature, was delivered by attenuated S. typhimurium. In a prophylactic 
setting, a pronounced CD8+ T cell response was induced which effectively 
suppressed dissemination of pulmonary metastases in mice (Lee, Mizutani et al. 
2006; Needham, Lee et al. 2006). Another strategy used the delivery of the 
endogenous angiogenic inhibitor, thrombospondin-1 (TSP-1), by S. choleraesuis  
was shown to be effective for the treatment of primary and metastatic melanomas 
(Yu, Lee et al. 2005). Platelet derived growth factor receptor beta (PDGFRβ) 
expressed by a Salmonella vaccine also showed the suppression of angiogenesis in 
vivo and reduction of tumour stromal cell proliferation (Kaplan, Kruger et al. 2006). 
Combined application of cyclophosphamide with a DNA vaccine targeting PDGFRβ 
not only completely inhibited the growth of different tumour types but also led to 
tumour rejections in mice (Loeffler, Le'Negrate et al. 2008). Legumain is highly 
upregulated on macrophages in many tumour tissues and consequently a valid 
tumour antigen for immunotherapy. Immunisation of mice with Salmonella vaccine 
encoding Legumain induced a robust CD8+ T cell response against tumour 
associated macrophages and in turn led to a suppression of tumour angiogenesis, 
tumour growth and metastasis by profoundly altering the tumour microenvironment 
(Luo, Zhou et al. 2006). Emergence of acquired multidrug resistance (MDR) remains 
a major challenge in the treatment of cancer following chemotherapeutic drugs and, 
thus, the MDR gene serves as an alternative cancer vaccine target. Salmonella 
vaccines against MDR-1 have also inhibited tumour growth and metastasis in 
preclinical studies (Niethammer, Wodrich et al. 2005). This also enabled the further 
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combination of targeting MDR-1 with traditional cytotoxic therapy in effective 
treatments of cancer. 
It has been shown that the immune responses mediated from bacteria delivering 
DNA vaccines can be dramatically improved by modifying the expression vectors or 
co-expression of immunostimulatory molecules. Optimisation of the bacterial vectors 
carrying DNA vaccine was shown to be achieved by several strategies: 
 The level of expression of the antigen can be enhanced by adding a post-
transcriptional regulatory acting RNA element. In experimental murine models,  
the anti-tumour effect can be further augmented by boosting with antibody-
cytokine fusion protein that targets IL-2 to the tumour microenvironment (Pertl, 
Wodrich et al. 2003).  
 Antigen-fusion to ubiquitin can also increase antigen processing and effective 
presentation in order to break peripheral T cell tolerance to a self-antigen 
(Xiang, Lode et al. 2000; Xiang, Primus et al. 2001).  
 Co-expression of invariant chain leads to preferential presentation in the 
context of MHC class II molecules (Weth, Christ et al. 2001).  
 Expression of CD40L (Urashima, Suzuki et al. 2000) alone or co-expression of 
CD40L/antigen (Xiang, Primus et al. 2001) up-regulated the expression of Fas, 
B7-1, and B7-2 molecules and improved antigen presentation to T cells.  
 Fusion of cytokine genes into DNA vaccine produced immune-modulatory 
effects, such as IL-2 (Niethammer, Xiang et al. 2001), IL-4/IL-18 (Rosenkranz, 
Chiara et al. 2003; Agorio, Schreiber et al. 2007), GM-CSF/IL-12 (Yuhua, 
Kunyuan et al. 2001), IL-12/VEGFR2 (or FLK-1) (Feng, Zhao et al. 2005), IFN-
γ (Paglia, Terrazzini et al. 2000),  IL-18 (Luo, Zhou et al. 2003) or combined 
FRA-1 (Luo, Zhou et al. 2003; Luo, Zhou et al. 2005), CCL21 with apoptosis 
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protein inhibitor (survivin) (Luo, Zhou et al. 2005),  NKG2D ligands (Zhou, Luo 
et al. 2005; Zhou, Luo et al. 2006), and Fas Ligand (FasL) (Loeffler, 
Le'Negrate et al. 2008). 
 Co-expression of LLO in addition to tumour antigen caused lysosomal escape 
and the antigenic epitope to be presented onto MHC class I complex (Radford, 
Higgins et al. 2002; Radford, Jackson et al. 2003; Critchley-Thorne, Stagg et 
al. 2006).  
 From the experience using bacterial vaccine against HIV infection (Gao, Xue 
et al. 2003; Tsunetsugu-Yokota, Ishige et al. 2007), the use of a prime-boost 
strategy to enhance and prolong CTL responses is also applicable in the field 
of cancer vaccines, such as priming with naked DNA vaccine and boosting by 
bacterial vaccine, or priming with bacterial vaccine boosting by antigen-loaded 
DCs (Weth, Christ et al. 2001).  
 
1.2.6 An alternative approach: Targeting hypoxic tumours using anaerobic 
bacteria 
 
Hypoxic or necrotic regions are characteristic of solid tumours in many murine and 
human tumours, including the majority of primary tumours of the breast and uterine 
cervix. The limitation of cancer gene therapy approaches in solid tumour treatment is 
the lack of specific, high-level of expression within tumour tissues or the tumour 
environment following systemic or parenteral administration. Accordingly, gene 
therapy for solid tumours that exploits and targets gene expression in hypoxic tumour 
cells is currently being investigated (Dachs, Patterson et al. 1997). It is known that 
certain species of anaerobic bacteria, including the genera Clostridium and 
Bifidobacterium, can selectively germinate and grow in the hypoxic regions of solid 
 50 
tumours after intravenous injection (Yazawa, Fujimori et al. 2000; Fujimori 2006). In 
such cases, bacteria proliferate between tumour cells and thus the therapeutic gene 
is not introduced into the tumour cell, but rather the therapeutic protein is produced in 
the tumour (Figure 2 (3)). Candidate bacterial vectors for gene introduction include 
species of Bifidobacterium, Clostridium and Salmonella. Bifidobacterium is a normal 
bacterial flora in the intestine. The nonpathogenic B. longum transformed with 
plasmid containing the gene for human endostatin, a potent inhibitor of angiogenesis, 
has been shown to inhibit liver tumour growth in BALB/c mice (Fu, Li et al. 2005). 
Theys J et al described C. acetobutylicum expressing murine TNF-α as a possible 
tool for cancer therapy (Theys, Nuyts et al. 1999).  
The use of anaerobic bacterial vaccine for the selective delivery of pro-drug-
activating enzymes has also been proven to be efficient in preclinical studies (Fox, 
Lemmon et al. 1996; Lemmon, van Zijl et al. 1997; Liu, Minton et al. 2002; Minton 
2003). In these studies, the E. coli enzyme cytosine deaminase (CD) (Fox, Lemmon 
et al. 1996; Theys, Nuyts et al. 1999; Liu, Minton et al. 2002) and nitroreductase 
(Lemmon, van Zijl et al. 1997) were expressed in Clostridium and were shown to 
convert the non-toxic pro-drugs 5-fluorocytosine and CB1954, respectively, into toxic 
compounds capable of diffusing in the tumours and killing the cancer cells through a 
bystander effect. Gram-negative Salmonella have also been proposed as oncolytic 
agents. In contrast to obligate anaerobic bacteria such as Clostridia and 
Bifidobacteria, Salmonella are facultative anaerobic bacteria and have the potential 
to colonise oxygenated small metastatic lesions as well as large tumours with a 
hypoxic centre. The anaerobic bacteria per se also could exert an oncolytic effect 
and thus potentiate cytotoxic chemotherapy. In the study by Lee et al, Salmonella 
choleraesuis in combination with cisplatin acted additively to retard tumour growth 
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and extensively prolong the survival time of mice bearing hepatomas or lung tumours. 
This enhanced antitumour immune responses, manifested by increased infiltrating 
neutrophils, CD8+ T cells, and apoptotic cells in the tumours, represents a promising 
strategy for the treatment of primary and metastatic tumours (Yu, Lee et al. 2005). 
Dang et al assessed 26 different strains of anaerobic bacteria systemically for their 
proliferative capacity to grow within avascular compartments of transplanted tumours. 
One (Clostridium novyi) appeared to be particularly promising (Dang, Bettegowda et 
al. 2001). This research group also demonstrated that intravenous injection of C. 
novyi-NT can potentiate the treatment effect of selected anti-microtubule agents 
(Dang, Bettegowda et al. 2004) or radiotherapy (Bettegowda, Dang et al. 2003) in 
animal models, without excessive toxicity. Another study carried out by Cheong et al 
demonstrated that C. novyi-NT plus a single dose of liposomal doxorubicin enhanced 
the tumour eradication effect (Cheong, Huang et al. 2006). 
One study applied this bacterial delivery of prodrug-activating enzyme into a 
clinical setting (Nemunaitis, Cunningham et al. 2003). Nemunaitis et al used 
Salmonella vector expressing E. coli CD in the therapy of chemotherapy-refractory 
colorectal cancer patients. Although the study was a pilot study with only three 
participating patients, the results were very promising and point towards the potential 
of this procedure (Nemunaitis, Cunningham et al. 2003). An earlier study published 
by Toso et al applying Salmonella vaccine (VNP20009) in clinical cancer patients 
with metastatic melanoma demonstrated that Salmonella vaccine could be safely 
administered intravenously to humans. The maximum tolerated dose was found to be 
3X108 cfu/m2 with the dose-limiting toxicities being thrombocytopenia, anaemia, 
persistent bacteraemia, hyperbilirubinemia, diarrhoea, vomiting, nausea, elevated 
alkaline phosphatase, and hypophosphatemia. Some tumour colonisation was 
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observed upon injection of the highest tolerated dose. However, no clinical anti-
tumour effects were seen in their study (Toso, Gill et al. 2002). Altering the kinetics of 
infusion failed to improve the response or colonisation in a small number of 
subsequently treated patients (Heimann and Rosenberg 2003). Another phase I trial 
of systemic administration of Salmonella vaccine to dogs with a spontaneous tumour 
model showed acceptable toxicity results in detectable bacterial colonisation of 
tumour tissue and significant antitumour activity in tumour-bearing dogs (Thamm, 
Kurzman et al. 2005).  
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Table 1.   Bacterial vectors in experimental cancer treatment   
Host immune responses 
Bacterial Vector 
Encoding antigen 
or protein Humoral Cellular Clinical References 
Listeria 
monocytogenes 
Influenza virus 
nucleoprotein 
NA + + 
(Pan, Ikonomidis et al. 
1995) 
Listeria 
monocytogenes 
Influenza virus 
nucleoprotein 
+ + + 
(Pan, Weiskirch et al. 
1999) 
Listeria 
monocytogenes 
HPV-16 E7 protein NA + + 
(Gunn, Zubair et al. 
2001) 
Salmonella 
typhimurium 
β-galactosidase 
(model Ag) 
+ + + 
(Paglia, Medina et al. 
1998; Weth, Christ et al. 
2001) 
Salmonella 
typhimurium 
gp100 (melanoma) + + + 
(Cochlovius, Stassar et 
al. 2002) 
Salmonella 
typhimurium 
gp100 (melanoma) + + - (Weth, Christ et al. 2001) 
Salmonella 
typhimurium 
CD40L NA NA + 
(Urashima, Suzuki et al. 
2000) 
Salmonella 
typhimurium 
Ubiquintinated 
gp100 and TRP-2 
(melanoma) 
NA + + (Xiang, Lode et al. 2000) 
Salmonella 
typhimurium 
tyrosine 
hydroxylase 
(neuroblastoma) 
NA NA + 
(Xiang, Lode et al. 2000; 
Pertl, Wodrich et al. 
2003) 
Clostridium 
sporogenes 
Cytosine 
deaminase 
NA NA + (Liu, Minton et al. 2002) 
Salmonella 
typhimurium 
Cytosine 
deaminase 
NA NA + 
(Nemunaitis, 
Cunningham et al. 2003) 
Salmonella 
typhimurium 
murine multidrug 
resistance-1  
(MDR-1) 
NA + + 
(Niethammer, Wodrich et 
al. 2005) 
Listeria 
monocytogenes 
HER-2/neu NA + + 
(Singh, Dominiecki et al. 
2005) 
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Host immune responses 
Bacterial Vector 
Encoding antigen 
or protein Humoral Cellular Clinical References 
Salmonella 
typhimurium 
Survivin and 
CCL21 
NA + + (Luo, Zhou et al. 2005) 
Salmonella 
typhimurium 
CEA NA + + 
(Niethammer, Primus et 
al. 2001; Zhou, Luo et al. 
2004) 
Salmonella 
typhimurium 
Fos-related Ag 1 
coexpressing  
IL-18 
NA + + 
(Luo, Zhou et al. 2003; 
Luo, Zhou et al. 2005) 
Salmonella 
choleraesuis 
Thrombospondin-1 
(TSP-1) gene 
NA NA + (Yu, Lee et al. 2005) 
Salmonella 
typhimurium 
Endoglin (CD105) NA + + 
(Lee, Mizutani et al. 
2006) 
Salmonella 
typhimurium 
NKG2D ligand-
pH60 or surviving 
NA + + (Zhou, Luo et al. 2005) 
Bifidobacterium 
longum 
Endostatin gene NA + + (Fu, Li et al. 2005) 
Salmonella 
typhimurium 
Legumain (Tumour-
associated 
macrophages) 
NA + + (Luo, Zhou et al. 2006) 
Salmonella 
typhimurium 
Murine PDGF 
receptor-beta 
NA + + 
(Kaplan, Kruger et al. 
2006) 
Salmonella 
typhimurium 
Murine vascular 
endothelial growth 
factor receptor-2 
(FLK-1) 
NA + + 
(Niethammer, Xiang et 
al. 2002; Luo, Markowitz 
et al. 2007) 
E. coli 
Ovalbumin  
(coexpressing LLO) 
+ + + 
(Radford, Higgins et al. 
2002; Radford, Jackson 
et al. 2003; Critchley-
Thorne, Stagg et al. 
2006) 
Salmonella 
typhimurium 
Fas Ligand NA + + 
(Loeffler, Le'Negrate et 
al. 2008) 
 NA: not available  
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1.2.7 Emerging Technologies for Bacterial Vectors 
 
One of the problems encountered when trying to transfect mammalian cells with 
large DNA molecules is the possibility of mechanical breakage of these large 
molecules during the purification process. In this context, the utilisation of bacteria to 
transfer large DNA molecules would simplify the procedure. The delivery of bacterial 
artificial chromosomes was first demonstrated into HeLa cells using an invasive E. 
coli (Narayanan and Warburton 2003). Direct DNA transfer of up to around 1 Mb was 
demonstrated and, as the bacterial vector is equipped with an inducible 
recombination system, modifications of the bacterial artificial chromosome 
sequences should be possible. More recently, an alpha-satellite DNA cloned into a 
P1-based artificial chromosome was stably delivered into the HT1080 cell line and 
efficiently generated human artificial chromosomes de novo (Klink, Schindelhauer et 
al. 2004). In the same report, a 160 kb construct containing the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene was transferred into the same 
cells, where it was transcribed and correctly spliced (Klink, Schindelhauer et al. 2004). 
In a study in mice, large DNA molecules carrying the viral genome of the murine 
cytomegalovirus (MCMV) were transferred using E. coli and S. typhimurium as 
delivery vectors (Cicin-Sain, Brune et al. 2003). This transfer led to a productive virus 
infection that resulted in elevated titres of specific anti-MCMV antibodies, protection 
against lethal MCMV challenge, and strong expression of additional genes 
introduced into the viral genome. Thus, the reconstitution of infectious virus from live 
attenuated bacteria presents a novel concept for multivalent virus vaccines launched 
from bacterial vectors. 
 56 
The second issue in bacterial vector therapy is to monitor delivery efficiency after 
vaccination. Soghomonyan et al demonstrated the possibility of using Salmonella 
(VNP20009) expressing HSV-thymidine kinase reporter gene to visualise the 
anatomical localisation of the bacteria within murine tumours by Positron Emission 
Tomography (PET). The ability to noninvasively detect Salmonella vectors by PET 
imaging has the potential to be conducted in a clinical setting, and could aid in the 
development of these vectors by demonstrating the efficiency and duration of 
targeting as well as indicating the locations of tumours (Soghomonyan, Doubrovin et 
al. 2005). 
The immune system can normally respond to bacterial vector and passenger 
antigen stimulation but mechanisms of immune regulation in hosts will be initiated to 
induce self-tolerance. Much of this immune regulation points to a particular group of 
T cells, currently described as Treg cells, which play a suppressive role in antitumour 
vaccinations (Kronenberg and Rudensky 2005). Few studies have demonstrated the 
effects of bacterial adjuvants on Treg cells. Hussain et al demonstrated that Treg cell 
inhibition is responsible for the differences in vaccine-mediated antitumour responses 
and less Treg cells were found in mice vaccinated with Listeria vector expressing 
LLO and antigen (Hussain and Paterson 2004; Hussain and Paterson 2005). By the 
increasing number of studies regarding the role of Treg cells in cancer patients (Betts, 
Clarke et al. 2006; Lizee, Radvanyi et al. 2006), there is a clear rationale for 
developing bacterial vaccines to manipulate these regulatory influences to augment 
antitumour immunity. 
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1.3 LLO-BASED PROTEIN EXPRESSING SYSTEMS IN BACTERIAL GENE 
THERAPY 
 
1.3.1 Using Listeria monocytogenes as gene therapy vectors 
 
During the past decade, the search for an effective system for the selective delivery 
of high therapeutic doses of anti-cancer agents to tumours has explored a variety of 
ingenious and increasingly complex biological systems. Intracellular bacteria are able 
to generate a strong, cell-mediated immune response within the host. Previous 
studies have demonstrated the ability of Listeria monocytogenes to be used as 
vaccine vectors in inducing directed immune responses to added antigens (Hussain 
and Paterson 2005). L. monocytogenes is especially attractive, as compared to other 
intracellular bacteria such as Salmonella or BCG, as a vaccine vector due to its 
unusual life cycle. As facultative intracellular bacteria, Listeriae are taken up primarily 
by APCs such as macrophages and DCs and enter their phagosomes. The majority 
of bacteria are killed and digested in the lysosomal compartment in vivo, thus 
targeting the antigens to the MHC class II pathway for antigen processing and cell 
surface presentation. At the same time, some of the bacteria will escape into the 
cytosol through the actions of the LLO protein. Antigens from Listeria that multiply in 
the cytosol are presented in an MHC class I–restricted manner to T cells, allowing 
the expansion of CD8+ T cells, which are necessary for clearance of virally infected 
host cells as well as being important for direct killing of tumour cells. The MHC class 
II antigen presentation of bacteria-derived antigens in the lysosome induces a CD4+ 
T-cell response, which is also necessary for a robust, cell-mediated immune 
response. 
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    LLO, produced by Listeria monocytogenes, is a member of the cholesterol-
dependent cytolysin (CDC) family of toxins. It is the main virulence factor in the 
pathogenesis of listeriosis, allowing the bacteria to escape from host-cell 
phagosomes to replicate in the cytoplasm without killing the host cells (Birmingham, 
Canadien et al. 2008). The use of a recombinant L. monocytogenes strain in which 
expression of LLO was placed under the control of an Isopropyl β-D-
thiogalactopyranoside (IPTG)-inducible promoter (Dancz, Haraga et al. 2002) 
confirmed that primary phagosomal escape and intracellular growth of L. 
monocytogenes was strictly dependent upon expression of LLO. Mutants of L. 
monocytogenes lacking LLO-secretion are generally non-virulent (Kayal and Charbit 
2006). 
    The advantage of LLO incorporation into vaccine resides in the fact that, after 
degradation of the vaccine strain within the phagolysosome, target antigens are 
released into the cytosol for endogenous processing and presentation for stimulation 
of CD8+ effector T cells. Using this principle, Bouwer et al (Brockstedt, Bahjat et al. 
2005) suggested that this approach could be used against intracellular bacterial 
pathogens. Ikonomidis et al had first shown the use of L. monocytogenes to deliver 
Influenza antigen to the class I pathway and induced antigen-specific CTLs in vivo 
(Pan, Ikonomidis et al. 1995). Further evidence is the preferential skewing 
differentiation of antigen-specific T cells into Th1 cells and inhibit Th2 (Yamamoto, 
Kawamura et al. 2005). 
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1.3.2 Recombinant E. coli expressing LLO as protein delivery vector 
 
Non-pathogenic bacteria, E. coli, harbouring plasmid encoding LLO, without the 
secretion signal, have been proposed as an alternative to Listeria. Higgins et al have 
shown that E. coli expressing cytoplasmic recombinant LLO can efficiently deliver co-
expressed proteins to the cytosol of macrophages (Higgins, Shastri et al. 1999). In 
this model, a large enzymatically active protein was delivered to the cytosol (Figure 
3). 
 
 
 
Figure 3. Antigen presentation pathway involved in OVA and LLO-expressing E. coli. 
Lysosomal digestion of the phagocytosed E. coli caused the release of encoded antigen 
(OVA) and pore-forming of lysosome by LLO. As a result, the digested bacterial products and 
OVA were transferred into the cytosol after disruption of the lysosomal membrane by LLO. 
The digested bacterial products or PAMPs can interact with cytosolic receptor or Toll-like 
receptor and OVA can be degraded and processed through proteosome/endoplasmic 
reticulum and presented onto cell surface in conjunction with MHC class-I complex. 
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Furthermore, they demonstrated that the E. coli-LLO system is very efficient for 
delivery of ovalbumin (OVA) to the MHC class I pathway for antigen processing and 
presentation, greater than 4 logs compared with E. coli expressing OVA alone 
(Higgins, Shastri et al. 1999). 
Previous experiments had demonstrated that vaccination with E. coli-LLO-pulsed 
DCs expressing OVA generated OVA-specific CTLs and tumour protection in a 
murine tumour model (Radford, Higgins et al. 2002). Direct injection of E. coli-
LLO/OVA resulted in more dramatic anti-tumour immunity than vaccination with 
pulsed DCs. Also, subcutaneous injection of paraformaldehyde-fixed E. coli-LLO 
provided an additional safety feature without compromising vaccine efficacy. Further 
experiments have shown that fixed E. coli-LLO expressing the well-characterised 
human melanoma antigen, MART1, efficiently deliver the HLA-A2-restricted 
MART127-35 epitope for processing and presentation on human MoDCs, suggesting 
the potential of this system as a novel strategy for human tumour immunotherapy 
(Radford, Jackson et al. 2003).  
 
1.3.3 Advantage of the E. coli-LLO model in antigen processing 
 
The E. coli-LLO system only requires expression of the target protein in the bacteria. 
High levels of protein can be delivered to the cytosol of virtually all cells in culture. 
The level of protein produced and ultimately delivered to the cytosol of macrophages 
can be controlled. By expressing invasive determinants from other bacterial species, 
the E. coli could be modified to enter cells other than macrophages or antigen-
presenting cells which are naturally phagocytic. Expression of Invasin could be used 
for delivery of proteins to epithelial cells (Critchley, Jezzard et al. 2004; Critchley-
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Thorne, Stagg et al. 2006). Invasin binds to β1-integrin expressed at the surface of 
mammalian cells. This binding to β1-integrin is necessary and sufficient for entry of 
the whole bacterium into the mammalian cell (Marra and Isberg 1996). It has been 
shown that diaminopimelate (DAP)-minus E. coli expressing invasin from Yersinia 
pseudotuberculosis has the ability to invade cultured mammalian cells and lyse within 
the phagosome (Grillot-Courvalin, Goussard et al. 1998).  
The E. coli-LLO system provides another advantage. Full-length tumour-antigen 
can be expressed safely in bacteria as opposed to the host cell. This has an added 
advantage in that antigenic epitopes do not need to be defined and treatment is less 
likely to be restricted to patients of specific HLA haplotypes. Many tumour antigens 
have already successfully been expressed as recombinant proteins in E. coli, 
demonstrating the simplicity of this technique. In addition, the injected bacterial cell 
components, PAMPs, also can potentiate the immune response against the antigen 
and thus play an adjuvant role in the treatment. 
 
1.4 AIMS OF THIS STUDY 
 
In previous studies in the host laboratory, E. coli-LLO/OVA have a superior effect in 
tumour protection. My main research aimed at unraveling the immune mechanism 
induced by the bacterial vaccination. In addition, chicken ovalbumin was exploited as 
a model tumour antigen. A key question was whether the previously described 
efficacy of E. coli-LLO can be obtained against a real tumour antigen– with clinical 
relevance and to assess the autoimmunity to normal tissues.  
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CHAPTER 2:  MATERIALS AND METHODS 
 
2.1 BACTERIAL STRAINS  
 
The E. coli strain MC4100 (DE3) used in our study was a gift from Prof. DE Higgins, 
Harvard Medical School, Boston, USA. It is a derivative of the K12 E. coli strain, 
harbouring the DE3 bacteriophage, which contains the T7 RNA polymerase gene 
that allows Isopropyl β-D-thiogalactopyranoside (IPTG)-inducible expression of gene 
under T7 promoter control. E. coli-LLO harbours the plasmid pDP-E3615 which 
encodes listeriolysin O lacking its secretion signal under the control of the constitutive 
tet promoter.  
The cDNA of WT1 protein was amplified from a mouse cDNA lacking the two 
alternative splicing donor sites (17aa-/KTS-) by PCR. The 5’ primer used as 5’-ATG 
CAC TCC TTC ATC AAA CAG GAG CCCA-3’. The 3’-primer used was 3’-TCA AAG 
CGC CAC GTG GAG TTT GGTC-5’. The PCR product was cloned using TOPO CT 
cloning kit (Invitrogen). The sequence of the PCR product was analysed by restriction 
enzyme digestion and capillary electrophoresis sequencer 3700 (Applied 
Biosystems), and shown to be identical to the previously published mouse WT1 gene 
sequence. The cloned WT1 gene expressed a truncated version of WT1 (67 amino 
acids at the N-terminus domain are missing), as it was impossible in our hands to 
express the whole coding sequence in bacteria (work performed by Dr. Josianne 
Nitcheu). Plasmid pCRT7/CT which encodes WT1 cDNA under the control of IPTG-
inducible T7 phage promoter was transformed into DE3 containing or not the plasmid 
encoding LLO (E. coli-LLO/WT1 or E. coli-WT1).  
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2.2 EXPRESSION OF TARGET PROTEINS BY IPTG 
 
Bacteria containing dual plasmids were cultured in medium containing Ampicillin (50 
μg/mL) and Chloramphenicol (40 μg/mL). Single colonies of E. coli-WT1 or E. coli-
LLO/WT1 were inoculated from an LB agar plate into 10 ml of LB medium containing 
appropriate antibiotics and grown overnight to stationary phase at 30°C with aeration 
and shaking. Starter cultures were diluted into 500 ml of LB medium in 1L flasks and 
continued to grow for 2 h with aeration and shaking at 30°C. Protein expression was 
induced by the addition of IPTG to 1 mM, and growth continued for an additional 4 h 
until cultures reached an OD600 of 0.7~1.0.  The bacterial concentration from cultures 
was estimated by measuring the optical density (O.D.) at 600 nm. Serial dilution 
assays to determine the bacterial number showed that an OD600 0.8 corresponds to a 
concentration of 109/mL MC4100 (DE3) E. coli and OD600 1.0 corresponds to a 
concentration of 5x108/mL E. coli WT1 or E. coli LLO/WT1. The bacteria were 
harvested by centrifugation at 4000 rpm for 10 minutes, and the resulting pellet was 
resuspended to the appropriate concentration in LB broth containing 15% Glycerol 
and stored at –80°C until further use for vaccination. 
 
2.3 CONFIRMATION OF PROTEIN EXPRESSION IN BACTERIA BY WESTERN 
BLOT 
 
Equivalent numbers of bacteria (108) were centrifuged (14,000 g) for 1 min and 
washed once with phosphate-buffered saline (PBS). Washed pellets were re-
suspended in Laemmli buffer (250 mM Tris pH6.8, 5% Sodium dodecyl sulphate 
(SDS), 20% glycerol, 0.01% bromophenol blue) and boiled for 5 min, and total 
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cellular protein was analysed by SDS-polyacrylamide gel electrophoresis (PAGE) 
followed by staining with Coomassie brilliant blue or specific primary/secondary 
antibodies in a Western Blot. For WT1 expression, (primary) mouse anti-WT1 Ab 
(1/1000, DAKO, U.S.) and (secondary) rabbit anti-mouse Ig- horseradish peroxidase 
(HRP) (1/2000, DAKO, U.S.) were used. For LLO expression, (primary) rabbit anti-
LLO Ab (1/2000, Diatheva, Italy) and (secondary) anti-rabbit Ig-HRP (1/1000, GE 
Healthcare, U.K.) were used. The signal was revealed by incubating the membrane 
with ECL detection agent (Amersham Biosciences, U.K.) according to the 
manufacturer's instructions. 
 
2.4 PEPTIDES SYNTHESIS 
 
Specific peptides were synthesised by the peptide synthesis laboratory of Cancer 
Research UK (London LIF, UK). The quality of the peptides was assessed by HPLC 
analysis and the molecular weight confirmed by mass spectrometry. All peptides 
were dissolved in distilled-water at 1 mM concentration and kept at -20°C. When 
required, 0.5-1% DMSO was added. Specific peptide sequences are shown in Table 
2.   
Table 2    Specific peptide sequence  
Peptide (sequence) Sequence  
OVA257-264 SIINFEKL  
pWT119 (pWT119-127) QASSGQARM  
pWT126 (pWT126-134) RMFPNAPYL  
pWT130 (pWT130-138) NAPYLPSCL  
pWT235 (pWT235-243) CMTWNQMNL  
pWT423 (pWT423-431) KKFARSDEL  
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The WT1 peptide library was generated from the human WT1 sequence (Minotopes, 
UK). It consisted of 106 15-mer peptides overlapping by 11 amino acids, spanning 
the length of the WT1 sequence (Table 3). The peptides were dissolved in a minimal 
volume of DMSO with 2mM DTT (Fischer Scientific, Loughbourough) where 
necessary. The peptides were then resuspended in water to make 5mM stock 
solution and stored at -80oC. For experimental use individually the peptides were 
diluted with media to an intermediate concentration of 100 μM. 
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Table 3.  Human WT1 peptide library 
Peptide 
number Aminoacid Sequence From To  
Peptide 
number Aminoacid Sequence  From To 
1 MGSDVRDLNALLPAV 1 15  54 QALLLRTPYSSDNLY 213 227 
2 VRDLNALLPAVPSLG 5 19  55 LRTPYSSDNLYQMTS 217 231 
3 NALLPAVPSLGGGGG 9 23  56 YSSDNLYQMTSQLEC 221 235 
4 PAVPSLGGGGGCALP 13 27  57 NLYQMTSQLECMTWN 225 239 
5 SLGGGGGCALPVSGA 17 31  58 MTSQLECMTWNQMNL 229 243 
6 GGGCALPVSGAAQWA 21 35  59 LECMTWNQMNLGATL 233 247 
7 ALPVSGAAQWAPVLD 25 39  60 TWNQMNLGATLKGHS 237 251 
8 SGAAQWAPVLDFAPP 29 43  61 MNLGATLKGHSTGYE 241 255 
9 QWAPVLDFAPPGASA 33 47  62 ATLKGHSTGYESDNH 245 259 
10 VLDFAPPGASAYGSL 37 51  63 GHSTGYESDNHTTPI 249 263 
11 APPGASAYGSLGGPA 41 55  64 GYESDNHTTPILCGA 253 267 
12 ASAYGSLGGPAPPPA 45 59  65 DNHTTPILCGAQYRI 257 271 
13 GSLGGPAPPPAPPPP 49 63  66 TPILCGAQYRIHTHG 261 275 
14 GPAPPPAPPPPPPPP 53 67  67 CGAQYRIHTHGVFRG 265 279 
15 PPAPPPPPPPPPHSF 57 71  68 YRIHTHGVFRGIQDV 269 283 
16 PPPPPPPPHSFIKQE 61 75  69 THGVFRGIQDVRRVP 273 287 
17 PPPPHSFIKQEPSWG 65 79  70 FRGIQDVRRVPGVAP 277 291 
18 HSFIKQEPSWGGAEP 69 83  71 QDVRRVPGVAPTLVR 281 295 
19 KQEPSWGGAEPHEEQ 73 87  72 RVPGVAPTLVRSASE 285 299 
20 SWGGAEPHEEQCLSA 77 91  73 VAPTLVRSASETSEK 289 303 
21 AEPHEEQCLSAFTVH 81 95  74 LVRSASETSEKRPFM 293 307 
22 EEQCLSAFTVHFSGQ 85 99  75 ASETSEKRPFMCAYP 297 311 
23 LSAFTVHFSGQFTGT 89 103  76 SEKRPFMCAYPGCNK 301 315 
24 TVHFSGQFTGTAGAC 93 107  77 PFMCAYPGCNKRYF 305 319 
25 SGQFTGTAGACRYGP 97 111  78 AYPGCNKRYFKLSHL 309 323 
26 TGTAGACRYGPFGPP 101 115  79 CNKRYFKLSHLQMHS 313 327 
27 GACRYGPFGPPPPSQ 105 119  80 YFKLSHLQMHSRKHT 317 331 
28 YGPFGPPPPSQASSG 109 123  81 SHLQMHSRKHTGEKP 321 335 
29 GPPPPSQASSGQARM 113 127  82 MHSRKHTGEKPYQCD 325 339 
30 PSQASSGQARMFPNA 117 131  83 KHTGEKPYQCDFKDC 329 343 
31 SSGQARMFPNAPYLP 121 135  84 EKPYQCDFKDCERRF 333 347 
32 ARMFPNAPYLPSCLE 125 139  85 QCDFKDCERRFSRSD 337 351 
33 PNAPYLPSCLESQPA 129 143  86 KDCERRFSRSDQLKR 341 355 
34 YLPSCLESQPAIRNQ 133 147  87 RRFSRSDQLKRHQRR 345 359 
35 CLESQPAIRNQGYST 137 151  88 RSDQLKRHQRRHTGV 349 363 
36 QPAIRNQGYSTVTFD 141 155  89 LKRHQRRHTGVKPFQ 353 367 
37 RNQGYSTVTFDGTPS 145 159  90 QRRHTGVKPFQCKTC 357 371 
38 YSTVTFDGTPSYGHT 149 163  91 TGVKPFQCKTCQRKF 361 375 
39 TFDGTPSYGHTPSHH 153 167  92 PFQCKTCQRKFSRSD 365 379 
40 TPSYGHTPSHHAAQF 157 171  93 KTCQRKFSRSDHLKT 369 383 
41 GHTPSHHAAQFPNHS 161 175  94 RKFSRSDHLKTHTRT 373 387 
42 SHHAAQFPNHSFKHE 165 179  95 RSDHLKTHTRTHTGK 377 391 
43 AQFPNHSFKHEDPMG 169 183  96 LKTHTRTHTGKTSEK 381 395 
44 NHSFKHEDPMGQQGS 173 187  97 TRTHTGKTSEKPFSC 385 399 
45 KHEDPMGQQGSLGEQ 177 191  98 TGKTSEKPFSCRWPS 389 403 
46 PMGQQGSLGEQQYSV 181 195  99 SEKPFSCRWPSCQKK 393 407 
47 QGSLGEQQYSVPPPV 185 199  100 FSCRWPSCQKKFARS 397 411 
48 GEQQYSVPPPVYGCH 189 203  101 WPSCQKKFARSDELV 401 415 
49 YSVPPPVYGCHTPTD 193 207  102 QKKFARSDELVRHHN 405 419 
50 PPVYGCHTPTDSCTG 197 211  103 ARSDELVRHHNMHQR 409 423 
51 GCHTPTDSCTGSQAL 201 215  104 ELVRHHNMHQRNMTK 413 427 
52 PTDSCTGSQALLLRT 205 219  105 HHNMHQRNMTKLQLA 417 431 
53 CTGSQALLLRTPYSS 209 223  106 HNMHQRNMTKLQLAL 421 435 
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2.5 CELL LINES 
 
RMA (KbDb), their derivative RMA-S, MBL2, MBL2-WT1, TRAMP-C cell lines were 
kindly provided by Prof. HJ Stauss (Royal Free Hospital, London). RMA is a murine 
thymoma cell line, and RMA-S is a TAP-deficient variant that was obtained by 
mutagenesis of RMA followed by selection of MHC class I-loss variants. MBL2 is a 
leukaemia cell line isolated from M-MuLV-infected C57BL/6 mouse. The prostate 
cancer cell line TRAMP-C (kind gift from Dr. N. Greenberg) was isolated from 
transgenic mice expressing SV40 large T antigen in the prostate tissue. RMA-WT1 
and MBL2-WT1 cells were transfected with a plasmid containing the WT1 gene 
under the control of a CMV promoter. RMA and RMA-S cells were cultured in 
complete RPMI containing 10% Fetal calf serum (FCS). MBL2 cells were cultured in 
complete RPMI containing 50 µM β-Mercaptoethanol and 10% FCS. Transfected 
cells (MBL2-WT1 and RMA-WT1) were maintained in the presence of appropriate 
concentration of G418 (Geneticin, Invitrogen). TRAMP-C cells were cultured in 
DMEM (Dulbecco’s Modified Eagle Medium, Invitrogen) supplemented with 10% FCS, 
10% Nu-SerumTM (BD Biosciences), 5 μg/mL insulin, and 0.01 nM testosterone.  
B16-OVA murine melanoma cells were provided by Cancer Research UK Cell 
Services (LIF, London) and grown in DMEM, 10% FCS and G418 (400 µg/mL). All 
cell lines were routinely tested and found to be free of mycoplasma. 
 
2.6 IMMUNISATION WITH PEPTIDE  
 
Mice were immunised subcutaneously in the flank with 100 μg of peptide diluted in 
phosphate-buffered saline emulsified 1:1 with Incomplete Freuds adjuvant (IFA) 
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(Sigma). Mice were immunised 3 times at one week intervals. In some experiments 
mice were also injected with fixed E. coli-LLO resuspended in PBS (108/mouse) and 
100 μg of peptide. 
 
2.7 ANIMALS 
 
C57/BL6 mice (KbDb) from Harlan (Harlan Ltd, Bicester, UK) were used at 6-8 weeks 
of age (weight 18-20 gm) for immunisation and as a source of accessory cells for in-
vitro CTL stimulation. They were maintained in a specific pathogen-free containment 
facility at Queen Mary University of London Biological Resources Unit (Charterhouse 
Square). Experiments were conducted after appropriate ethical approval and 
licensing was obtained in accordance with the United Kingdom “Guidance on the 
operation of animals (Scientific Procedure) Act 1986”. The mice were subcutaneously 
injected 3 times at one week intervals with 108 Paraformaldehyde-fixed bacteria 
resuspended in 100 μL PBS. One week after the last vaccination, syngeneic TRAMP-
C cells (106/mouse), MBL2-WT1 cells (5x106/mouse), or B16-OVA cells 
(5x105/mouse) were injected subcutaneously to each mouse. The tumour size was 
monitored and measured in 2-dimensions (mm2). The dose of tumour cells inoculated 
was optimised in preliminary experiments. 
 
2.8 PREPARATION OF BMDCS 
 
Total mononuclear cells were harvested by flushing of the bone marrow content of 
the femur and tibia of C57BL/6 mice. Cells were cultured in RPMI-1640 at 106 
cells/mL with GM-CSF (5 ng/mL). The culture was refed with fresh medium and G-
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CSF on 3rd day and all the non-attached cells were collected after 5 days as for the 
BMDCs. For loading, 1x108 of each bacteria were added to 1x106 BMDCs in a 
volume of 1 ml in polypropylene tubes in RPMI-1640 medium supplemented with 10% 
FCS. After 1 h of incubation, Ag-pulsing medium was decanted by several washes 
before the BMDCs were used for assay.  
 
2.9 IN VITRO CTL STIMULATION AND CHROMIUM-51 RELEASE (CTL) ASSAY 
 
Splenocytes from immunised mice (3X106 cells/mL) were stimulated in vitro with 
LPS-stimulated syngeneic spleen cells (splenic blasts, 106 cells/mL) loaded with 
specific peptides. Spleen cell blasts were prepared by stimulating B6 spleen cells 
(1.5X106 cells/mL) with 25 μg/mL LPS (Sigma) and 7 μg/mL dextran sulphate (Sigma) 
(Sette, Vitiello et al. 1994). Three days after activation cells were irradiated (30 cGy) 
and incubated with peptide (106 cells/100 μL irradiated blasts in 100 μM peptide 
concentration, 1 hour in 37ºC before mixing with spleen cells from immunised mice. 
Stimulated cells were collected 5 or 6 days later for the effector cells in CTL assay. 
CTL cultures were analysed in standard 51Cr release assay after in-vitro stimulation. 
A standard chromium release assay was used (Dahl, Beverley et al. 1996) and 106 
target cells were incubated at 37°C with 50 μCi 51Cr (Amersham Biosciences) for 60 
minutes in the presence of specific peptides. Cells were washed 3 times and 
resuspended in RPMI with 5% FCS. When peptide-loaded RMA-S cells were used as 
target cells, they were temperature induced (26°C) overnight before the assay. 
Assays were performed by mixing 5X103 51Cr-labeled cells with varying dilutions of 
effector cells (in 100 μL) and incubated at 37°C for 4h. At the end of the incubation, 
100 μL of the supernatant was analysed on a γ-counter (1470 Wizard Gamma 
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Counter, Perkinelmer, UK). CTL were always tested against the specific peptide as 
well as an irrelevant control peptide. All assays were performed at least in triplicate. 
Specific cytotoxicity was calculated using the formula: ((experimental release-
spontaneous release) / (maximal release-spontaneous release)) x 100%.  
 
2.10 ANTIBODIES AND IN-VIVO DEPLETION OF T CELL SUBSETS 
 
The anti-CD4 (GK1.5), anti-CD8 (YTS 169.4), and PLTY-1 (isotype control) mAbs 
were purified from relevant hybridomas (Cancer Research-UK). Anti-CD25 mAb 
(clone PC61) and its isotype control (rat IgG1) were purchased from BioExpress 
(West Lebanon, NH). On days 0, 7 and 14, C57BL/6 mice were vaccinated 
subcutaneously (s.c.) with 108 of either bacterium. Depletion of CD4+ was achieved 
at the time of CD8+T cell priming by intra-peritoneal (i.p.) administration of 300 μg of 
GK1.5 on days -5 and 10. CD8 + T cells were depleted by in-vivo administration of 
300 μg of YTS 169.4 depleting mAbs on days 10 and 17. Control mice were treated 
with the same doses of the relevant isotype control mAbs or PBS. To deplete CD25+ 
cells, a total of 400 μg of PC61 Ab was injected i.p. on day -1. Optimal conditions of 
depletion of these T cell subsets were determined according to previous publications 
(Rice and Bucy 1995; Noort, Benner et al. 1996; Haeryfar, DiPaolo et al. 2005), and 
were shown to totally delete CD25+ cells in peripheral blood and significantly 
diminish the percentage of CD25+ in the spleen and LN for at least 10 days following 
the injection. 
 
 71 
2.11 TREG, CD4+, OR CD8+ PURIFICATION AND FLOW CYTOMETRIC ANALYSIS 
 
Single-cell suspensions were obtained from the spleens of naïve or vaccinated mice. 
CD4+ cells were negatively selected and fractionated into CD4+CD25low and 
CD4+CD25high subsets by magnetic antibody cell sorting (MACS, Miltenyi Biotech, 
Germany), using PE-labeled anti-CD25 mAb followed by anti-PE microbeads, 
according to the manufacturer’s instructions. The purity of cells was confirmed by 
FACS analysis, and > 90% of the cells were shown to be either CD25low or CD25high. 
CD4+ or CD8+ subsets were selected positively by anti-CD4 or anti-CD8 microbeads 
according to the manufacturer’s instruction (MACS, Miltenyi Biotech, Germany). 
Enriched CD4+ and CD8+ subset purity was analysed by flow cytometry. 
 
2.12 ELISPOT ASSAYS 
 
Ninety-six-well ELISpot plates (Millipore) were coated with 100 μl/well of 15 μg/mL 
purified anti-mouse IFN-γ mAb (BD Bioscience) overnight at 4°C. Plates were 
washed 5 times with PBS before addition of 8X105 splenocytes in triplicate wells and 
10 μM of peptide. Concanavalin A was used as a positive control. After 20 h 
incubation at 370C in 5% C02, plates were developed by incubating with 50 μL per 
well of biotinylated anti-IFN (BD Biosciences) at 1g/mL in PBS for 2h at 37°C. 
Streptavidine alkaline phosphotase (100 μL) (Caltag, UK) was added to each well 
after 5 washes and incubated for 1 h at RT. The plate was developed using 100 μL of 
alkaline phosphatase conjugate substrate (BioRad). Spots were counted by an 
automated ELISpot reader and a response was considered positive when spot 
numbers in triplicate assays in the presence of the specific peptide significantly 
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exceeded the cutoff value, corresponding to the number of non specific spots in the 
presence of irrelevant peptide. 
 
2.13 LYMPHOCYTE PROLIFERATION ASSAY 
 
Splenocytes from 2 bacteria-vaccinated mice of each group (E. coli, E. coli WT1, and 
E. coli LLO/WT1) were used as responder cells (2x105 cells/well) and mixed with 
irradiated splenocytes as feeder cells from naïve mice (2x105 cells/well). These cells 
were stimulated with various peptides (20 μM with/without Interleukin-2), which were 
selected from previous ELISpot screening of whole WT1 peptide library. The plates 
were incubated at 37°C in 5% CO2 for 72 hours and pulsed with 1 μCi/well of 3H-
Thymidine (Amersham Biosciences). The radioactivity incorporated into DNA, which 
correlates with the cell proliferation, was measured in a liquid scintillation counter 
after harvesting the cell cultures onto the glass fiber filters 18 hours after adding 3H-
Thymidine. All assessments of proliferative responses were carried out at least in six 
replicate, and the results corresponded to the mean values. 
For proliferatory/regulatory assays, 105 CD4+CD25high regulatory cells or 
CD4+CD25low responder cells or both were cultured in RPMI medium containing 10 
% FCS, 50 μM 2-mercaptoethanol with 0.5 μg/mL anti-CD3 Ab (purified anti-CD3, 
Pharmingen) in the presence of 2x105 naïve irradiated splenocytes. The cells were 
cultured for 5 days and proliferation was measured by adding 1μCi of 3H-Thymidine 
(Amersham, UK) to each well for the last 18hr of the culture period. The cells were 
harvested and the 3H-Thymidine incorporation was determined. The suppression of 
Tconv proliferation by Treg (% inhibition) is calculated as [Proliferation (Tconv only) - 
Proliferation (Treg+Tconv)] x 100% / Proliferation (Tconv only). 
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2.14 RNA EXTRACTION AND REVERSE TRANSCRIPTION-POLYMERASE 
CHAIN REACTION  
 
Total cellular RNA was prepared from 107 cells in TRIzol reagent (Invitrogen, 
Carlsbad, CA). Following chloroform extraction, total RNA was precipitated in 
isopropanol, washed with ethanol, suspended in an RNase-free solution by RNeasy 
Mini kit (Qiagen), and stored at −80°C until used for cDNA synthesis. Total RNA was 
quantified spectrophotometrically based on an absorbance at 260 nm of one equal to 
an RNA concentration of 40 μg/mL. 
RNA was converted into cDNA with RT-PCR kit (Taq Man Reverse Transcription 
Agent, Applied Biosystems). RNA integrity was verified by RNA 6000 Nano LabChip 
(Agilent Technologies) and quantified by a spectrophotometer according to the 
absorbance at 260 nm and 280 nm. Up to 2 µg of total RNA were processed in 30 µL 
volume, with 94 u MultiScribe™ Reverse Transcriptase (Applied Biosystems) using 
random hexamer primers. In brief, 1µg of total RNA was mixed with 1.5 µL random 
hexamer primers (50 µM), 6 µL deoxynucleotide mix (2.5 mM), 3 µL Taq Man RT 
buffer (10X), 6.6 µL MgCl2 (25 mM), and 0.6 µL RNase inhibitor (20 u/L). The RT 
programme was set as: 25°C for 10 min, 37 °C for 60 min, 95°C for 5 min for heat 
inactivation, and finally stopped at 4°C.  
    For standard curves, a 10-fold serial dilution of RNA of the human leukaemic cell 
line K562 was performed in DEPC-treated water, ranging from 1X10-1 to 1X10-5.  
Every dilution step was processed in duplicate and all samples were tested in 
triplicate.  
 Real-time quantitative PCR was performed using the ABI Prism 7500 detection 
system (Applied Biosystems) with SYBR® Green RT-PCR Reagents. The cDNA was 
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serially diluted and WT1 mRNA was amplified using the appropriate oligonucleotide 
primers by PCR for 50 cycles in PCR machine. Primer for WT1 was: sense, 5’-TAC 
CCA GGC TGC AAT AAG AGA TAT TTT AAG-3’, antisense, 5’-CCT TGG GTG 
TCTTTT GAG CTG GTC-3’. The reaction was performed in 20 µL volume. For each 
reaction, cDNA (equivalent of 100 ng RNA) was processed to detect WT1 expression. 
The concentration of forward and reverse primers was 750 nM. The cycler 
programme consisted of an initial 94°C step for 3 min followed by denaturation at 
72°C for 10 min, The q-PCR includes further 50 cycles with one denaturation (94°C, 
45 s), annealing step (56°C, 45 s), and 72°C, 60 s. The expected size for the WT1 
PCR product was 147 bp. To assure that the PCR products were not being assayed 
on the plateau of the amplification curve, all cDNA samples were amplified at three 
10-fold dilutions. This procedure allowed quantitative comparisons to be made of the 
levels of cDNA present in different samples.  
 
2.15 MEASUREMENT OF BINDING STABILITY OF WT1 PEPTIDES FOR MHC 
CLASS-I   MOLECULES (H2-Db/Kb) 
 
The ability of synthetic WT1 peptides to bind to H2-Db or H2-Kb class I molecules 
was detected by using the leukaemia cell line RMA-S, as described previously 
(Ljunggren, Stam et al. 1990). In brief, RMA-S cells were cultured for 12 hours at 
26°C in complete RPMI supplemented with 10% FCS. A total of 106 RMA-S cells 
were added to each well of a 96-well plate and incubated either alone or with the 
designated peptide (100 µM) for 2 hours at 37°C. Cells were then washed once and 
stained with fluorescein isothiocyanate (FITC)-conjugated anti-Db or anti-Kb antibody 
(Pharmingen, San Diego, CA). Labeled cells were washed twice, resuspended, and 
fixed in 500 µL phosphate-buffered saline with 1% paraformaldehyde and were 
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analyzed for fluorescence intensity in a flow cytometer (FACScalibur; Becton 
Dickinson). The percentage of increase of Db or Kb molecules on the surface of the 
RMA-S cells was measured by increased mean fluorescence intensity of cells 
incubated with peptide compared with that of cells incubated in medium alone or 
OVA257-264 peptide, SIINFEKL. 
 
2.16 ANALYSIS OF THE ANTIBODY RESPONSE IN WT1 VACCINATED 
ANIMALS 
 
The recombinant WT1 protein (Santa Cruz Biotechnologies) 1.5 μg per lane was 
resolved on a 10% SDS-PAGE and transferred to a nitrocellulose membrane 
(Amersham, UK) by semi-dry transfer. The membrane was then blocked in PBS 
containing 0.01% Tween 20 and 5% nonfat dry milk overnight at 4°C and incubated 
first with serum from vaccinated mice (1:100 in blocking solution) for 2 hours at room 
temperature and then with HRP-conjugated rabbit anti-mouse immunoglobulin 
(1:2000 in blocking solution) for 1 hour at room temperature. The signal was revealed 
by incubating the membrane with ECL detection agent (Amersham) according to the 
manufacturer's instructions. 
 
2.17 TREG RNA MICROARRAY ANALYSES 
 
2.17.1 Total RNA extraction 
 
Total RNA was extracted from purified CD4+CD25+ cells (~106 cells in each group) 
using Qiagen RNeasy micro-columns according to the manufacturer's protocol. RNA 
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yields were determined spectrophotometrically at 260 nm and RNA integrity checked 
by capillary electrophoresis using an Agilent 2100 bioanalyzer (Agilent, South 
Queensferry, UK). 
 
2.17.2 Production of fragmented labeled cRNA and Array hybridisation 
 
First-strand cDNA was synthesised from 1 µg total RNA by incubation (42°C, 1 hr) in 
a 20-µL reaction volume containing 2.5 mM T7-(dT)24 primer, 50 mM Tris-HCl pH 
8.3, 75 mM KCL, 3 mM MgCl2, 10 mM DTT and 500 mM dNTP, 10 U/µL Superscript 
II reverse transcriptase (Invitrogen, Carlsbad, CA). Second-strand cDNA was 
synthesized directly by adding 91 µL RNase-free water, 30 µL 5 times second-strand 
reaction buffer (Invitrogen), 3 µL 10 mM dNTP, 1 µL Escherichia coli DNA ligase (10 
U/µL), 4 µL E. coli DNA polymerase I (10 U/µL), 1 µL E. coli RNase H (2 U/µL) 
followed by incubation (2 hr, 16°C). The ends of the double-stranded cDNA were 
polished using T4 DNA polymerase (20 U, 5 min, 16°C). The cDNA was purified and 
concentrated by phenol/chloroform extraction and ethanol precipitation. 
Generation of biotin-labeled RNA was accomplished by in-vitro transcription with 
the T7 RNA polymerase using the IVT kit (Affymetrix). Biotin-labeled cRNA was 
subsequently purified from the transcription reaction using the RNeasy system 
(Qiagen, Hilden, Germany). Hybridisation of biotin-labeled cRNA to GeneChip Mouse 
Genome 430 2.0 Array, washing, staining, and scanning were performed according 
to the protocols published by the manufacturer (Affymetrix). The GeneChip Mouse 
Genome 430 2.0 Array comprises more than 40,000 transcripts on a single array 
probe set. 
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2.17.3 Data processing 
 
Samples were profiled using the Affymetrix Mouse Genome 430 2.0 Array. Data were 
analysed using Bioconductor (http://www.bioconductor.org/) packages within the 
open source R statistical environment (www.r-project.org). We used the QC metrics 
recommended by Affymetrix and the probe level models as well as boxplots and 
intensity histograms for quality assessment. After background correction and 
normalisation by robust multi-array analysis (RMA), we applied a filter using the 
standard deviation (SD) of gene expression values to select the top 6000 genes on 
the array. We used Limma (Wettenhall and Smyth 2004) for differential expression 
analysis. Briefly, Limma fit a linear model to the expression data for each probe. 
Empirical Bayes is used to obtain information across genes making the analyses 
stable even for experiments with small number of arrays. We set a double cutoff of 
false discovery rate (FDR) < 0.05 and a fold change ≥ 2.   
 
 
2.17.4 Meta-analysis 
 
With the assistance from Dr. Claude Chelala, we performed a meta-analysis using 
the raw data from Gene Expression Omnibus data 
http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSM44980. We applied 
the same analysis pipeline described above. 
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2.17.5 Verification of the expression patterns for the selected genes by RT-PCR 
 
RNA was converted into cDNA with RT kit (Taq Man Reverse Transcription Agent, 
Applied Biosystems) as described in 2.13. The cDNA quantity of both samples (E. 
coli and E. coli-LLO) was adjusted by housekeeping genes (6S and GAPDH). 
Selected genes were amplified using the appropriate oligonucleotide primers by 
polymerase chain reaction (PCR) for 30 cycles in a Mendel PCR machine (Gene 
Legends Ltd, Ringmer, UK) in the thermal programme of: initial 94ºC-3 min, followed 
by 30 cycles of 94ºC-30 sec, 60ºC-45 sec, and 68ºC-45 sec, then final denaturation 
68ºC-7min. Specific amplified DNA products were migrated on ethidium bromide-
containing agarose gel and visualised under UV light.  
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Table 4.  List of primers for RT-PCR verification  
 
Gene  Forward Primer Reverse Primer 
S100 A8 NM_013650 GGAAATCACCATGCCCTCTA TGGCTGTCTTTGTGAGATGC 
S100 A9 NM_009114 TCATCGACACCTTCCATCAA GTCCTGGTTTGTGTCCAGGT 
Lipocalin-2 X14607 GCCTCAAGGACGACAACATCAT GGCTCTCTGGCAACAGGAAAG 
NGP NM_008694 CCACTCCGCCTTCTAGTCAG AGGTCAAGGTCAGGGAGGTT 
CCR1 AV231648 GTTGGGACCTTGAACCTTGA CCCAAAGGCTCTTACAGCAG 
TGFβi NM_009369 TGATAAGAGGGGACGGTTTG ATTGGTGGGAGCAAAAACAG 
IL1β NM_008361 GCCCATCCTCTGTGACTCAT AGGCCACAGGTATTTTGTCG 
IL17 NM_010552 TCCAGAAGGCCCTCAGACTA AGCATCTTCTCGACCCTGAA 
CXCL2 NM_009140 AAGTTTGCCTTGACCCTGAA AGGCACATCAGGTACGATCC 
IL-22 NM_016971 ATACATCGTCAACCGCACCTTT AGCCGGACATCTGTGTTGTTAT 
IL-10 NM_010548 CCAAGCCTTATCGGAAATGA TTTTCACAGGGGAGAAATCG 
Amphiregulin NM_009704 GACTCACAGCGAGGATGACA GGCTTGGCAATGATTCAACT 
Foxp3 NM_054039 CACCCAGGAAAGACAGCAACC GCAAGAGCTCTTGTCCATTGA 
RORγt NM_011281 GCGGAGCAGACACACTTACA TTGGCAAACTCCACCACATA 
STAT3 NM_213659 GAAGACCAAGTTCATCTGTGTG GTAGCACACTCCGAGGTCAGAT 
STAT4 NM_011487 CATCCCTGAAAACCCTCTGA GACATGGGGAGAAGGTCTGA 
STAT6 NM_009284 TGGCCACCATCAGACAAATA ACCAGGACCATTGACAGGAG 
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2.18 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using the GraphPad InStat software program 
(GraphPad Prism version 5.0). Differences in the tumour protection effect among 
various groups were evaluated by one-way ANOVA and Tukey test for multiple 
comparisons. Dual comparisons were made using the paired Student’s t test, and p< 
0.05 was considered statistically significant. Differences in the survival of mice were 
analysed using the Kaplan-Meier method, and groups were compared using the Log-
rank (Mantel-Cox) test. 
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CHAPTER 3:  MECHANISTICAL STUDY OF THE EFFECTS OF THE E. 
COLI-LLO VACCINE 
 
3.1 INTRODUCTION  
 
Previous in-vitro experiments demonstrated that subcutaneous injection of E. coli-LLO 
expressing OVA antigen (E. coli-LLO/OVA) could trigger a very strong anti-tumour 
response against the highly aggressive B16-OVA melanoma cell line (Radford, Higgins 
et al. 2002), far superior to that of vaccination using E. coli expressing OVA only (E. coli-
OVA). Considering that improved MHC class I presentation of antigenic peptides is 
unlikely to be the sole mechanism responsible for the striking difference in efficacy 
between E. coli-OVA or E. coli-LLO/OVA vaccines, I wanted to see if CD8+ T cells are 
indispensable in tumour eradication. It is crucial to determine how the additional LLO co-
expressed within the bacteria can help a marginally-active vaccine (E. coli-OVA) to turn 
into a potent anti-tumour one (E. coli-LLO/OVA). 
In the study by Gunn GR et al (Gunn, Zubair et al. 2001) with the LLO-antigen (HPV-
16 E7 protein) fusion protein secreted by L. monocytogenes (Lm-LLO-E7), the 
immunotherapeutic effect could be abrogated by transfer of CD4+ cells from Lm-E7-
immunised mice. In addition, the in-vivo tumour protection effect was dramatically 
increased upon CD4+ or CD25+ depletion.  Regulatory T cells (Treg), usually defined 
by the expression of CD4 and CD25 in natural Treg, seem particularly to be 
particularly adept at controlling immune responses to self antigens as well as 
pathogens. Therefore, I also aimed to determine the impact of LLO-based bacterial 
vaccine on immune regulation system and the effect of CD25 depletion.  
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3.2 RESULTS  
 
3.2.1 H2-Kd-Pentamer Analysis 
 
To determine the number of OVA specific CTLs, a commercially-available pentamer 
was used. Animals were given two or three s.c. injections of 108 paraformaldehyde-
fixed E. coli, E. coli-LLO, E. coli-OVA, or E. coli-LLO/OVA or PBS, and enumeration 
of OVA-specific CD8+ T lymphocytes was performed by FACS 1 week after the last 
injection. Plots depicting percentages of CD8+, pentamer-positive cells gated on live 
lymphocytes are shown in Figure 4. Mice receiving E. coli-OVA vaccines showed  a 
small, but non-significant increase of SIINFEKL/H2-Kb specific CD8+ T lymphocytes 
above the background levels observed in E. coli, E. coli-LLO, or PBS-vaccinated 
animals (1±0.2 vs 0.5±0.2% of total splenocytes, respectively). By contrast, E. coli-
LLO/OVA-vaccinated mice induced significant levels of SIINFEKL/H2-Kb-specific 
CD8+ T cells. The highest percentage and absolute numbers (4% of total splenocytes, 
3.8±1.2 x106 cells) was achieved following one boost injection of E. coli-LLO/OVA 
(Figures 4 and 5). As it has been shown that LLO induces apoptosis of infected cells 
and activated lymphocytes (Carrero, Calderon et al. 2006), it is likely that multiple 
boosts may lead to the death of these cells, altering the response. Thus, vaccines 
combining LLO and OVA allow the activation of OVA-specific CD8+ T cells, 
confirming the previously-reported (Radford, Higgins et al. 2002) importance of the 
incorporation of LLO in the bacterial vaccine. 
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Figure 4.  E. coli-LLO/OVA vaccination allows the activation of OVA-specific CD8+T 
cells as measured by multimeric MHC-peptide analyses. Mice received two 
immunisations of bacteria at a 1-week interval. Splenocytes were collected 7 days after the 
last injection and stained with the CD8-FITC and SIINFEKL/H-2Kb pentamers-PE 
(ProImmune Ltd, UK). Representative experiments depicting percentages of CD8+, 
pentamer-positive cells gated on live lymphocytes are shown. 
 
 
 
 
Figure 5. The absolute numbers of SIINFEKL/H-2Kb-specific T cells in the spleen. Mice 
received several immunisations of bacteria at 1-week intervals. Splenocytes were collected 7 
days after the last injection and stained with the CD8-FITC and SIINFEKL/H-2Kb pentamers-
PE (ProImmune Ltd, UK) on the live cells (50,000 events) to determine the percentage. The 
absolute numbers of CD8-Pentamer cells in each mouse were obtained from total splenocyte 
numbers multiplied by the percentage determined by FACS (mean ± SD); one or two boost 
injections are shown. *** p < 0.001. 
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3.2.2 Specific cytotoxicity 
 
Because OVA-specific CD8+ T cells expressing the immunodominant T cell epitope 
OVA257-264 SIINFEKL are clearly critical to the anti-tumour effect leading to the in-vivo 
rejection of B16-OVA tumour (Bellone, Cantarella et al. 2000; Radford, Higgins et al. 
2002), the presence of CTLs specific for SIINFEKL was tested in mice in a 
prophylactic vaccination setting. To characterise the specificity of the cytotoxic 
responses, splenocytes from vaccinated mice were re-stimulated in vitro with 
SIINFEKL-loaded LPS-activated splenocytes and specific cytotoxicity was measured 
6 days later using SIINFEKL-loaded RMA-S and B16-OVA cells as targets. The 
results are summarised in Figure 6. Splenocytes from E. coli-LLO/OVA-vaccinated 
animals showed a strong response against SIINFEKL-loaded RMA-S cells and B16-
OVA tumour cells (>75% killing at the highest effector to target ratio), suggesting that 
the CTLs are OVA-specific. By contrast, relatively weak CTL responses against 
SIINFEKL-loaded RMA-S cells and B16-OVA tumours (< 25% killing at the highest 
effector to target ratio) were detected in splenocyte cultures from E. coli-OVA 
vaccinated mice, and no cytotoxic activity was found in splenocyte cultures from E. 
coli or E. coli-LLO control mice.  
 
 
Figure 6. E. coli-LLO/OVA vaccination generated specific CTL responses. C57BL/6 
mice received two s.c. injections of bacteria at a 1-week interval. Splenocytes prepared from 
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spleens collected 1 week later were restimulated in vitro with LPS-stimulated spleen cells 
loaded with the OVA-restricted class I SIINFEKL peptide. Cytotoxicity was measured 6 days 
later by 51Cr-release assay against SIINFEKL (■) or irrelevant peptide-loaded RMA-S (□) 
cells as well as B16-OVA (△) and the parental B16 tumour cell lines (▼). Results from 
individual mice are plotted against the E:T ratio, and are representative of two experiments.  
 
3.2.3 Tumour Protection Effect 
 
3.2.3.1 Subcutaneous tumour implantation 
 
The next step was to determine whether the specific CTLs observed in vitro would 
provide anti-tumour activity. Mice were first immunised with different bacteria (E. coli, 
E. coli-OVA, E. coli-LLO/OVA), twice with one week intervals and challenged with 
B16-OVA cells one week after the last bacterial injection. Figure 7 shows that E. coli-
LLO/OVA caused a significant tumour inhibition compared to the other groups.  
 
 
Figure 7.  E. coli-LLO/OVA vaccine inhibits subcutaneous tumour growth. C57BL/6 
mice were given two s.c. injections of bacteria at a 1-week interval, then were challenged a 
week after the boost injection by s.c. implantation of 106 B16-OVA cells. Tumour volume was 
assessed 3 weeks after tumour challenge by the maximal 2-dimension measurement and 
expressed in mm2. Results are expressed as mean  SD. ** p<0.01 
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3.2.3.2 Mimicking metastasis 
 
To examine the ability of the vaccines to control the tumour in a metastasis-
mimicking model, animals received two injections of each of the E. coli vaccines at 
one week intervals followed by intravenous challenge of 5X105 B16-OVA cells. In this 
model, B16-OVA cells target to the lungs where the cells form multiple tumour 
nodules in lung parenchyma. When the first mice started to show signs of sickness 
(typically 24-26 days following B16-OVA cells injection), the whole cohort was culled 
and the tumour-load was accessed by counting tumour nodules in the lungs (100 
nodules as maximum).  
    Figure 8 shows that the lungs of animals vaccinated with E. coli or E. coli-LLO 
were intensely infiltrated by metastatic tumours (82±11 and 86±12 nodules, 
respectively). The burden was modestly but significantly reduced in mice vaccinated 
with E. coli-OVA (60 ± 12 per set of lungs, p = 0.01 vs E. coli) and dramatically 
reduced in E. coli-LLO/OVA-vaccinated animals (5 ± 2, p <0.0001 vs. E. coli-LLO).  
The efficacy of the recombinant E. coli vaccines on tumour development was next 
assessed in a therapeutic setting. Mice challenged with 5X105 B16-OVA cells were 
treated with s.c. injections of the various bacteria 8 and 15 days later. As for the 
vaccination protocol, treatment with E. coli or E. coli-LLO did not affect the tumour 
load compared to PBS-vaccinated animals, treatment with E. coli-OVA led to a 
modest but statistically significant reduction in the tumour burden and treatment with 
E. coli-LLO/OVA dramatically reduced the tumour load (Figure 8). 
Importantly, none of these effects were observed upon challenge with parental 
B16 cells (which had been previously performed by Dr. Nitcheu-Tefit), demonstrating 
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that E. coli-LLO/OVA vaccine resulted in the establishment of an appropriate 
adaptive OVA-specific immune response.  
 
                 E. coli                                       E.coli-OVA                              E. coli-LLO/OVA 
 
 
Figure 8.  E. coli-LLO/OVA vaccine inhibits lungs metastasis induced by tail vein 
injection of B16-OVA cells. (A) C57BL/6 mice were given two s.c. injections of bacteria at a 
1-week interval, then were challenged a week after the boost injection by tail-vein injection of 
5 x 105 B16/OVA cells. Animals were sacrificed when the first mouse showed signs of 
disease (typically 24–28 days following tumour challenge) and the tumour growth was 
assessed by counting tumour nodules in the lungs. (B) C57BL/6 mice were first injected by 
tail-vein injection of 5 x 105 B16/OVA cells and given two s.c. injections of bacteria on Day 8 
and 15. Animals were sacrificed when the first mouse showed signs of disease (typically 24–
28 days following tumour challenge) and the tumour growth was assessed by counting 
tumour nodules in the lungs. Results are expressed as mean ± SD. The experiments 
presented are representative of at least two experiments involving six animals per group. *, p 
< 0.05; ***, p < 0.001. (Lower panel) Excised lung specimens were obtained from E. coli-, E. 
coli-OVA-, and E. coli-LLO/OVA-vaccinated mice, which clearly demonstrated the effects of 
tumour metastasis by E. coli-LLO/OVA vaccine.  
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3.2.4 CD8-mediated Cytokine Responses upon Bacterial Vaccination 
 
The cytokine responses to different bacterial vaccines in the sera were analysed by 
ELISpot and ELISA. The IFN-γ ELISpot demonstrated that E. coli-LLO/OVA 
vaccination could largely enhance CD8-mediated reponses compared to E. coli, E. 
coli-LLO, and E. coli-OVA (Figure 9).  (250 ± 84 spots/well vs 48 ± 8 or 80 ± 16 
spots/well in E. coli and E. coli-OVA vaccinated animals, respectively; p = 0.004). 
 
             
 
Figure 9. IFN-γ ELISpot responses in immunised mice. Mice received two s.c. injections 
of bacteria at a 1-week interval. Splenocytes were collected after the boost injection and 
incubated overnight with the SIINFEKL peptide, and ELISpot assay was used to measure 
IFN-γ secretion. Results are expressed as mean ± SD. Splenocytes from mice that received 
vaccines coexpressing LLO and OVA induced a significant strong response (**, p = 0.0043). 
The experiments presented are representative of two separate experiments involving three 
animals per group. (Lower panel) Representative plates from ELISpot assay. 
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Sera were collected one week after the boost vaccination, in SIINFEKL-stimulated 
splenocytes cultures (from spleens collected one week after the boost vaccination), 
and in BMDCs cultures activated by the various E. coli, as described in materials and 
methods. Results are summarised in Table 5. IL-2, IL-4, IL-10 and IFN-γ serum 
levels, analysed by ELISA, were just above the threshold of detection and not 
significantly different between any of the animals given the E. coli vaccines. IFN-γ 
levels were significantly lower in splenocyte cultures from animals that received the E. 
coli-OVA vaccines as compared to animals that received E. coli-LLO/OVA vaccines 
(450±14 vs. 841± 102 pg/ml). The same trend was found in BMDCs cultures that 
were activated by E. coli and E. coli-OVA as compare to BMDCs cultures that were 
activated by E. coli-LLO and E. coli-LLO/OVA, while the inverse correlation was 
observed for IL-10 production. Altogether, these data indicate that E. coli-LLO/OVA 
vaccine is more potent in stimulating CD8-mediated cytokine responses. 
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Table 5. CD8-mediated cytokine responses in the sera of immunised animals.  
a Mice received two vaccinations of 108 E. coli, E. coli-LLO, E. coli-OVA, or E. coli-LLO/OVA 
at a 1-week interval. Sera were collected 1 week after the boost injection and were analysed 
for cytokine production by ELISA. The experiments presented are representative of two 
separate experiments involving six animals per group.  
b BMDCs were pre-activated with different bacteria as described in Materials and Methods 
then cultured for 48 h before being assayed for cytokine production. The experiments 
presented are representative of two separate experiments. ***, p < 0.001, E. coli-OVA vs. E. 
coli-LLO/OVA.  
c Mice received two injections of 108 E. coli, E. coli-LLO, E. coli-OVA, or E. coli-LLO/OVA at a 
1-week interval. Single-cell suspensions were prepared from the spleens collected 1 week 
after the boost injection. Splenocytes were left unstimulated or were restimulated in vitro for 3 
days with the SIINFEKL peptide before being assayed for cytokine production. The 
experiments presented are representative of two separate experiments involving three 
animals per group. ***, p < 0.001 E. coli-OVA vs. E. coli-LLO/OVA. 
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3.2.5  Antibody Depletion Study 
 
Depletion of CD4+ or CD25+ T cells in E. coli-OVA vaccinated animals allows the 
establishment of CD8+ T cell-mediated tumour-protective immune responses  
 
To assess the relative contribution of T cell subsets in tumour protection, CD8+ as 
well as CD4+ and CD25+ cells were depleted in vivo (Figure 10) in the vaccination 
model. CD4 depletion was carried out 5 days before and 10 days after the first 
bacterial injection by intraperitoneal injections of the GK1.5 mAb. CD8 depletion 
experiments were conducted using intraperitoneal injections of the YTS169.4 mAb 
(on days 5 and 10 after the first vaccination).  
 
 
Figure 10. Schematic representation of the specific Ab depletion in bacterial immunisation. 
CD4 or CD25 depletion in vivo was started before the first immunisation (at the T-cell priming 
stage) and CD8 depletion was performed after the first immunisation (at the effector stage). 
 
CD8 depletion abolished the protection in E. coli-LLO/OVA vaccinated animals 
as well as the modest but significant protection observed upon E. coli-OVA 
vaccination, demonstrating the indispensable role of CD8+ T cells in tumour 
protection (Figure 11). Depletion of CD4+ T cells at the stage of T cell priming had no 
impact on E. coli-LLO/OVA vaccination, suggesting that CD8+ T cell priming in vivo 
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can occur in the absence of CD4+ T cell help. However, CD4 depletion unexpectedly 
turned E. coli-OVA into a vaccine as effective as E. coli-LLO/OVA suggesting that a 
subset of CD4+ cells inhibited the cells mediating the anti-tumour response. Moreover, 
mice receiving combined treatments with depleting antibodies against CD4 and CD8 
showed progressive tumour growth, confirming that the anti-tumour activity 
unmasked by CD4+ T cell depletion is dependent on the presence of CD8+ T cells 
(Figure 11). 
I next attempted to characterise the CD4 subset inhibiting the CD8 response. NK 
cells depleted with PK136 antibodies allowed us to exclude the possibility of any 
regulation by NK or NKT cells (Dr. J Nitcheu-Tefit). CD4+CD25high Treg have been 
shown to enhance tumour growth by regulating cells mediating tumour immuno-
surveillance (Sakaguchi 2004). Treg may therefore exert suppressor functions 
following E. coli-OVA vaccination. To assess the involvement of these cells, mice 
were depleted of CD25 cells by i.p. administration of the PC61 mAb (anti-CD25) one 
day before bacterial vaccination and the tumours were inoculated one week after the 
boost vaccination. The tumour burden in different conditions is presented in Figure 
11. When compared to depletion using an irrelevant control mAb (RatIGg1), CD25 
depletion had no statistically significant effect on the number of tumour nodules in 
mice vaccinated either with E. coli or E. coli-LLO/OVA. By contrast, this depletion 
resulted in a dramatic, statistically significant reduction in the tumour load in E. coli-
OVA-vaccinated animals (p<0.001 compare to control Ab-treated mice), turning E. 
coli-OVA into a vaccine as potent as E. coli-LLO/OVA. Interestingly, IFN-γ secretion, 
as measured by ELISpot analysis, was restored in mice that received E. coli-OVA 
vaccines and that were depleted of CD4+ or CD25+ cells (Figure 13). Splenocytes 
from Ab-treated controls stimulated low IFN-γ secretion (50 ± 16 spots/well) that was 
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boosted by CD4 depletion (400± 250 spots/well, p = 0.002) or by CD25 depletion 
(175 ± 90 spots/well, p = 0.001) (Figure 13). These data strongly suggest that E. coli-
OVA vaccines induce OVA-specific CD8+ T cells that are necessary for the anti-
tumour effect but that Treg cells prevent their expansion and effector function. 
 
 
Figure 11. CD8+ T cells are the key mediators for tumour protection and CD4+ cell 
depletion enhanced anti-tumour effect in mice receiving the E. coli-OVA vaccines. a. 
Mice received two s.c. injections of bacteria on days 0 and 7. Depletions were conducted by 
i.p. injection of GK1.5-depleting mAb (anti CD4) at the stage of T cell priming (on days –5 
and 10) in combination or not with i.p. injections of YTS169.4 (anti-CD8) on days 10 and 17. 
As a control, an irrelevant mAb control (PYLT-1) was used. Mice were challenged on day 14 
by tail-vein injection of 5 x 105 B16-OVA cells and sacrificed when the first mouse showed 
signs of disease (typically 24–28 days following tumour challenge), then the tumour load was 
assessed in the lungs. Results are expressed as mean ± SD. The experiments presented are 
representative of two experiments involving six animals per groups;  ***, p < 0.001.  
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Figure 12. CD25+ cells depletion effects. Depletion of CD25+ cells was conducted by i.p. 
injection of the PC61 mAb on day -1 before s.c. bacterial vaccinations on days 0 and 7. As a 
control, an irrelevant mAb (RatIGg1) was used. Mice were challenged on day 14 by tail-vein 
injection of 5 x 105 B16/OVA cells and sacrificed when the first mouse showed signs of 
disease (typically 24–28 days following tumour challenge), then the tumour load was 
assessed in the lungs. Results are expressed as mean ± SD. The experiments presented are 
representative of two experiments involving six animals per groups. ***, p < 0.001.  
 
 
Figure 13. IFN-γ ELISpot responses following CD4+/CD25+ depletion. Depletion of CD4+ 
or CD25+ cells was conducted as previously described, then splenocytes, from E. coli-OVA-
immunised mice, harvested 1 week after the boost injection were incubated overnight with 
the SIINFEKL peptide. ELISpot assay was used to measure INF-γ secretion. The 
experiments presented are representative of three experiments involving three animals per 
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groups. Results are expressed as mean ± SD. **, p = 0.0016 (GK1.5 vs isotype Ab control 
treatment); **, p = 0.0023 (PC61 vs isotype control treatment). 
 
3.2.6 Analysis of Treg Prevalence and Phenotype 
 
In the experience of Gunn et al, the Listerial vaccine altered Treg prevalence and 
relocation to tumour microenvironment (Gunn, Zubair et al. 2001). To investigate 
whether LLO expression affects Treg expansion, we compared the prevalence of 
these cells in the spleen and draining lymph nodes close to the site of inoculation in 
vaccinated animals. No significantly different CD4+CD25high T cell allocation was 
found within the spleens and inguinal lymph nodes in all groups of mice, as assessed 
by FACS analysis, and Foxp3+ expression within this population was similar (80-
100%) (Table 6)  
    To further investigate whether LLO expression in the bacterial vaccine could affect 
the expansion of Treg, splenocytes from naïve mice were cultured with the various E. 
coli-activated BMDCs, used as APCs, and the kinetics of CD4+CD25high Treg 
appearance were established in the cultures. The level of expression of co-
stimulatory and MHC class I/II molecules on BMDCs were similar following activation 
with the various bacteria (Table 7).  
 
Table 6.  Treg prevalence in spleens and drainage LNs. Single-cell suspensions were 
prepared from the spleens and inguinal LNs collected 7 days after the boost injection then 
stained with the CD4+CD25+Foxp3+ Regulatory T Cell Staining kit (eBioscience). 
CD4+CD25High T cell frequencies and Foxp3 expression within this population as measured 
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by FACS analysis are shown. The data presented are representative of two separate 
experiments involving six animals per group.  
 
 
 
Table 7. Expression of costimulation molecules of activated BMDCs. BMDCs incubated 
with either E. coli-LLO/OVA or E. coli-OVA for 24h and the expression of surface molecules, 
CD40, CD80, CD86, and MHC class I and MHC class II complexes were analysed by FACS. 
 
CD4+CD25high T cells arising from the cultures increased over time, however no 
significant differences in the frequencies as well as in Foxp3 expression were 
noticeable between groups (Figures 14 and 15). From these results I concluded that 
LLO expression in the vaccine does not affect antigen-induced Treg expansion.  
 
 
Figure 14 and 15.   Induced Treg from bacteria-activated BMDCs. Splenocytes prepared 
from naive C57BL/6 mice were cultured with BMDCs that have been previously activated 
with E. coli, E. coli-LLO, E. coli-OVA, or E. coli-LLO/OVA. Cells were harvested at different 
time points then stained for CD4, CD25, and Foxp3 expression (eBioscience Treg Staining 
kit) before being analysed by FACS. The experiments presented are representative of two 
separate experiments. 
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3.2.7 Treg Functional Assay 
 
Since the prevalence and Foxp3 expression of Treg in spleens and drainage lymph 
nodes was not significantly affected by the E. coli-LLO vaccine, it was speculated 
that the immunosuppressive function of Treg had been changed. Therefore, an in-
vitro assay to assess the functionality of Treg was required to confirm the speculation. 
CD4+CD25high cells were separated by magnetic antibody cell sorting (MACS, 
Miltenyi Biotech, Germany) according to the manufacturer’s instructions. The purity of 
cells was confirmed by FACS analysis, and > 90% of the cells were shown to be 
either CD25low or CD25high (Figure 16). 
A  
                B                     
 
Figure 16. Purity of in vitro sorted Tconv and Treg cells. (A) Purified CD4+ cells: Tconv 
(CD4+CD25low) and Treg (CD4+CD25high) subsets, were stained with CD4-FITC and 
analysed on FACSCalibur (BD Biosciences). Both cell groups showed >90% purity upon 
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FACS analysis. (B) Most of the purified CD4+CD25high cells (>90%) positively expressed the 
master regulator of Treg functions, Foxp3. 
 
E. coli-LLO vaccination reduced the Treg suppression on Tconv proliferation 
 
To test their functionality, Treg were purified after the vaccination regimen and 
yielded a CD4+CD25high population that was more than 90% pure. I performed 
titration studies with different amounts of Treg mixed with their corresponding 
CD4+CD25low responders (Tconv) (105 per assay). Cultures were stimulated with a 
purified anti-CD3 monoclonal antibody. Treg from each of the vaccine systems did 
not proliferate upon TCR stimulation (not shown). In the mixed leukocyte reaction, 
Tconv proliferation from E. coli or E. coli OVA-vaccinated animals was gradually 
reduced according to Treg dosing, and > 50% inhibition was observed at a 
Tconv/Treg cells ratio of 1:1 (Figure 17). By contrast, inhibition of Tconv proliferation 
was dramatically reduced with Treg cells from E. coli-LLO or E. coli-LLO/OVA-
vaccinated mice (< 20% at the highest ratio).  
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Figure 17. Altered Treg suppression by E. coli-LLO vaccine. CD4+CD25+ T cells 
isolated from E. coli-OVA or E. coli-LLO/OVA-vaccinated animals induce different levels of 
suppression. Mice received two s.c. injections of E. coli, E. coli-LLO, E. coli-OVA, or E. coli-
LLO/OVA and splenocytes prepared from spleens harvested 7 days after the boost injection 
were separated into CD4+CD25+ and CD4+CD25– cells. In a MLR, CD4+CD25high (variable 
number) were cultured with CD4+CD25– (105) T cells for 4 days in the presence of 0.5 µg/ml 
anti-CD3 and 2 x 105 naive irradiated splenocytes. Proliferation of responders was measured 
by adding 3H-Thymidine for the last 18 h of culture period and inhibition of proliferation was 
determined. The experiments presented are representative of three independent 
experiments. ***, p < 0.001 E. coli vs E. coli-LLO and E. coli-OVA or E. coli-LLO/OVA.  
 
The susceptibility of Tconv was not altered  
 
To confirm that the observations were only due to a loss of Treg function, responder 
cells from E. coli-LLO-vaccinated animals were mixed with Treg from E. coli-
vaccinated animals and vice versa. The question was whether these reduced 
suppressions were attributable to suppressors or responders. Was the E. coli-LLO 
vaccine prone to activate the Tconv with resisting Treg effects? Therefore, I tested 
the Tconv proliferation capabilities from different vaccination strategies. Treg from E. 
coli-OVA vaccine system inhibited the proliferation of CD4+CD25low or CD8+ 
responders from E. coli-LLO/OVA system as effectively as they inhibited their 
corresponding responders (Figure 18), showing that the vaccine did not affect the 
susceptibility of Tconv to Treg suppression. Thus animals receiving E. coli-LLO or E. 
coli-LLO/OVA vaccines had reduced overall Treg function compared to Treg from 
mice receiving E. coli or E. coli-OVA vaccines, suggesting that LLO expression in the 
E. coli vaccines inhibits Treg function. 
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Figure 18. Unaltered Tconv susceptibility to Treg suppression. Mice received two s.c. 
injections of E. coli-OVA or E. coli-LLO/OVA and splenocytes prepared from spleens 
harvested 7 days after the boost injection were separated into CD4+CD25+ and CD4+CD25– 
cells. CD8+ T cells were also purified from E. coli-LLO/OVA-vaccinated animals. In a MLR, 
CD4+CD25+ (variable numbers) from E. coli-OVA were cultured with 105 of their 
corresponding responders (CD4+CD25– T cells) or responders from E. coli-LLO/OVA-
vaccinated animals (CD4+CD25– or CD8+ T cells) for 4 days in the presence of 0.5 µg/ml 
anti-CD3 and 2 x 105 naive irradiated splenocytes. Proliferation of responders was measured 
by adding 3H-Thymidine for the last 18 h of culture period and inhibition of proliferation was 
determined.  
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3.2.8 Suppressive Cytokine Profiles in Activated Treg  
 
Suppression by inhibitory cytokines is one of the proposed potential mechanisms 
related to Treg from a functional perspective. TGF-β and IL-10 are the key cytokines 
within this context. From the sera of vaccinated animals, there is no significant 
difference in the level of inhibitory cytokines (Table 5). However, the activated Treg 
from E. coli-LLO/OVA secreted higher levels of TGF-β and IL-10 than E. coli-OVA in 
response to anti-CD3+IL-2 stimulation in culture (Figures 19 and 20). 
 
 
Figures 19 and 20. Suppressive cytokines secreted by the activated Treg. CD4+CD25+ 
populations obtained from the spleens of E. coli-OVA- and E. coli-LLO/OVA- vaccinated mice 
were stimulated in culture with or with a combination of IL-2 (10 ng/ml) and anti-CD3 Ab (0.5 
μg/ml) for 5 days. TGF-β and IL-10 production were measured by ELISA (* p<0.05).  
 
 
3.3 CONCLUSION 
 
The results of this project showed that, following vaccination or treatment in mice, E. 
coli-LLO/OVA bacterial vaccine demonstrated remarkable levels of protection against 
OVA-expressing tumour cells. By contrast, E. coli-OVA showed rather poor 
protection. OVA-specific cytotoxic T lymphocytes were induced in E. coli-LLO/OVA 
vaccinated mice, and CD8+ depletion, but not NK cell depletion, completely abolished 
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the anti-tumour activity of the E. coli-LLO/OVA vaccine. Similarly to the results 
observed by Gunn et al (Gunn, Zubair et al. 2001), CD4+ depletion turned E. coli-
OVA into a vaccine as effective as E. coli-LLO/OVA and recovered the cytokine 
responses suggesting that a subset of CD4+ cells suppressed the CD8+ T cell-
mediated anti-tumour response. Subsequent data demonstrated that these 
suppressive cells consisted of CD4+CD25high Treg cells. I found that, although 
CD4+CD25high expansion and Foxp3 expression within this population was similar in 
vaccinated animals, Treg cells from E. coli-LLO/OVA vaccinated animals were 
unable to suppress conventional T cell (Tconv) proliferation. These findings provide 
the first evidence that LLO expression affects Treg cell function and may have 
important implications for enhancing anti-tumour vaccination strategies in humans. 
 
 103 
CHAPTER 4: EXPLORING THE TREG SUPPRESSION SIGNATURE BY 
MICROARRAY ANALYSES  
 
4.1 INTRODUCTION 
 
Treg cells control the delicate balance between immunity and tolerance, explaining 
their important role in autoimmune diseases, cancer, transplantation tolerance, and 
even allergy. In the field of immunotherapy, the correlation of treatment efficacy and 
the impact on Treg has been increasingly discussed. However, only a handful of 
publications has addressed this issue but none of them has proposed the mechanism 
of how the inhibitory nature of Treg is affected by the vaccine. From the results of 
Chapter 3 which show the effect of E. coli-LLO vaccine on Treg, I intended to identify 
the differences in inactive versus functional Treg. 
Microarrays have illustrated their potential to unravel gene expression of various 
subsets of leukocytes. There have been a few studies analysing gene expression in 
Treg (compared to other T cell groups) using microarrays (Pfoertner, Jeron et al. 
2006; Sfanos, Bruno et al. 2008), but none with comparison of differently-conditioned 
Treg. Our microarray analysis aimed at determining the difference in Treg gene 
expression under different immunisation conditions. 
 
4.2 EXPERIMENTAL SETTING 
 
Previous experiments in Chapter 3 have demonstrated that LLO-expressing E. coli 
vaccine can dampen Treg suppressive effects through functional reversal instead of 
reducing Treg prevalence (Nitcheu-Tefit, Dai et al. 2007). A comparative microarray 
analysis to screen the genome-wide mRNA expression difference between the 
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primary Treg from E. coli- and E. coli-LLO-immunised mice was initiated. Pooled 
splenocytes were harvested from 10 mice, which had received three bacterial 
vaccinations with one-week intervals (Figure 21). CD4+CD25High Treg were purified 
and total RNA (between 1.0 and 2.0 µg in each group) was extracted by Trizol and 
Chloroform as described in Chapter 2.  
 
 
Figure 21.  Schematic representation of the experiment setting for comparative 
microarray.  10 mice were immunised with 108/mouse E. coli or E. coli-LLO 3 times at 1-
week intervals. Total pooled splenocytes were harvested one week after the last vaccination 
and Treg/Tconv were separated by MACS (Miltenyi Biotech).  
 
To check the degree of functionality of the two Treg populations, simultaneous mixed 
Treg/Tconv proliferation assay was carried out when harvesting the splenocytes from 
immunised mice. The data showed that there is a significant difference of Treg 
suppression on Tconv proliferation between E. coli and E. coli-LLO-vaccinated group 
in various Tconv/Treg ratios (Figure 22). 
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Figures 22.  Simultaneous Treg suppression/proliferation assay. CD4+CD25+ T cells 
isolated from E. coli- or E. coli-LLO- vaccinated animals induce different levels of 
suppression. Mice received three s.c. injections of E. coli or E. coli-LLO and splenocytes 
were harvested 7 days after the last injection. All the pooled splenocytes were separated into 
CD4+CD25+ and CD4+CD25– cells. In a MLR, CD4+CD25+/High (variable number) were 
cultured with CD4+CD25– (105) T cells for 4 days in the presence of 0.5 µg/ml anti-CD3 and 2 
x 105 naive irradiated splenocytes as feeders. Proliferation of responders was measured by 
adding 3H-Thymidine for the last 18 h of culture period and inhibition of proliferation was 
determined. The experiments presented are representative of two independent experiments. 
**p <0.01, ***, p < 0.001, E. coli vs E. coli-LLO. 
 
4.3 RESULTS 
 
4.3.1 RNA Integrity 
 
The results of the Bioanalyser run are visualised in a gel image and an 
electropherogram (Figure 23) using the Agilent 2100 Bioanalyzer expert software. In 
addition to this visual control, the software allows the generation of a RNA Integrity 
Number (RIN) to check integrity and overall quality of total RNA samples. The RIN 
value is calculated by a proprietary algorithm that takes several QC parameters into 
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account, for example, 28S RNA/18S RNA peak area ratios and unexpected peaks in 
the 5S RNA region (Fleige and Pfaffl 2006). Here, both RNA samples (E. coli and E. 
coli-LLO) revealed RIN values between 9.3 and 9.6 and RNA yields between 1.7 μg 
and 2.5 μg. 
 
 
Figure 23.  Gel image (A) and electropherogram (B) of total RNA samples. As a reference, 
the RNA molecular weight ladder (in nucleotides, nt) is shown in the first lane. The lowest 
migrating green band represents an internal standard. The two prominent peaks within the 
electropherograms represent ribosomal RNA: left 18S RNA, right 28S RNA. Scaling of the y-
axis is done automatically, relative to the strongest signal within a single run.  
 
4.3.2 RNA Microarray GeneChip Analysis 
 
1 µg of total RNA sample in each group was used as starting material, reverse 
transcribed to cDNA and transcribed in vitro to cRNA. 15 µg of cRNA in adjusted 
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quantity was labeled with biotin, fragmented, and hybridised to AffymetrixTM 
GeneChip Mouse Genome 430 2.0 Array. The GeneChip Mouse Genome 430 2.0 
Array comprises more than 40,000 transcripts on a single array probe set. All the raw 
expression values in one genechip were plotted in a single figure. Red and green 
spots were indicative of expression differences.  2 repetitive analyses were carried 
out in the same experiment setting (Figure 24).  
 
 
Figure 24.   Scatter plot of signal intensities of all spots. The signal intensity of each spot 
represented by a dot is shown in double logarithmic scale. X-axis: log signal intensity from E. 
coli; Y-axis: log signal intensity from E. coli-LLO. Red/green spots define the areas of 2-fold 
differential signal intensities. Blue spots: unchanged genes. Each figure represents an 
separate microarray analysis. The first and second experiments were performed in the 
Institute of Cancer, Queen Mary University of London, and analysed by Bioconductor and R 
Statistical software (with the assistance of Dr. Claude Chelala). The data were plotted by 
GraphPad Prism  5.0. The third experiment was performed at the microarray technical 
platform, Université de Nantes, Faculté de Médecine, Nantes, France. The data were 
processed by Feature Extraction Software (FES) and Rosetta Resolver gene expression 
data analysis system (Rosetta Biosoftware) with the assistance of Dr. Bernhard Gerstmayer 
(Miltenyi Genomic Services). 
 
 
Data were analysed as described in the Data processing section (2.17.3) and 
compared to previously published data available from the GEO database (Fontenot, 
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Rasmussen et al. 2005) (RNA from CD4+CD25HighFoxp3+ cells as the naïve group, 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM44980).  
Regarding the functional impact and reversal of Treg suppression, my interests are 
focused on the genes which are related to inflammation, cytokines/chemokines, 
growth factors, transcriptional factors, and otherwise genes involved in immune 
regulation. A comprehensive literature review was also performed to see if these 
genes are involved in immune augmentation/tolerance. I focused on genes reported 
as significantly up- or down- regulated in two consecutive microarray analyses with 
literature-accessible evidence. Table 8 shows the genes I selected which could be 
responsible for the functional reversal of Treg (25 up-regulated and 13 down-
regulated genes).  
 
Table 8  List of differentially expressed genes in Non-functional Treg  
Upregulated Genes   
Inflammation-
associated genes 
S100 calcium binding protein A8 (Calgranulin 8) 
S100 calcium binding protein A9 (Calgranulin 9) 
Lipocalin-2 (LCN-2) 
Cathelicidin antimicrobial peptide (Camp) 
Secretory Leukocyte protease inhibitor (SLPI) 
 
Cytokine and 
chemokines genes 
IL-1β (IL1b) 
IL-17  
IL-22 
IL-10 
chemokine (C-C motif) receptor 1 (CCR1) 
chemokine (C-X-C motif) ligand 2 (CXCL2) 
transforming growth factor- beta induced (TGF-βi) 
 
Growth factor genes Amphiregulin (AmR)  
Surface marker/ protein 
/ receptor 
CD24a antigen (CD24a) 
Tumour necrosis factor receptor superfamily, member 
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13c (Tnfrsf13c, CD268)  
Membrane-spanning 4-domains subfamily A (Ms4a1) 
Neutrophic granular protein (NGP) 
Interferon induced transmembrane protein 6 (Ifitm6) 
Cytoplasmic protein / 
Metabolism 
Granzyme B (GzmB) 
Lactotransferrin (Ltf) 
Cathepsin H (Ctsh) 
 
Others  
Lysozyme (Lsz) 
Chitinase 3-like 3 (C3L3) 
Immunoglobulin heavy chain 6 (Igh6) 
B lymphoid kinase (BLK) 
 
Down regulated genes   
 
Tumour necrosis factor (alpha-induced protein 1) 
(Tnfaip1) 
Tumour necrosis factor superfamily, member 11 
(Tnfsf11, CD254) 
Heat shock protein 1a (Hspa1a) 
Prostaglandin E receptor 1 (subtype EP1) (Ptger1) 
Extracellular proteinase inhibitor (Expi) 
Apoptosis, caspase activation inhibitor (Aven) 
DAZ interacting protein 1 (Dzip) 
CD 28 antigen (CD28) 
Proteasome activator subunit 4 (Psme4) 
Basic transcription factor 3 (Btf3) 
src family associated phosphoprotein 1 (Skap1) 
Glyoxalase 1 (Glo1) 
Eosinophil-associated ribonuclease 3 (Ear3) 
 
 
4.3.3 Expression of Control Genes in Each Group 
 
In the reference of commonly-used housekeeping genes, both samples showed 
equivalent RNA quantity in the hybridisation reaction. Here I also compared the 
expressions of other control genes which are the well-recognised Treg phenotype 
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markers (Figure 25): Forkhead box P3 (Foxp3), Cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4, CD152), and Glucocorticoid-induced TNF receptor (GITR, as 
known as Tnfrsf18). In addition, IL-35, which is an Ebi3-IL-12α heterodimeric cytokine, 
is recently proposed as a novel inhibitory cytokine specifically produced by Treg cells 
and is required for maximal suppressive activity (Vignali, Collison et al. 2008). We 
can see the near equivalent RNA amount in each group from the usual housekeeping 
genes. From the phenotype marker genes for Treg, variable expression with minimal 
difference was seen but not consistently limited to one specific group. Additionally, 
some large variations observed between the repetitive experiments (eg, CTLA-4 and 
GITR) may have been due to experimental differences or the primary nature of the 
cells. Such variation may limit the interpretation of subsequent results and the data 
obtained need to be further validated. 
 
 
Figure 25.  Housekeeping genes and common Treg phenotype markers expression. 
Housekeeping genes and common Treg phenotype markers were expressed between the 
CD4+CD25High cells from E. coli- and E. coli-LLO-immunised mice. 2 separative microarray 
data were shown in RNA expression intensity (Log). 
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4.3.4 Expression of up-regulated genes 
 
Significantly upregulated genes in E. coli-LLO Treg were demonstrated in Figure 26. 
The gene expression difference ranged from 0.3 to 6 log. When compared to the 
gene expression in naïve Treg, most of genes were at a similar level to Treg from E. 
coli group (except IL-22, IL-17A, CXCL2, SLPI, Igh6, and BLK). Notably, S100 A8/A9, 
IL-17A, C3L3, LSZ, LCN2, NGP, and Ltf were up-regulated throughout 3 repetitive 
microarray analyses.  
 
 
 
 
Figure 26.  Up-regulated genes expressed in the Treg from E. coli-LLO-immunised 
mice compared to E. coli.  Data were plots by 2 microarray analyses. 
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4.3.5 Expression of down-regulated genes 
Significantly down-regulated genes in E. coli-LLO Treg (compared to E. coli) are 
shown in Figure 27. The gene expression difference ranged from 0.3 to 1.5 log. Only 
Hspa1a was found to be consistently down-regulated throughout 3 microarray 
analyses.  
 
 
 
Figure 27.   Down-regulated genes expressed in the Treg from E. coli-LLO-immunised 
mice compared to E. coli.  Data were plots by 2 microarray analyses. 
 
4.3.6 Verification of Microarray Data by RT-PCR 
 
The genes selected from microarray data were verified by PCR following reverse 
transcription of total RNA extracted from different batches of immunised mice (E. coli 
and E. coli-LLO). While 6S is routinely used as an endogenous control for cDNA 
quantity, it may not be an ideal internal standard under conditions of variable 
lymphocyte activation. Therefore in addition to 6S, GAPDH was also used as an 
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internal reference. More importantly, I also included Foxp3 as an additional internal 
control since this is a transcriptional factor specific for the suppressive Treg and the 
Foxp3+ Treg prevalence did not change by the bacterial vaccine in previous 
experiments. Parts of the up-regulated genes were verified by RT-PCR (Figure 28) 
and most of them were cytokines/chemokines (IL-17A, IL-22, IL-10, IL-1β, CCR1, 
CXCL2, TGF-βi), growth factor (AmR) or inflammatory-related genes (S100A8/A9, 
LCN-2, NGP). Meanwhile, CD4+CD25-/Low cells, which were separated during the 
Treg sorting, were used for a comparison in the verification (Figure 29).  In those 
CD4+CD25-/Low cells, most of the genes were either less significantly expressed or 
not differentially expressed between E. coli and E. coli-LLO group. Notably, Foxp3 
expression was detected by PCR in both groups, which could be attributed to the 
presence of CD4- Treg, trace CD25+ Treg, or some activated CD4+CD25- cells 
expressing Foxp3. 
 
 
Figure 28. Verification of the differentially expressed genes by RT-PCR.  
10 Mice were immunised 3 times with E. coli or E. coli-LLO at one-week intervals and 
CD4+CD25High Treg were purified from pooled splenocytes one week after the last 
vaccination.  
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Figure 29. (A) Comparison of the selected genes expression in CD4+CD25-/Low (Tconv) cells 
which were prepared at the same time as Treg were sorted. (B) The purity of isolated Tconv 
cells was analysed by FACS (>85%) 
 
 
4.3.7 Repeat RT-PCR Verification in the Tumour-harboured Mice   
 
In an attempt to better visualise the differentially expressed genes which could be 
another functional determinant of Treg, I compared the RNA expression between 
Tregs from mice that received E. coli-LLO/OVA vaccination and  rejected the tumours 
and Tregs from mice that received E. coli-OVA and were unprotected (Figure 31). 
Most of the expression differences remained valid (as E. coli vs. E. coli-LLO) except 
IL-10 and TGF-βi.  
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Figure 30.    Schematic representation of RT-PCR from Treg in tumour-harboured mice. 
15 mice in each group were immunised with E. coli-OVA or E. coli-LLO/OVA on day 0, 7 and 
14. 106/mouse B16-OVA cells were inoculated between the 2nd and 3rd vaccinations (day 10) 
and mice were chosen from each group based on the performance of tumour protection. 10 
mice were chosen in each group with near- or completely tumour-rejection in the E. coli-
LLO/OVA group and significantly advanced tumour growth in the E. coli-OVA group. Total 
RNA was extracted from purified Treg (CD4+CD25high).  
 
 
 
Figure 31. RT-PCR comparison of the expression of selected genes in CD4+CD25+ cells 
which were purified from tumour-established mice as previously described in Figure 29. 
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4.3.8 Analysis of Committed helper T cell-related Transcriptional Factors  
 
Uncommitted (naive) murine CD4+ T helper cells (Thp) can be induced to 
differentiate towards T helper 1 (Th1), Th2, Th17 and Treg phenotypes according to 
the local cytokine milieu (Afzali, Lombardi et al. 2007; Zhu and Paul 2008). This can 
be demonstrated most readily both in vitro and in vivo in murine CD4+ T cells. The 
presence of IL-12 (signalling through signal transduction and activator of transcription 
STAT-4) skews towards Th1, IL-4 (signalling through STAT-6) towards Th2, TGF-β 
towards Treg and IL-6 and TGF-β towards Th17. The committed cells are 
characterized by expression of specific transcription factors, T-bet for Th1, GATA-3 
for Th2, Foxp3 for Tregs and RORγT for Th17 cells (Figure 32). Since the Treg 
obtained from E. coli-LLO/OVA-immunised cells could demonstrate IL-17A gene 
expression, it is crucial to examine the expression of relevant transcription factors 
specific for Th17.. 
 
 
Figure 32.   T helper cell commitment towards specific lineages in mice. T helper cell 
precursors (ThP) can be skewed toward mutually exclusive Th1, Th2, Th17 and Treg 
phenotypes on the basis of the cytokine environment. Development of Th17 and Treg 
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phenotypes both require the presence of TGF-β but the presence of IL-6 preferentially skews 
the response towards a Th17 phenotype, Treg are characterised in mice by expression of 
Foxp3.  
 
In Figure 33, the RNA expression intensities of STAT-3 (3 variants). STAT-4, STAT-5, 
STAT-6, GATA-3, and RORγT were plotted. None of these transcription factors 
demonstrated significantly different expression in microarray analysis. However, in 
RT-PCR (Figure 34), STAT-3 showed slightly higher expression in E. coli-LLO- or E. 
coli-LLO/OVA-vaccinated Treg. 
 
 
Figure 33.   RNA expression of helper T cell transcription factor genes. Data were plots 
by 2 microarray analyses. 
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Figure 34. RT-PCR of the genes relevant to transcription factors of committed helper T cells. 
 
 
4.4 CONCLUSION  
 
I have used the genome-wide screening of the conditioned-Treg RNA as the first step 
with an attempt to unravel the underlying mechanisms of how E. coli-LLO vaccine 
affected regulatory immune responses. Many upregulated and downregulated genes 
were found within the categories of cytokine/chemokines, inflammation-related, 
growth factors, or surface/cytoplasmic proteins. Apart from specific gene expression, 
some changes of the transcription factors of committed T helper cells were also 
demonstrated but the nature of these changes needs to be examined further. 
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CHAPTER 5:  IS E. COLI-LLO ACTIVE AGAINST A “REAL” TUMOUR 
ANTIGEN? WILMS’ TUMOUR ANTIGEN-1 AS AN 
EXAMPLE  
 
5.1 INTRODUCTION 
 
Antigens, whether “shared” or “unique” tumour antigens, used in cancer vaccines 
should preferably be molecules that are different between normal cells and tumour 
cells, ensuring that the immune response generated by vaccination will target for 
destruction antigen-bearing tumour cells but spare normal cells. In cancer, most 
antigens are derived from mutated or modified self-proteins against which there is 
often a certain level of immune tolerance. This creates particular challenges for the 
appropriate design of vaccines that have to overcome this tolerance in order to elicit 
anti-tumour immunity with limited autoimmunity. The E. coli-LLO vaccine expressing 
model antigen, OVA, has demonstrated its efficacy. However, OVA is a non-self 
antigen in mice, it is therefore required to determine the effect and toxicity of this 
vaccine expressing a real tumour antigen. A very large number of tumour antigens 
have been characterised to date and most of them are melanocyte differentiation 
antigens or tumour-specific mutated gene products, which are not expressed in 
normal tissues. Therefore, we are keen to choose an oncofetal protein, expressed 
differentially in tumour and normal tissues. In the collaboration with Prof. HJ Stauss 
(Royal Free Hospital), we chose Wilms’ tumour antigen-1 (WT1) as our experimental 
tumour antigen. This choice was mainly dictated by the availability of a peptide library 
covering the whole coding sequence, allowing the determination of the antigenic 
motif involved. 
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5.1.1 WT1 proteins: functions in growth and differentiation  
 
Wilms' tumour or nephroblastoma is a paediatric kidney malignancy that was first 
described by Max Wilms in 1899. So far, the Wilms' tumour 1 gene (WT1) at 11p13 is 
the only gene involved in development of Wilms' tumour that has been cloned and 
initially classified as a tumour suppressor gene. It is now recognised that WT1 is 
homozygously mutated in 5–10% of Wilms' tumours. The WT1 protein has 4 different 
isoforms due to alternatively splicing of exon 5 and 9 in mammals (Call, Glaser et al. 
1990). 
    Extensive structure and function analyses of the mammalian WT1 protein have 
been performed by many groups. From the primary structure of the WT1 proteins, it 
was predicted that they could function as transcription factors. They may also be 
involved in post-transcriptional regulation of target genes because of a potential RNA 
recognition motif (Kennedy, Ramsdale et al. 1996). A number of putative target 
genes, comprising growth factor genes/receptors, transcription factors genes, and 
protein-encoding genes have been identified previously (Scharnhorst, van der Eb et 
al. 2001). In addition, WT1 is also known to bind to several other proteins, which are 
also transcription factors and/or alter the transcriptional regulatory properties of WT1. 
    WT1 plays an essential role in urogenital development and is expressed during all 
stages of kidney development, especially in differentiation of the metanephric 
mesenchyme (Pritchard-Jones, Fleming et al. 1990). It has been demonstrated that 
WT1 can induce features of renal epithelial differentiation in mesenchymal fibroblasts 
(Hosono, Luo et al. 1999). Wilms' tumour is thought to arise from the condensed 
metanephric mesenchyme that is destined to differentiate into the epithelial 
components of the nephron but fails to do so properly and instead continues to 
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proliferate (Hastie 1994). Apart from the urinary system during embryogenesis, WT1 
is expressed in the adult, but only in low amounts in the nuclei of some normal 
tissues, such as early haematopoietic precursor, kidney, and gonadal cells (Baird 
and Simmons 1997).  
 
5.1.2 The oncogenic role of WT1   
 
Recent studies demonstrated that the WT1 gene is overexpressed in most types 
of adult leukaemia, including acute myeloid leukaemia (AML), chronic myeloid 
leukaemia, and acute lymphocytic leukaemia (ALL) and in some patients with 
myelodysplastic syndromes (MDS) (Miwa, Beran et al. 1992; Miyagi, Ahuja et al. 
1993; Inoue, Sugiyama et al. 1994; Keilholz, Menssen et al. 2005). WT1 is also 
expressed in many types of lung, thyroid, breast, testicular, and ovarian carcinomas 
and in melanoma (Bruening, Gros et al. 1993; Silberstein, Van Horn et al. 1997; Oji, 
Ogawa et al. 1999). WT1 overexpression represents the result of several factors, 
including the occurrence of genetic damage on the progenitor cell compartment. An 
in-vitro study (Inoue, Tamaki et al. 1998) showed that increased WT1 expression can 
block normal differentiation and enhance proliferation of haematopoietic progenitor 
cells, implicating the potential of WT1 contributing to leukaemogenesis. For MDS 
patients, a significant correlation was found between WT1 expression levels, blast 
cell percentage, and the presence of cytogenetic abnormalities. There is also a 
significant correlation between the amount of WT1 transcripts and the IPSS score, 
which currently represents the most reliable risk index of disease progression 
(Spanaki, Linardakis et al. 2007). In patients with leukaemia, solid tumours or soft 
tissue sarcoma, the level of WT1 expression correlates with the clinical tumour 
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progression and also the prognosis (Oji, Miyoshi et al. 2002; Chiusa, Francia di Celle 
et al. 2006; Netinatsunthorn, Hanprasertpong et al. 2006; Sotobori, Ueda et al. 2006). 
Furthermore, RT-PCR-based quantification of WT1 mRNA may serve as marker for 
minimal residual disease monitoring in AML or following bone marrow transplantation 
(Ogawa, Tamaki et al. 2003; Weisser, Kern et al. 2005). Osaka et al demonstrated 
that WT1 expression was detected in most 7,12-dimethylbenzanthracene-induced 
erythroblastic leukaemias and a tendency for cells with high levels of WT1 
expression to turn into leukaemic cells (Osaka, Koami et al. 1997). The growth of 
leukaemic and solid tumour cells could be inhibited by treatment with WT1 antisense 
oligomers (Yamagami, Sugiyama et al. 1996; Glienke, Maute et al. 2007).  
    In summary, WT1 has received increasing attention as a candidate for 
immunotherapy based on previous experim ents and preclinical studies. WT1 
vaccination by means of bacterial vehicle expressing LLO to enhance antigen 
presentation has not been studied in the past. In this context, we may observe the 
immune response from this natural adjuvant and the advantage of LLO in modifying 
antigen presentation pathway.  
 
5.2 RESULTS 
 
5.2.1 Expression of Target protein in E. coli (MC4100/DE3) 
 
5.2.1.1 Expression of LLO 
 
The expression of LLO in E. coli harbouring the plasmid pDP-E3615, which 
encodes listeriolysin-O lacking its secretion signal under the control of the 
constitutive tet promoter, was first analysed. Coomassie brilliant blue staining of the 
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gel (Figure 35) visualised a band at 58 kDa in E. coli-LLO and E. coli-LLO/WT1, 
which was absent in either E. coli-WT1 or E. coli. This observation was confirmed by 
Western Blot using an anti-LLO antibody (Figure 36).  These results demonstrated 
the expression of LLO in pDP-E3615 transformed E. coli. 
 
 
 
Figure 35. LLO protein expression in IPTG-induced bacteria. Proteins from 108 bacteria 
were resolved on 10% SDS–polyacrylamide gels and visualised by Coomassie brilliant blue 
staining. Migration of molecular weight standards is shown to the left of each panel in kDa.  
 
 
 
Figure 36. Detection of LLO expression in Western Blot by specific antibody. (primary) 
LLO-specific antibodies (1/2000, Diatheva, Italy) and (secondary) polyclonal anti-mouse 
immunoglobulins/horseradish peroxidase (HRP)-conjugated antibody (1/5000, 
DakoCytomation, U.S.) were used to detect the presence of LLO in IPTG-induced bacteria. 
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5.2.1.2 Expression of WT1  
 
The expression of WT1 in E. coli harbouring the plasmid pCRT7/CT, which encodes 
40 kDa truncated WT1 protein under the control of Isopropyl β-D-
thiogalactopyranoside (IPTG)-inducible T7 phage promoter, was analysed by 
Western Blot. Figure 37 demonstrates the presence of WT1 in the relevant bacteria. 
 
 
 
Figure 37. WT1 expression in IPTG-induced bacteria. Detection of WT1 expression in 
protein obtained from 108 bacteria by (primary) monoclonal mouse anti-human Wilms’ tumour 
1 protein (6F-H2 clone) antibodies (1/1000, DAKO, California, USA) and (secondary) 
polyclonal anti-mouse immunoglobulins/horseradish peroxidase (HRP)-conjugated antibody 
(1/2000, DakoCytomation, USA) and revealed by ECL (GE Healthcare, UK). 
 
5.2.2 WT1 mRNA expression 
 
RT-PCR and quantitative real-time PCR were carried out to determine the WT1 
mRNA expression in various tumour cell lines and normal tissues. K562 cells 
(derived from a CML patient in blast crisis), TRAMP-C (TRansgenic Adenocarcinoma 
of the Mouse Prostate, a transgenic line of C57BL/6 mice), WT1 plasmid transfected 
MBL2 (MBL2-WT1, originated from a Moloney virus-induced C57BL/6 lymphoma) 
and RMA (RMA-WT1, originated from a Rauscher virus-induced C57BL/6N T cell 
lymphoma) were shown to express WT1. A trace of WT1 expression was seen in 
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normal mouse kidney tissue (Figures 38 and 39). From these experiments, TRAMP-
C and MBL2-WT1 were chosen to test our in-vivo tumour challenge model following 
vaccination.  
 
 
Figure 38. WT1 RNA expression in tumour cell lines and normal tissues by RT-PCR. 
The amplified WT1 product is 147 bp long. The RNA of the housekeeping 18S gene was 
amplified to indicate the amount of RNA in each sample. The 18S product is -200 bp long. 
 
 
Figure 39.  WT1 RNA expression in tumour cell lines and normal tissues by qRT-PCR.  
Total mRNA from BM, kidney cells, and cell lines were reverse transcribed to cDNA, and 
WT1 gene expression was determined by real-time RT-PCR. Results are expressed relative 
to 100-fold dilution of the total RNA from K562 cells. Mean values of triplicates are depicted. 
The RNA of the reference 18S gene was amplified to normalise the amount of RNA in each 
sample. 
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5.2.3 Tumour protective effect in immunised mice 
 
5.2.3.1 Challenge with WT1 naturally-expressed tumour cells   
 
Male C57BL/6 mice received 3 subcutaneous injections of paraformaldehyde-fixed 
bacteria (108 /mouse) at one-week interval then were challenged with TRAMP-C (106 
cells/mouse) one week after the last vaccination (7 mice in each group). In mice 
vaccinated with E. coli-LLO/WT1, the tumour growth was significantly reduced 
compared to E. coli or E. coli-WT1 (Figure 40). There is no significant difference 
between the groups of E. coli and E. coli-WT1. In the mice immunised with E. coli-
LLO/WT1, even though the tumour outgrowth was significantly inhibited at earlier 
time-point, most of these mice finally had to be sacrificed after 30 days due to 
advanced tumour. 
 
 
Figures 40. Protection of TRAMP-C tumour cells challenge following bacterial 
vaccinations.  Male C57BL/6 mice received 3 subcutaneous injections of fixed bacteria (108 
/mouse) or PBS at one-week intervals then were challenged with TRAMP-C (106 cells/mouse) 
one week after the last vaccination (7 mice in each group). Tumour volume was assessed by 
the maximal 2-dimension measurement and expressed in mm2. Results are expressed as 
mean  SD.  *** p<0.001, ** p<0.01 
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5.2.3.2 Challenge with WT1-transfected tumour cells   
 
Male C57BL/6 mice received 3 subcutaneous injections of paraformaldehyde-fixed 
bacteria (108 /mouse) at one-week interval then were challenged with MBL2-WT1 
(5x106 cells/mouse) one week after the last vaccination (7 mice in each group). In 
mice vaccinated with E. coli-LLO/WT1, the tumour growth was significantly reduced 
compared to the other groups (Figure 41) and most of these mice were long-term 
protected (>40 days).  
 
 
Figures 41. Protection of MBL2-WT1 tumour cells challenge following bacterial 
vaccinations.  Male C57BL/6 mice received 3 subcutaneous injections of fixed bacteria (108 
/mouse) at one-week interval then were challenged with MBL2-WT1 (5x106 cells/mouse) one 
week after the last vaccination (6 mice in each group). Tumour volume was assessed by the 
maximal 2-dimension measurement and expressed in mm2. Results are expressed as mean 
 SD. * p<0.05, *** p<0.001 
 
From the results in 5.2.3.1 and 5.2.3.2, the E. coli LLO/WT1-vaccinated mice were 
better protected than E. coli-WT1- or E. coli-vaccinated ones, implicating that LLO is 
required for optimal anti-tumour effect. However, the efficacy of long-term tumour 
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protection by E. coli-LLO/WT1 vaccine was different against these two tumour cell 
lines. This could be attributed to the difference in WT1 expression in tumour cells 
based on RT-PCR (Figure 39).  
 
5.2.4 The effects of CD4 or CD25 cells depletion 
 
In previous experiments in Chapter 3.3, I have shown that the removal of CD4+ cells 
or CD25+ cells at the immune priming stage with antibody depletion could enhance 
the anti-tumour effect of E. coli-OVA vaccine.  Those data support the conclusion that 
Treg cells (CD4+CD25+ subset) play an important role in preventing the expansion of 
OVA-specific CD8+ T cells following E. coli-OVA vaccination and that E. coli-LLO 
vaccine overcame this effect. 
    To address whether this observation can be extended in the context of WT1 as an 
antigen, E. coli-WT1 vaccinated animals were depleted in CD4+ or CD25+ cells 
during the priming stage and challenged with MBL2-WT1 cells. Figure 42 shows that 
depletion with either monoclonal antibody resulted in a dramatic increase in E. coli-
WT1 anti-tumour activity indistinguishable to E. coli-LLO/WT1 vaccine. These results 
suggest that incorporation of LLO in the bacterial vaccine reduces Treg-mediated 
suppression of CD8+ T cell expansion and tumour killing effects, as in the case of E. 
coli-OVA.  
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Figures 42. Tumour protection following CD4+/CD25+ depletion.  (A) In the model of E. 
coli expressing WT1 vaccination with MBL2-WT1 cells challenge, the mice received 3 
bacterial vaccinations on days 0, 7 and 14. Depletions were carried out by intra-peritoneal 
injection of GK1.5 depleting mAb (anti-CD4) (on days –5 and 10) or PC61 mAb (anti-CD25) 
on day -1 at the stage of T cell priming in the mice with E. coli WT1 vaccination. Mice were 
challenged on day 21 by s.c. injection of 5X106 MBL2-WT1 cells.  The anti-tumour effect in 
CD4 or CD25 depletion group was similar to the mice vaccinated with E. coli LLO/WT1. (B) 
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The specific time-point tumour measurement was taken on the 20th day after MBL2-WT1 
challenge. *** p<0.001, * p<0.05 
 
5.2.5 Assessment of altered Treg function 
  
In Chapter 3.6, animals receiving E. coli-LLO or E. coli-LLO/OVA vaccines had 
reduced Treg suppressive function compared to Treg from mice receiving E. coli or E. 
coli-OVA vaccines, suggesting that LLO expression in the E. coli vaccines dampened 
the suppressive function of Treg cells. 
In the E. coli-LLO expressing WT1 system, I intended to determine whether the 
LLO-containing vaccination regimen can elicit a similar effect on the Treg cells 
function as we observed in E. coli-LLO/OVA model.  In this experiment, I purified the 
CD4+CD25high (Treg) and CD4+CD25low (Tconv) cells and co-cultured in the presence 
of anti-CD3 antibody. A 50% inhibition of Tconv proliferation was seen in E. coli-WT1 
group and 20% in E. coli-LLO/WT1 group at 1:1 Treg/Tconv ratio (Figure 43). From 
this experiment, a similar inhibition effect on Treg cells resulting from incorporation of 
LLO into vaccine was observed. 
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Figure 43. Treg suppression assay in WT1-expressing E. coli vaccine model.  Mice 
received 3 s.c. vaccinations of either E. coli WT1 or E. coli LLO/WT1 and their splenocytes 
were harvested 7 days after the last boost injection before being separated into 
CD4+CD25High and CD4+CD25low cells. In a mixed leukocyte reaction, CD4+CD25high (Treg 
cells, in variable number) were co-cultured with 105 CD4+CD25-  T cells (Tconv) for 4 days in 
the presence of 0.5 μg/ml purified anti-CD3 antibody and 2x105 naïve irradiated splenocytes. 
Proliferation of Tconv was measured by the incorporation of 3H-Thymidine for the last 18hr of 
culture period. The data were plotted as percent inhibition (of Tconv proliferation) reflecting 
suppressive functionality of Treg and calculated as [Proliferation (Tconv only)-Proliferation 
(Treg+Tconv)]x 100%/[Proliferation (Tconv only)]. * p<0.05 
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5.2.6 Production of anti-WT1 specific antibody 
 
In order to determine the humoral immune responses to E. coli-LLO/WT1 vaccination, 
the presence of WT1 specific antibody was verified by Western Blot. Sera obtained 
from 6 mice, one week after the last vaccination with E. coli, showed no trace of 
WT1-antibody. The plasma of the 7/11 mice that received E. coli-WT1 vaccination 
were positive for WT1 antibodies and all of the 11 mice received E. coli-LLO/WT1 
vaccination (Figure 44). Even though previous experiments (Karre, Ljunggren et al. 
1986) had shown that the antigen presentation through E. coli-LLO vaccination 
mainly involved MHC class I pathway, this result demonstrated that some helper T-
cell responses via MHC class II were also involved.  
 
 
 
Figure 44. Detection of WT1-specific antibodies by Western Blot. Sera were obtained 1 
week after the third immunisation. The presence of antibodies specific for WT1 was 
determined by Western Blot. Sera from E. coli-WT1 (7/11) and E. coli-LLO/WT1 (11/11) 
vaccinated mice showed the production of antibodies specific for WT1. Representative 
samples from 6 mice in each group are shown here. In contrast, no antibodies were detected 
in sera from E. coli- or E. coli-LLO-vaccinated mice (0/6, 2 representative samples).  
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5.2.7 Characterisation of immunodominant epitope following E. coli-LLO/WT1       
          vaccination 
 
5.2.7.1 Cytokine ELISpot screening of WT1 peptide library 
 
In order to characterise the immune dominant antigenic motifs involved in the anti-
tumour effect of E. coli-LLO/WT1, a library of peptides (provided by Prof Stauss HJ, 
Royal Free hospital, London) covering the entire human WT1 protein (the human 
WT1 protein is 96% identical to the mouse protein) was screened (15-mer peptides, 
overlapping by 10-mer). Splenocytes extracted from 10 mice vaccinated with E. coli-
LLO/WT1 were pooled and mixed with individual peptides in a 96-well plate. After 
twenty-four hours of stimulation, an ELISpot assay for interferon-γ (IFN-γ) and IL-2 
was carried out (Figure 45). This screening identified 12 different peptides (three 9-
mer peptides and nine 15-mer peptides) capable of inducing significant IFN-γ 
production, suggesting an involvement of these peptides in the anti-tumour effect 
(Figure 46, four peptides were shown).  
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Figure 45. ELISpot screening of the WT1 peptide library. Pooled splenocytes were 
harvested from mice immunised with fixed E. coli-LLO/WT1. The specific IFN-γ (red) and IL-2 
(blue) responses were measured by spots counting in ELISpot when stimulated with the 
whole panel of WT1 peptide library (total 106 15-mer peptides). Data represent 3 times of 
ELISpot screening. The selected 12 peptides are demonstrated by red closed triangles. 
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Peptide No. Peptide Sequence 2nd ELISpot 3rd ELISpot 
22 85-99 28 32 24 19 13 14 
30 117-131 18 12 8 12 8 14 
32 125-139 15 18 31 14 11 19 
33 129-143 25 7 43 12 20 16 
52 205-219 10 6 19 11 5 24 
53 209-223 7 19 20 10 18 16 
57 225-239 22 20 23 25 26 5 
58 229-243 19 23 13 12 24 15 
59 233-247 25 19 42 10 12 24 
68 269-283 11 13 17 18 17 17 
69 273-287 6 8 19 11 5 17 
105 417-431 15 12 26 20 14 14 
Medium - 3 4 2 2 1 4 
 
 
Table 9. IFN-γ ELISpot responses in selected peptides. IFN-γ responses to 12 selected 
peptides and medium control from the 2nd and 3rd ELISpot screening were presented as spot 
numbers per well.  
 
5.2.7.2 Lymphocyte proliferation assay (LPA)  
 
LPA on pooled splenocytes  
 
Since the numbers of spot obtained from ELISpot screenings were generally low 
(between 15-30 spots/well), the peptide-specific cytokine responses needed to be 
validated by peptide-induced lymphocyte proliferation. Subsequently, these 12 
peptides selected were used to stimulate in vitro the splenocytes obtained from 
animals vaccinated with E. coli-LLO/WT1 or E. coli-WT1 and splenocytes from E. 
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coli-vaccinated animals were used as controls (Figure 46, the number indicated the 
starting sequence of the peptide and peptides marked with * are 9-mer, otherwise are 
15-mer). In preliminary experiments, no significant response was observed when 
stimulated with 10 μM or 20 μM peptide without IL-2. Therefore, subsequent 
experiments regarding proliferation assays were all carried out with peptide (20 μM) 
in the presence of IL-2 co-stimulation. In consideration of the effect of DMSO within 
the peptide solution, a DMSO control group was also included in addition to medium-
only control. pWT 130* had the consistently best responses among all the peptides. 
In addition, peptide pWT 235*, pWT 269, pWT 273, pWT 418 also gave significant 
proliferative responses compared to E. coli group. pWT 113, pWT 205 and pWT 209 
had moderate responses compared to E. coli group and non-peptide medium control. 
In further experiments examining the antigenic epitope related to E. coli-LLO/WT1 
vaccination, we re-tested all the peptides mentioned above. In addition, the 
overlapping 9-mer peptides between pWT 205/209 and pWT 269/273 (pWT 209* and 
pWT 273*), and the 9-mer peptide within pWT 418, were synthesised to be included 
in the panel of proliferation assay.  In this experiment, pWT 130 and pWT 235 
induced proliferations consistently compared to either E. coli-vaccination group or 
non-peptide control. The 9-mer peptide (pWT423-431) showed improved responses 
compared to 15-mer pWT418-432, whereas the selected pWT 209* and pWT 273* did 
not demonstrate any better results than the original separated 15-mer peptides 
(Figure 47).  
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Figures 46 and 47.  Lymphocyte proliferative responses to selected WT1 peptides. In 
culture plates stimulated with peptide 20 μM in the presence of, overall proliferative response 
was significantly better in lymphocytes from E. coli-LLO/WT1-vaccinated mice than from E. 
coli or E. coli-WT1-vaccinated mice. When looking into the results in E. coli-LLO/WT1-
vaccinated mice and compared to the other 2 groups, pWT130*, pWT 235*, pWT 269, pWT 
273, and pWT 423 elicited better proliferation than other peptides. The results were 
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consistent with previous data (not shown) that pWT 130* gave the consistent proliferative 
response in vitro. In another experiment testing the lymphocyte proliferation, three 9-mer 
peptides, pWT 209*, pWT 273*, and pWT 423* were included in the panel of examining 
peptides. The OVA257-264 epitope, SIINFEKL, which is a well-documented motif, was also 
included in the tested peptide. Another group of mice vaccinated with E. coli-LLO/OVA was 
included for another control. 
 
LPA on purified CD4 and CD8 cells 
 
To determine the cell-type stimulated by the various peptides, we purified CD4+ and 
CD8+ cells before peptide stimulation. Subsequent proliferation testing was 
performed in the presence of IL-2 co-stimulation and 20 μM peptide (Here I chose 
three 9-mer peptides which have the best proliferative responses). All the peptides 
led to significant CD8+ cells proliferation rather than CD4+ cells. pWT 130 had shown 
the consistent significant responses compared to other peptides (Figure 48).  
  
 
Figure 48.  CD4+ or CD8+ lymphocyte proliferative responses to WT1 peptides. CD4+ or 
CD8+ cells from immunised mice were purified by anti-CD4 or anti-CD8 magnetic 
microbeads (MACS, Miltenyi Biotech, Germany) and stimulated by WT1 peptide 20 μM in 
vitro in the presence of IL- 2 and irradiated syngeneic splenocytes as feeders. Medium 
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without peptide was used as control group. The overall T-cell subset proliferation determined 
by 3H-Thymidine incorporation is prominent in CD8+ cells. 
 
 
5.2.7.3 Cytotoxicity assay 
 
MHC class I expression in peptide-loaded RMA-S cells 
 
RMA-S cells were used in MHC binding assays to determine the class I binding 
efficiency of synthetic WT1 peptides. In this experiment, I used pWT 130 for testing 
MHC class I expression in RMA-S cells. RMA-S cells express 5% of the level of H2-
Kb/Db (Rammensee, Bachmann et al. 1999). When RMA-S cells are cultured at 26°C, 
this leads to increased expression of empty class I molecules. These empty class I 
molecules are unstable and fragile when RMA-S cells are shifted to 37°C but can be 
stabilised when class I binding peptides are present in the culture medium. The MHC 
class I expression (H2-Kb) after pWT130 loading to temperature-induced RMA-S cells 
can achieve 96.2% (Figure 49) indicating the stable expression of MHC-I and ideal 
for the target in CTL assay.  
 140 
100 101 102 103 104
FL1-H
H2-Kb (MHC class I) FITC
C
ou
nt
s
Non temp-induced without 
peptide loading 15.1%
Temp-induced without 
peptide loading 26.2%
Non temp-induced with pWT
130 loaded 82.3%
Temp-induced with pWT 130 
loaded 96.2%
Non-stained
C
ou
nt
s
 
Figure 49. Temperature-induced MHC class I expression in RMA-S. The highest 
expression of MHC class I in RMA-S cells was shown upon specific temperature (26˚C)-
induction and loaded with an immunogenic peptide (pWT 130).  
 
 
Peptide binding stability 
     
Selected 9-mer WT1 peptides/motifs to stabilise MHC class I (H-2b) expression were 
tested. Results shown in Figure 50 show that few chosen WT1 peptides stably bind 
to MHC class I molecules. In comparison to SIINFEKL, OVA257-264, which is a well-
documented CTL antigenic epitope of OVA, only pWT 130 (both H2-Kb and H2-Db) 
and pWT 126 (predominantly H2-Db) showed significant superior binding stability to 
the MHC class I expressed by RMA-S.  
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Figure 50.  MHC class I binding stability of WT1 peptides. Temperature-induced RMA-S 
cells were incubated with each WT1 peptide in 10 μM concentration. Cells were cultured at 
37°C for 2 hours, labeled with anti-Db or anti-Kb mAb and then analysed by flow cytometry to 
determine the level of MHC class I expression. Results from a representative experiment are 
shown where the mean fluorescence intensity is represented against each WT1 peptide. The 
OVA257-264 epitope, SIINFEKL, was used as a positive control. 
  
 
    To sum up from all the results obtained from ELISpot screening, lymphocyte 
proliferation assay, and the peptide binding stability on MHC class-I, I chose three 9-
mer peptides, pWT 130, pWT 235, and pWT 423, to be tested in subsequent CTL 
assay (Figure 51). In reviewing all previous published CTL or HTL epitopes related to 
WT1 peptide, pWT 126 has been the most commonly discussed and applied. In 
addition, 9-mer pWT 235 has been applied in phase I/II clinical trial for cancer 
immunotherapy and some pilot studies in leukaemic patients. Several websites are 
also available to provide the prediction algorithm for CTL or HTL epitopes and I 
hereby selected two 9-mer peptides with highest estimated binding score to H2-Db in 
2 separate websites: pWT 119 from http://bio.dfci.harvard.edu/Tools/rankpep.html 
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and pWT 126 from http://www.uni-tuebingen.de/uni/kxi/ and SYFPEITEI 
http://www.syfpeithi.de/home.htm  (Edelman and Tacket 1990). pWT 209 and pWT 
273 that gave moderate responses from lymphocyte proliferation assay were not 
selected into the panel of CTL assay because of their poor MHC class-I binding 
ability and relative low prediction MHC binding score. Figure 52 shows all the 
selection strategies I have used and the final choice of five candidate epitopes to be 
further examined in subsequent CTL assay. In addition, pWT130, which consistently 
provided the best results in previous experiments, was considered for the generation 
of peptide-MHC tetramer/pentamer. However, this strategy was abandoned as this 
MHC-pentamer failed to be manufactured by ProImmune Ltd (Oxford, U.K.). 
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Figure 51. Schematic representation of the strategies to select the candidates of WT1 
immunodominant epitopes. Five peptides (9-mer) were chosen based on the data of 
ELISpot screening, published WT1 CTL epitope (for either in vitro study or in vivo 
application), in vitro lymphocyte proliferation by peptide stimulation, and two CTL epitope 
prediction websites. These peptides were considered to be the potential antigenic epitope 
recognised by CD8+ T-cell through E. coli-LLO/WT1 vaccination and they will be assessed 
by in vitro CTL killing (51Cr releasing assay).  
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Cytotoxicity (51Cr release) assay  
 
To characterise the presence of the antigen-specific cytotoxic responses and 
determine the CTL epitope related to E. coli-LLO/WT1 vaccination, splenocytes from 
vaccinated mice were re-stimulated in vitro with WT1 peptide-loaded LPS-activated 
splenocytes and CTL activity was measured 6 days later using WT1 peptide-loaded 
RMA-S and WT1-expressing cells, TRAMP-C and MBL2-WT1 as targets. When 
peptide-loaded RMA-S cells were used as target, irrelevant peptide (SIINFEKL)-
loaded RMA-S cells were used as control target cells. The results are summarised in 
Figures 52-54.  
    Splenocytes from vaccinated mice were re-stimulated in vitro with WT1 peptide-
loaded LPS-activated splenocytes and CTL activity was measured 6 days later using 
WT1 peptide-loaded RMA-S. RMA-S loaded with irrelevant peptide (SIINFEKL) was 
used as control target. A significant cytotoxicity killing to pWT 130-loaded RMA-S 
was obtained in the E. coli-LLO/WT1 and E. coli-WT1-vaccinated group compared to 
the naïve or E. coli-vaccinated group. A moderate cytotoxicity killing to pWT 235-
loaded RMA-S at the highest E/T ratio was observed in the E. coli-LLO/WT1 and E. 
coli-WT1-vaccinated groups compared to naïve or E. coli-vaccinated groups. 
Especially, the yield of specific CTLs from pWT 130 stimulation was higher in E. coli-
LLO/WT1 group than E. coli-WT1 because of persistent killing from high to low E/T 
ratio. There was no significant killing to pWT 119 or pWT 423-loaded RMA-S in all 
groups (Figure 52). 
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Figure 52.  E. coli-LLO/WT1 vaccination generates specific CTL responses (1). C57BL/6 
mice received 3 s.c. injections of bacteria at one week intervals. Splenocytes were harvested 
one week later and re-stimulated in vitro with LPS-activated spleen cells loaded with five 
selected WT1 peptides. Cytotoxicity was assayed 6 days later by 51Cr release assay against 
WT1 peptide or irrelevant -loaded RMA-S cells. Specific 51Cr release was measured as 
described in the methods. Results from individual groups are plotted against the E:T ratio. 
    Splenocytes from vaccinated mice were re-stimulated in vitro with WT1 peptide-loaded 
LPS-activated splenocytes and CTL activity was measured 6 days later using WT1 peptide-
loaded RMA-S and tumour cells (TRAMP-C and MBL2-WT1) as target cells. RMA-S loaded 
with irrelevant peptide (SIINFEKL) and MBL2 were used as control target. A significant 
cytotoxicity killing to pWT 130-loaded RMA-S was obtained in E. coli LLO/WT1 but not in E. 
coli WT1-vaccinated group.  
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Figure 53.  E. coli-LLO/WT1 vaccination generates specific CTL responses (2). C57BL/6 
mice received 3 s.c. injections of bacteria at one week intervals. Splenocytes were harvested 
one week later and re-stimulated in vitro with LPS-activated spleen cells loaded with five 
selected WT1 peptides. Cytotoxicity was assayed 6 days later by 51Cr release assay against 
WT1 peptide-loaded RMA-S cells or WT1-expressing tumour cells (TRAMP-C and MBL2-
WT1 cells). Irrelevant peptide (SIINFEKL)-loaded RMA-S and parental cells MBL2 were used 
as control target. Specific 51Cr release was measured as described in the methods. Results 
from individual mice are plotted against the E:T ratio. 
 
 
In the vaccination protocol (Figure 41 in Section 5.2.3.2), the mice in the E. coli-
LLO/WT1 group survived the challenge with MBL2-WT1 and were considered as 
“cured”. A second MBL2-WT1 tumour challenge was performed to the tumour-free 
mice 40 days after the first tumour challenge. There was no tumour re-growth in all 
the re-challenged mice 30 days after second challenge. Splenocytes from these mice 
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were collected, in vitro stimulated, and used as effector cells. A significant cytotoxic 
killing was demonstrated to pWT 130-loaded RMA-S and MBL2-WT1 compared to 
control targets (>80% specific killing at the highest effector to target ratio), suggesting 
the significant presence of antigen-specific CTLs (Figure 54).  
 
 
 
Figure 54.  Specific CTLs obtained from tumour-resistant mice. The mice received 3 
immunisations of E. coli-LLO/WT1 and were challenged with MBL2-WT1 (5x106 cells/mouse) 
one week after the last injection. Tumour-free mice were re-challenged (MBL2-WT1 5x106 
cells/mouse) 40 days after the initial challenge. All the mice were protected from the tumour 
re-challenge without tumour re-growth and the total splenocytes were harvested and 
stimulated with (A) irradiated MBL2-WT1 cells or (B) LPS-activated lymphocytes loaded with 
pWT130 and then used as effector cells. These cells demonstrated 80-100% specific 
cytotoxicity of target cells (A) MBL-2-WT1 or (B) RMA-S/130 at the highest effector/target 
ratio attributed to the specific CTLs. 
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In summary, pWT 130 appears to be the major antigenic epitope that stimulates T 
cell proliferation (CD8+) and mediates E. coli-LLO/WT1 anti-tumour effect. pWT 130 
gave consistent results compared to other testing peptides. However, the role of pWT 
126, pWT 235, and pWT 423 involved in this vaccine are not conclusive as they had 
inconsistent target killing abilities in one of these experiments (pWT 126 to TRAMP-C, 
pWT 423 to RMA-S, and pWT 235 to RMA-S) and also had modest stimulatory effect 
to lymphocyte proliferation.   
 
5.3 CONCLUSION 
 
The data demonstrated that an E. coli-LLO vaccine, which expresses an oncofetal 
tumour antigen, WT1, is capable of inducing a strong anti-tumour effect against 
implanted WT1-expressing tumours in vivo. The mechanisms were mainly attributed 
to its ability to induce specific CTLs and inhibit the suppressive function of Foxp3+ 
Treg, as we have seen in the model antigen system. Furthermore, we have 
characterised the immunodominant epitope (pWT130-138, NAPYLPSCL) involved in 
this effect. Even though the MHC multimeric assay is technically not feasible to 
detect the antigen-specific CTLs, the presence of CTLs against this peptide was 
demonstrated using a 51Cr-release assay. 
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CHAPTER 6:  THE ADJUVANT ROLE OF E. COLI-LLO BACTERIA IN    
PEPTIDE VACCINE 
 
6.1 INTRODUCTION  
 
Vaccination works by manipulating the immune response through selecting, 
activating and expanding the memory of B and T cells. To determine the magnitude 
and quality of immune response, suitable vaccine adjuvants are required; therefore, 
much effort is going into finding new, effective and non-toxic adjuvant formulations 
focussed on the activation of key immune targets for inducing a long-term, potent and 
safe immune response. Vaccine adjuvants can act in several, non-mutually exclusive 
ways to augment the adaptive immune response and to generate effective 
immunological memory through contacting with APC, such as DCs. Thereby 
adjuvants can affect the migration, maturation, antigen presentation, and expression 
of costimulatory molecules by DCs, and these events in turn improve the responses 
to antigen of T and B cells. Adjuvants can also affect the nature of CD4+ T helper 
(Th), CD8+ T cell, and B cell responses, with some adjuvants promoting Th1-related 
responses and others preferentially inducing Th2-biased effects. Furthermore, some 
adjuvants enhance cross-presentation by DCs of MHC I-restricted antigens to CD8+ 
T cells. Adjuvants may also act directly in improving the effector cells proliferation 
and/or conversion into memory cells that are essential for the success of vaccines. 
Adjuvants are generally immunogenic, mainly function to target associated 
antigens into APCs and create a depot for sustained immune stimulation. 
Immunostimulatory adjuvants are predominantly derived from microbials and often 
represent PAMPs. A practical categorisation of different types of immunostimulatory 
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adjuvants has been proposed by Edelman and Tackett (Cox and Coulter 1997). 
Three general types are proposed: adjuvants per se; carriers; and vehicles. The 
adjuvant per se includes aluminium salts, saponin, muramyl di- and tripeptides, 
monophosphoryl lipid A, Bordetella pertussis, cytokines, and many others. The 
carriers, which mainly provide T cell help, include bacterial toxoids, fatty acids, and 
living vectors. The vehicle category includes mineral oil emulsions (e.g. incomplete 
Freund’s adjuvant), biodegradable oil emulsions (e.g. emulsions containing peanut oil, 
squalene, or squalane), non-ionic block copolymer surfactants, liposomes, and 
biodegradable polymer microspheres. Another categorisation of adjuvants is based 
on five potential modes of adjuvant action: immunomodulation (modification of 
cytokine networks); presentation (maintenance of antigen conformation); CTL 
induction; targeting; and depot generation (McKee, Munks et al. 2007). 
In some studies, delivery systems and immunostimulatory agents have been 
combined to prepare adjuvant delivery systems, which are designed for more 
effective delivery of the immunostimulatory adjuvant into APC (Wack, Baudner et al. 
2008). A coupling of immunopotentiator on a delivery device may prolong its 
residence or target it to more relevant antigen presenting cells. O’Hagan et al 
showed that decoration of CpG motifs (signal 2 facilitators) onto PLG particles (Ag 
delivery devices) synergistically improves immunopotentiator functions and 
concomitantly reduces systemic side effects (Warger, Osterloh et al. 2006). Recent 
progress in the knowledge of innate immunity is beginning to yield insight into the 
initiation of immune responses and the ways in which immunostimulatory adjuvants 
may enhance this process. However, a rational approach to the development of new 
and more effective vaccine adjuvants will require much further work to better define 
the mechanisms of action of existing adjuvants.  
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Many of the vaccines currently used in humans contain adjuvants that are 
intrinsic to the immunogen. For example, vaccines that contain attenuated live or 
heat-killed viruses or bacteria include components that can engage TLRs. These 
components therefore act as natural adjuvants because TLR signalling has many of 
the effects on DC antigen presentation that one would wish for an adjuvant: 
improvement in antigen presentation and increases in costimulatory molecules and 
cytokine production, leading usually to improved Th1-related responses. Importantly, 
incorporation of TLR as an adjuvant in vaccination can reverse the Treg suppression 
and potentiate the adaptive immune responses counterbalanced by Treg (Conroy, 
Marshall et al. 2008). However, a problem with TLR agonists that has not been fully 
appreciated is that they can generate suppressive as well as inflammatory responses 
in innate immune cells and can promote the induction of regulatory as well as effector 
T cells (Smith and Cerundolo 2001). Peptide vaccines combined with IFA were 
insufficiently immunogenic and did not elicit robust anti-tumour immune responses in 
the absence of exogenous cytokines (Gupta, Relyveld et al. 1993). Although IFA 
stands as one of the most successful adjuvants, both for animals and humans, its 
potential toxicity has been proposed (Heit, Gebhardt et al. 2008). 
The primary goal in the development of vaccine adjuvant is to induce potent and 
long-lasting immune effectors and memory cells. However, the primary immune 
responses raised by vaccination are also characterised by the activation of counter-
regulatory mechanisms, which are necessary to prevent excess T cell expansion or 
maintenance of autoreactive T cells. Treg seem particularly to be adept at controlling 
immune responses to self antigens as well as pathogens. In particular, antigen-
induced Treg, instead of natural Treg, can recognise foreign antigens and develop 
during prolonged antigen exposure such as immunisation with purified antigens with 
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conventional adjuvants (Heit, Gebhardt et al. 2008).  This is a drawback when 
attempting to create a sustained antigen stimulation depot by an adjuvant.  Because 
of their potent suppressive activity on immune responses in vivo, temporary down-
modulation of Treg by the vaccine adjuvant has been suggested as an attractive 
target to improve the efficacy of vaccines. Heit et al have showed that depletion of 
Treg can lead to generation of long-living memory T cells (Peng, Guo et al. 2005). 
Moreover, the positive adjuvant effect of TLR ligands has been partially linked to the 
Treg compartment, either by direct reversion of Treg function (Pasare and Medzhitov 
2003) or by TLR-induced cytokines (such as IL-6, by TLRs upon recognition of 
microbial products), which make responding T cells refractory to suppression by Treg 
(Dannull, Su et al. 2005).  
 
6.2 RATIONALE AND AIM  
 
 In Chapter 3 and Chapter 5, I have demonstrated that E. coli-LLO vaccination can 
reduce the Treg suppression on Tconv proliferation in vitro (Figures 17 and 22) but 
without emergence of specific CTLs. The aim of this study is to determine whether 
the vehicle, E. coli-LLO, can be simply exploited as an adjuvant to peptide 
vaccination. If successful this approach could be extended more easily to human 
study. 
In this part, I intended to compare the immunological responses of peptide 
vaccination with E. coli-LLO adjuvant to antigen expression within E. coli-LLO (E. 
coli-LLO/OVA and E. coli-LLO/WT1).  
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6.3 RESULTS 
 
6.3.1 Cytokine ELISpot analysis  
 
In the mice vaccinated with E. coli-LLO with OVA257-264, there was a significantly 
better response in the IFN-γ ELISpot analysis compared to E. coli and E. coli-LLO, 
even though this response was not as good as OVA-expressing E. coli-LLO (Figure 
55). 
 
 
Figure 55.  IFN-γ ELISpot response. Mice received two s.c. immunisations of E. coli-LLO, E. 
coli-LLO+SIINFEKL, or E. coli-LLO/OVA, (at 108 bacteria /mouse or 100 μg peptide/mouse) 
at one week intervals. Splenocytes were collected one week after the boost injection and 
incubated overnight with the SIINFEKL peptide, and ELISpot assay was used to measure 
IFN-γ secretion. Results are expressed as mean ± SD. (** p<0.01, E. coli-LLO+SIINFEKL v.s. 
E. coli-LLO) 
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6.3.2 Tumour protection effects with peptide vaccination with E. coli-LLO 
 
    To determine whether there is a requirement to deliver the antigen within the 
bacterial vaccine or whether it can be administered separately, I compared the 
protection obtained with vaccination with E. coli-LLO/OVA to that obtained with a 
vaccination with E. coli-LLO with OVA257-264 (SIINFEKL). Regarding the anti-tumour 
effect in vivo, the mice were immunised twice with E. coli-LLO, SIINFEKL, E. coli-LLO 
with SIINFEKL, OVA plasmid prime and E. coli-LLO/SIINFEKL boost, or E. coli-
LLO/OVA. The mice immunised with E. coli-LLO with SIINFEKL had a significant 
tumour protection effect similar to E. coli-LLO/OVA (Figure 56).  
 
Figure 56.   Tumour protection by peptide vaccination with E. coli-LLO adjuvant. Feale 
C57BL/6 mice received 2 s.c. injections of fixed bacteria (108/mouse with/without 100 
μg/mouse peptide) at one-week intervals and were then challenged with B16-OVA (5X105 
cells/mouse) one week after the last vaccination (5 mice in each group). Tumour volume was 
assessed by the maximal 2-dimension measurement and expressed in mm2. Results are 
expressed as mean  SD. ** p<0.01 
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In the model of clinically relevant tumour antigen-WT1, most of the mice were 
protected from lethal tumour challenge in the group of E. coli-LLO/WT1 or E. coli-LLO 
with pWT130 (Figure 57). By contrast, in PBS- or pWT130 with IFA-vaccinated 
animals, no tumour rejection was seen. In the mice vaccinated with E. coli-LLO, two 
out of the six mice showed tumour regression but the tumours continued to grow 
after 15 days in others.  
 
 
Figure 57.  Preventive vaccination with pWT130 with E. coli-LLO adjuvant in tumour 
inhibition. In the preventive model, female C57BL/6 mice received 3 subcutaneous 
injections of PBS, pWT130+IFA, E. coli-LLO, pWT130+E. coli-LLO, or E. coli-LLO/WT1 (108 
bacteria/mouse, 100 µg peptide/mouse) at one-week intervals and were then challenged with 
MBL2-WT1 (5x106 cells/mouse) one week after the last vaccination (6 mice in each group). 
The effect was represented by tumour volume assessment (A) (mean  SD, * p<0.05) and 
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survival (B) (** p<0.01). This experiment has been repeated once with similar results and the 
survival (B) represented the pooled data from 2 experiments. 
 
In the therapeutic setting (Figure 58), the mice vaccinated with E. coli-LLO/WT1 and 
E. coli-LLO with pWT130 demonstrated superior tumour growth inhibition responses 
at early time-points but this effect did not provide a significant benefit on survival in 
mice vaccinated with E. coli-LLO with pWT130. In contrast, the E. coli-LLO/WT1 
vaccine caused tumour regression in 50% of the mice. 
 
 
Figure 58.  Therapeutic vaccination with pWT130 with E. coli-LLO adjuvant in tumour 
rejection. In the therapeutic model, female C57BL/6 were first inoculated with MBL2-WT1 
(5x106 cells/mouse) on Day 0 and vaccinations with PBS, pWT130+IFA, E. coli-LLO, 
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pWT130+E. coli-LLO, or E. coli-LLO/WT1 (108 bacteria/mouse, 100 µg peptide/mouse) were 
given on Days 5, 10, and 15. The effect was represented by tumour volume assessment (A) 
(mean  SD, * p<0.05) and survival (B) (** p<0.01). This experiment has been repeated once 
with similar results and the survival (B) represented the pooled data from 2 experiments. 
 
 
6.4 CONCLUSION 
 
In this chapter, I have demonstrated that E. coli-LLO per se can act as an 
immunostimulatory adjuvant. It can be exploited in conjunction with peptide 
vaccination with beneficial effects compared to peptide vaccination with/without IFA. 
In both the model tumour antigen and real tumour antigen settings, applying E. coli-
LLO with single antigenic (CTL) epitope vaccination can help to potentiate the 
cytokine responses and tumour rejection.   
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CHAPTER 7: DISCUSSION   
 
7.1 SPOTLIGHT OF TREG INHIBITION IN E. COLI-LLO VACCINATION 
 
Naturally-occurring regulatory T (Treg) cells have been shown to suppress immune 
responses to self-antigens, thereby limiting autoimmunity. In the case of tumours, 
where immune responses to self-antigens are beneficial and lead to elimination of 
the tumour, such suppressive activity is detrimental. In the light of recent evidence, it 
would seem that the most promising and synergistic approaches for cancer 
immunotherapy will be ones designed to augment specific anti-tumour immunity 
while simultaneous reducing the effect of immunoregulatory mechanisms in vivo. 
This type of strategy has already been tested in humans (O'Mahony, Morris et al. 
2007; Ribas, Hanson et al. 2007). Therefore, the strategies which modulate Treg 
cells hold great promise for immunotherapy of cancer and the interaction between 
vaccine and Treg cells will be examined upon the development of newer generations 
of cancer vaccines.  
    This project demonstrated that the presence of LLO in a vaccine formulation can 
inhibit Treg suppressive functions. Using the model tumour antigen OVA, the results 
show that E. coli-LLO/OVA is a powerful tool for successful anti-tumour vaccination, 
through its ability to generate specific CTL and to affect Treg function. Recombinant 
E. coli have already been described as protein delivery vectors for professional 
phagocytic cells (Higgins, Shastri et al. 1999; Radford, Higgins et al. 2002), and 
presentation of the OVA epitope on MHC class I by E. coli-LLO/OVA has been 
shown to be orders-of-magnitude more efficient than E. coli-OVA strains (Nitcheu-
Tefit, Dai et al. 2007). Therefore, the difference in efficacy of the two strains may be 
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attributed to a difference in efficiency of MHC class I presentation on antigen-
presenting cells. This hypothesis is partly confirmed by the observation that higher 
frequencies of OVA-specific CD8+ T cells were found in E. coli-LLO/OVA vaccinated 
animals. However, additional data demonstrated that the removal of CD4+ or CD25+ 
T cells at the priming stage allowed the activation of OVA-specific CD8+ T cells in E. 
coli-OVA-immunised animals, resulting in efficient tumour immunity. Although 
conventional CD4+ T cell participates in memory T cell generation during vaccination, 
the absence of this pathway is more than compensated for by the potency of Treg 
depletion. 
To mediate anti-tumour effects in vivo, T cells, especially specific CTLs, of 
sufficient avidity for recognition of tumour antigen, must present in sufficient 
quantities, traffic to the tumour site, extravasate from the circulation, and then 
mediate effector function to eradicate the cancer cells (Gunn, Zubair et al. 2001). The 
results from the current study showed equivalent anti-tumour effects and IFN-γ 
responses in both groups (E. coli-LLO/OVA and E. coli-OVA) after removal of a 
specific group of cells, thus reinforcing the notion that overcoming immune tolerance 
is required in cancer immunotherapy. 
 
7.2 THE IMPACT OF BACTERIAL VACCINE ON TREG  
 
In a previous report (Gunn, Zubair et al. 2001), a recombinant Listeria 
monocytogenes strain that expresses and secretes the human papilloma virus E7 
protein fused to a non-hemolytic form of LLO (Lm-LLO-E7) was shown to be effective 
against established E7-expressing tumours. It is interesting that no protection was 
observed with a strain that expresses and secretes E7 alone, not fused to LLO, (Lm-
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E7) and depletion of CD4+, CD25+ cells, or TGF-β turned Lm-E7 into an effective 
treatment (Hussain and Paterson 2004). Both recombinant Listeria vaccines, Lm-
LLO-E7 and Lm-E7, induce measurable anti-E7 CTL responses. The authors found 
increased numbers of CD4+CD25high in the spleens and tumours of Lm-E7-
vaccinated mice compared to Lm-LLO-E7-immunised animals and no difference in 
the Treg suppressive activity. In a more recent study by Shahabi et al., immunisation 
with Lm-LLO-PSA, which encodes the prostate specific antigen (PSA), caused a 
decline in Treg prevalence in the tumour-infiltrative lymphocytes but not in spleens 
(Shahabi, Reyes-Reyes et al. 2008). Therefore, Listeria-based vaccine can cause a 
decrease in Treg allocation to tumours in a non-antigen specific manner. To date, 
there are only limited studies regarding the factors affecting Treg trafficking to tumour. 
but none has proposed the mechanisms by which bacterial vaccine affects Treg 
prevalence or trafficking into the tumour microenvironment (Curiel, Coukos et al. 
2004; Wei, Kryczek et al. 2007; Haas, Schopp et al. 2008). 
 
7.3 MECHANISM INVOLVED IN TREG SUPPRESSION 
 
Significant progress has been made over the past few years in defining the 
mechanisms that Treg cells use to mediate their suppressive function. The main 
mechanisms include (1) secretion of inhibitory cytokines (non-contact), (2) direct 
cytolysis of effectors (contact), (3) local metabolic disruption, and (4) modification 
DCs co-stimulation (Figure 59) (Vignali, Collison et al. 2008). However, many 
questions remain unanswered. First, are there more undiscovered mechanisms 
and/or molecules that mediate Treg suppression? It is becoming clear that the 
transcriptional landscape of Treg cells is very different from naïve or activated 
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effector T cells, with literally thousands of genes differentially regulated (McHugh, 
Whitters et al. 2002). Although it seems unlikely that all or many of these will be 
important for Treg-cell function, it is quite possible that a few undiscovered genes 
might be important. It should be noted that although we are discussing functions here, 
it is clear that some of these molecules may also be essential in Treg-cell homing, 
homeostasis and other key functions, which might indirectly influence Treg-mediated 
suppression in vivo without directly contributing to their inhibitory activity. Of course, it 
is also possible that some of these unknown molecules may represent more specific 
markers for the functionality of Treg in vivo, reflecting the status of immune tolerance. 
In addition, as a particularly important issue for the analysis and use of human Treg 
cells, we may be able to characterise and separate Treg cells by these unknown 
molecules.  
 
 
Figure 59.  Depiction of the various regulatory T (Treg)-cell mechanisms centred 
around four basic modes of action. (a) Inhibitory cytokines include IL-10, IL-35 and TGF-β; 
(b) Cytolysis includes granzyme-A- and granzyme-B-dependent and perforin-dependent 
killing mechanisms; (c) Metabolic disruption includes high-affinity CD25 (also known as IL-
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2α)-dependent cytokine-deprivation-mediated apoptosis, cyclic AMP (cAMP)-mediated 
inhibition, and CD39- and/or CD73-generated, adenosine receptor 2A (A2AR)-mediated 
immunosuppression; (d) Targeting dendritic cells (DCs) includes mechanisms that modulate 
DC maturation and/or function such as lymphocyte-activation gene 3 (LAG3; also known as 
CD223)–MHC-class-II-mediated suppression of DC maturation, and CTLA4–CD80/CD86-
mediated induction of indoleamine 2,3-dioxygenase (IDO), which is an immunosuppressive 
molecule made by DCs.  (Rubtsov, Rasmussen et al. 2008) 
 
    At present, it remains difficult to assess which molecular marker is the most 
important one. Recent studies using mutant mice with a regulatory component 
specifically deleted in Treg (IL-10) (Rubtsov, Rasmussen et al. 2008) suggest that 
Treg utilise multiple means to restrict immune responses. It almost goes without 
saying that, although defining the Treg mode of action is of great academic 
importance, it is also imperative to develop effective approaches for the manipulation 
of Treg cells. Given the capacity of Treg to block effective anti-tumour immunity, it 
seems probable that a clear understanding of how Treg lose their suppression will 
lead to the development of therapeutic interventions. 
 
7.4 HYPOTHESIS ON HOW LLO INFLUENCES TREG FUNCTION 
 
The recombinant Listeria vaccines (Gram-positive) are likely to reach the cytosol 
intact and will actively secrete either E7 and LLO-E7 proteins, while in the case of E. 
coli-LLO/OVA (Gram-negative), LLO perforates the lysosomal membrane and allows 
the release of the bacterial contents into the cytosol (LLO is not fused to the antigen 
and lacks its secretion signal sequence).   
The key question highlighted in my work is how the expression of LLO in the 
bacterial vaccine affects the functionality of Treg. A hypothetical mechanism of action 
involves the binding of PAMPs to members of an emerging family of intracellular 
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receptors, NOD-LRRs (nucleotide-binding oligomerisation domain-leucin-rich 
repeats), that may sense intracellular pathogens (Inohara, Chamaillard et al. 2005; 
Martinon and Tschopp 2005). NOD-LRRs are involved in the regulation of apoptosis 
and inflammation and have been linked to chronic inflammatory disorders (Inohara 
and Nunez 2003). Thus, activation of this pathway may result in the inhibition of Treg 
suppression. Another potential mechanism is that the bacterial products could bind to 
the cytosolic TLRs since there is more and more evidence to support the fact that 
TLR ligands can directly or indirectly abolish Treg suppression in vitro or in vivo 
(Peng, Guo et al. 2005; Wang, Miyahara et al. 2008). In addition, one previously 
unrecognised action is the cytoplasmic dissemination of perforating LLO. In the 
Listeria infection model, Gekara et al demonstrated the depletion of intracellular Ca2+ 
stores by LLO and desensitisation of immune cells resulted from impaired Ca2+-
dependent signalling (Gekara, Groebe et al. 2008).  
 
7.5 EXPLORING THE SUPPRESSION SIGNATURE OF TREG BY MICROARRAY 
ANALYSES 
 
Since the discovery of IL-2 receptor alpha-chains (CD25) as a Treg marker in 1995 
(Sakaguchi, Sakaguchi et al. 1995), several other markers related to suppressive 
function have been reported such as Foxp3, CTLA-4, GITR, PD-1, OX40, CD101, 
and IL-35 (Eikmans, Roos-van Groningen et al. 2005; Santamaria-Kisiel, Rintala-
Dempsey et al. 2006; Lehner 2008). Interestingly, array analyses demonstrated that 
there is no significant expression difference of the genes previously postulated 
between these two groups of Treg, implying that other genes may be responsible for 
Treg functional reversal by bacterial vaccine. Inflammation-related genes, including 
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S100 A8 (Calgranulin 8), S100 A9 (Calgranulin 9), Lipocalin-2 (LCN-2), Chitinase 3-
like-3, Lactotransferrin, Cathelicidin antimicrobial peptide (Camp), and Secretory 
Leukocyte protease inhibitor (SLPI), were found up-regulated in non-functional Treg 
(i.e, Treg from E. coli-LLO-immunised mice). Of note, S100 A8/A9 were found to be 
substantially up-regulated genes in Treg from E. coli-LLO-immunised animals 
(greater than 2 log differences) in all repetitive analyses. The heterodimers have 
been suggested as an indicator of early rejection in renal grafts. Another study by 
Vogl et al demonstrated that this complex can amplify the endotoxin-triggered 
inflammatory responses of phagocytes and could be the endogenous ligand of TLR4 
(Vogl, Tenbrock et al. 2007). Although limited evidence supports the pro-
inflammatory role of S100 A8/A9 complexes, there is no proposed direct correlation 
between S100 expression and the development of dysfunctional Treg. Other 
inflammatory genes upregulated in non-functional Treg, such as Lipocalin-2, 
Chitinase 3-like-3, and Lactotransferrin, have been found up-regulated in certain 
infectious or autoimmune disease (Legrand, Elass et al. 2005; Rubinstein, Pitashny 
et al. 2008) but again no direct effect on Treg has been demonstrated. 
When examining other differentially-expressed cytokine/chemokine genes, several 
genes were identified which could be relevant to the Treg functional alteration, such 
as IL-1β, IL-10, IL-22, IL-17, TGF-βi, CCR1 and CXCL2. Even though different levels 
of IL-10 and TGF-β secretion in activated Treg were observed in vitro (Figures 19 
and 20), the levels of these cytokines was not modified in vivo (Table 5). IL-17 has 
recently been widely described for its capability of bridging the adaptive and innate 
immune systems. A specific subset of committed helper T cells secreting IL-17 is 
known as Th17 cells (Ouyang, Kolls et al. 2008). Th17 cells play indispensable roles 
in graft rejection and autoimmune disease (Afzali, Lombardi et al. 2007) and more 
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attention has been drawn toward the interplays between Th17 and Treg (Oukka 
2007). More recently, in-vitro and in-vivo experiments have shown that in the 
stimulation of IL-6 and TGF-β, Treg can be differentiated into Th17 or even other T 
effectors (Radhakrishnan, Cabrera et al. 2008). This points to an interesting issue 
relevant to our microarray findings about the functional status of Treg and IL-17 gene 
expression. Meanwhile, skewed Th17 differentiation seems to reduce Treg 
prevalence within the tumour microenvironment, reflecting the balance of Th17/Treg 
in the tumour infiltrated lymphocytes (Sfanos, Bruno et al. 2008). Chen et al 
demonstrated that pertussis toxin can dampen Treg suppression by the generation of 
IL-6-dependent Th17 cells (Chen, Howard et al. 2007). Recently, evidence 
suggested that the inhibition of Th17 polarisation may enhance Foxp3 expression in 
Treg (Elias, Laurence et al. 2008) and suggesting a role in the balance between Treg 
and Th17 cells. 
IL-1β, one of the pro-inflammatory cytokines, has been described for its 
capability of attenuating CD4+CD25+FoxP3+ Treg function, and escape of 
CD4+CD25- autoreactive effectors from suppression (O'Sullivan, Thomas et al. 2006). 
In conjunction with IL-6 and TNF-α, IL-1β also involve in the Th17 skewed 
differentiation and reduce the ability of Foxp3+ Treg to maintain tolerance to self 
(Kimura, Naka et al. 2007). Within the microarray analysis, many IFN or TNF 
ligands/receptors have shown different degrees of up- or down regulation in Treg 
from E. coli-LLO-immunised mice. In addition, growth factor (amphiregulin) and other 
membranous/cytosolic protein (Granzyme B, Neutrophilic granular protein, lysozyme, 
B-lymphoid kinase, and Cathepsin H) have also come out in the genome-wide 
screening and the literature has demonstrated their role in anti-microbial responses 
and immune modulation (Zaiss, Yang et al. 2006; Malmsten, Davoudi et al. 2007). It 
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is speculated that all the sophisticated cytokine/chemokine networks need to work 
simultaneously or sequentially rather than single one of them can shut the Treg 
suppression down. In the case of the non-tolerised immune state, such as cancer 
eradication following vaccination, graft rejection, or autoimmunity, the key factor 
affecting Treg may be different.  All of these speculations need to be tested in well-
controlled in-vitro and in-vivo settings.  
 
7.6 THE ROLE OF LYMPHODEPLETION FOR EFFECTIVE IMMUNOTHERAPY 
 
Although Foxp3 has been proposed to be the master regulator of Treg cells, 
controlling the expression of multiple genes that mediate their regulatory activity, this 
notion has recently been challenged, raising the possibility that other transcriptional 
events may operate upstream of and/or concurrently with Foxp3 to mediate Treg 
development (Hill, Feuerer et al. 2007). In mice, the elimination of CD4+ suppressor T 
cells, using various strategies, has been extensively reported to enhance anti-tumour 
immunity (North 1984; North and Awwad 1987; Awwad and North 1988; North and 
Awwad 1990; Sakaguchi, Sakaguchi et al. 2001; Sutmuller, van Duivenvoorde et al. 
2001). Many studies have reported elevated levels of CD4+CD25+ T cells in patients 
with different types of cancers (Woo, Chu et al. 2001; Liyanage, Moore et al. 2002; 
Javia and Rosenberg 2003; Curiel, Coukos et al. 2004; Viguier, Lemaitre et al. 2004). 
Similarly, greater disease burden and poorer overall survival correlated to increased 
numbers of Treg cells (Ichihara, Kono et al. 2003; Sasada, Kimura et al. 2003; Curiel, 
Coukos et al. 2004; Beyer and Schultze 2006). These observations have led to the 
development of new therapeutic strategies aiming at the elimination of Treg cells in 
cancer patients and, so far, a small number of single clinical trials have been 
reported, involving an IL-2/diphtheria toxin conjugate (Ontak, Seragen) to target 
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CD25 at the surface of Tregs (Chong and Morse 2005; Dannull, Su et al. 2005; Kuzel, 
Li et al. 2007; Mahnke, Schonfeld et al. 2007; Rasku, Clem et al. 2008). When 
administered to patients with melanoma, this protein depletes the blood of Treg. In 
most patients (90%), this treatment has resulted in the production of melanoma-
specific CD8 T cells. 
    Another complementary strategy to potentiate the effect of immunotherapy and 
induce tumour regression is blocking the immunosuppressive CTLA-4 (O'Mahony, 
Morris et al. 2007; Hodi, Butler et al. 2008). Increasing early clinical trials have 
demonstrated the feasibility of targeting tumour-infiltrated Treg and enhancing 
cytotoxic effectors. These studies highlight the potential of manipulating these cells in 
cancer immunotherapy (Betts, Clarke et al. 2006). 
    To sum up the notions previously described, manipulating the regulatory arm of 
the immune system at Treg either quantitatively or qualititatively is feasible to 
potentiate anti-cancer therapies. However, variable degrees of auto-immunity, albeit 
nothing life-threatening has been reported, could occur when immune responses lose 
their delicate balance. In addition, in humans, the lack of a specific selective marker 
of Treg is an obstacle to the development of this type of therapeutic approach. 
Recently, a conditioned-elimination of Treg or temporary reversal of Treg 
suppression was postulated and it might be of greater safety when applied clinically 
(Guillot-Delost, Cherai et al. 2008). Moreover, since several categories of Treg have 
been discovered with different localisations, Treg-targeted intervention should be 
limited to one specific group, especially the antigen-specific Treg, to maintain 
tolerance to “real” self-antigen.  
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7.7 CHALLENGES OF WT1-RELATED CANCER VACCINES  
 
WT1 expression in adults appears to be limited to kidney podocytes and some 
haematopoietic precursors; therefore, oncogenic WT1 expression is a relatively 
tumour-specific target for therapeutic intervention. A clinical study in leukaemia and 
MDS patients showed that Th1-biased humoral immune responses against WT1 
protein were generated, rather than Th-2 (Wu, Oka et al. 2005). Gaiger and 
colleagues detected WT1-specific antibodies directed against the WT1 protein in the 
sera of leukaemia patients (25% with AML and 19% with CML) (Gaiger, Carter et al. 
2001). WT1-specific CTL can be expanded from the tumour-draining lymph nodes of 
breast cancer patients and they can display peptide-specific effector functions 
(Gillmore, Xue et al. 2006). Oka et al’s clinical study showed that the frequencies of 
WT1-specific CTLs were significantly higher in patients with MDS, AML, breast or 
lung cancer after WT1 peptide vaccination (Oka, Tsuboi et al. 2004; Gillmore, Xue et 
al. 2006). These findings indicated that WT1 protein was immunogenic and, thus, 
could induce WT1-specific T-cells.  
    The potential MHC-restricted CTL or HTL antigenic epitopes of 9-mer WT1 peptide 
(pWT235-243) had been reported previously and some peptides were applied for 
cancer immunotherapy (Gao, Bellantuono et al. 2000). Varied clinical responses 
were obtained in these pilot or phase I clinical trials, furthermore (Mailander, 
Scheibenbogen et al. 2004; Oka, Tsuboi et al. 2004), one research group in Japan 
has moved forward to a Phase II clinical trial on account of minute and acceptable 
toxicity of WT1 peptide vaccination (Morita, Oka et al. 2006). In-vivo studies also 
revealed that mice immunised with WT1 peptide rejected challenges by WT1-
expressing tumour cells and survived for a long time with no signs of auto-aggression 
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by CTL (Oka, Udaka et al. 2000). In-vitro expanded WT1-specific CTLs can 
selectively kill immature CD34+ cells from CML patients and spare the normal CD34+ 
cells (Bellantuono, Gao et al. 2002). A clinical trial of WT1 peptide vaccination using 
a combination of peptides derived from epitopes recognised by CD4+ HTLs as well 
as CD8+ CTLs (Guo, Niiya et al. 2005) is underway. 
    Apart from vaccination with WT1 peptide containing immunogenic epitopes, other 
strategies to augment the immune response to WT1-expressing malignancies have 
been reported. Nakajima et al reported that the use of WT1 peptide (pWT126-134) 
vaccination combined with BCG-CWS leads to rejection of WT1-expressing tumour 
cells in mice (Nakajima, Kawasaki et al. 2004). Tsuboi and colleagues showed that 
vaccination with WT1 plasmid DNA can elicit CTL responses specific for the WT1 
protein, resulting in the acquisition of rejection activity against challenges of WT1-
expressing tumour cells (Tsuboi, Oka et al. 2000). Savage et al reported the potential 
of immunotherapy with WT1-specific CTLs generated from recombinant HLA-A2 
monomers containing single WT1 peptide epitopes as immunogens in allogeneic 
donors (Savage, Gao et al. 2004).  
    
7.8 APPLICATION OF WT1 IN BACTERIAL VACCINES 
 
WT1 has long been considered as a valid target for cancer immunotherapy and the 
results of pre-clinical studies using this antigen are summarised in Table 9. In Gaiger 
et al’s study, WT1 peptide vaccination with IFA elicited the production of WT1-
specific CTLs and these in-vitro expanded CTLs demonstrated specific cytotoxicity to 
WT1 peptide-pulsed target cells or WT1-expressing tumour cells (Gaiger, Reese et al. 
2000). However, the in-vivo, protective effect against WT1-overexpressing TRAMP-C 
following WT1 peptide immunisation was disappointing. The immune responses to 
 170 
WT1 peptide immunisation might be too weak to elicit significant in-vivo tumour 
immunity. Alternatively, these CTLs may show low avidity to tumour cells. This could 
be also attributed to low MHC class I expression of TRAMP-C cells, which could 
pose a problem in clinical studies when MHC class-I are absent or downregulated in 
certain cancer cells. Another explanation is that those antigen-specific CTLs were 
somehow anergic or tolerised in the tumour microenvironment. However, in another 
study by Tsuboi et al (Tsuboi, Oka et al. 2000), vaccination by WT1 plasmid DNA 
generated CTL activity and significantly prolonged the survival of mice that were 
challenged by WT1-expressing tumour cells. In human studies using WT1 peptide 
injection (Oka, Tsuboi et al. 2004), 12 out of 20 cancer patients receiving WT1 
peptide injection showed clinical responses with tumour regression and immunologic 
responses by increasing WT1-specific CTLs (Table 10). Different vaccination 
strategies might explain this difference in vaccine efficacy even though the same 
immunotherapy target, WT1, was involved.  
   Our data showed that vaccination of E. coli-LLO/WT1 can elicit significant humoral 
and cellular immune responses by the generation of specific antibody and inhibition 
of WT1-expressing tumour challenge. Previous reports have shown that the level of 
WT1 antibodies correlates with WT1 expression in tumour or disease progression, i.e. 
the number of leukaemic blasts. Nevertheless, this antibody response did not 
contribute to any protective effect in rejecting WT1-overexpressing tumour (Wu, Oka 
et al. 2005). Despite its paucity of clinical relevance, the production of antibody 
probably correlates with helper T-cell (HTL) stimulation, especially in the E. coli-
LLO/WT1 vaccination group. Antibody might not have adequate access to the target 
protein to mediate therapy, however, in order to carry out an effective cancer 
immunotherapy, MHC class II-restricted responses that elicit anti-tumour CD4+ HTL 
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will be needed to help the specific CTL by cross-priming. Fujiki et al recently 
demonstrated that a WT1 helper epitope, WT1332-347, could help to improve the 
efficacy of CTL epitope (WT1235-243)-based cancer vaccine targeting WT1 in the 
clinical setting in terms of specific CTL induction and functional activity (Fujiki, Oka et 
al. 2007). 
Further experiments have verified the tumour-protective effect by means of in-
vitro antigen-specific T-cell proliferation and WT1-specific CTL killing. Since WT1 is a 
self protein and is expressed in a limited number of tissues at low level, it is assumed 
that CTL will be the most effective immune mechanism for vaccine and T-cell therapy. 
CTL lysis requires the target WT1 peptides to be endogenously processed and 
presented in association with tumour cell MHC class I molecules. Our study showing 
CTL lysis of TRAMP-C and MBL2-WT1 provides evidence that WT1 peptides can be 
presented by MHC class I of tumour cells in high enough amounts to be recognised 
by WT1-specific CTL, generated by immunisation with E. coli-LLO/WT1.  
    The role of bacteria as an adjuvant in delivering a tumour antigen in cancer 
immunotherapy has been extensively discussed (Loessner and Weiss 2004; 
Epaulard, Toussaint et al. 2006; Palffy, Gardlik et al. 2006; Singh and Paterson 2006; 
Vassaux, Nitcheu et al. 2006). Bacterial vehicles carrying relevant antigens can 
mount immune responses through APC activation mediated by PAMPs. Apart from 
this, incorporation of LLO in the vaccine formulation can also lead to improved MHC 
class I presentation of injected antigen and, therefore, elicit specific CTL response. 
This may be why the in-vivo tumour inhibition was prominent in E. coli-LLO/WT1 
vaccinated mice but not in E. coli-WT1 or WT1 peptides immunised mice. Another 
study conducted by Ramirez et al has showed that vaccination with WT1 peptide 
(pWT126-134 or pWT330-337)-loaded DCs could not elicit WT1-specific CTLs and reject 
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WT1-tumour growth in vivo (Ramirez, Ghani et al. 2007).  Collectively, this points to 
the fact that an appropriate adjuvant and a specific CTL epitope presentation to MHC 
class-I are of paramount important for effective anti-tumour response.  
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Table 10.  Summary of published pre-clinical studies involving WT1-related    
                cancer immunotherapy 
Vaccination strategy 
CTL-
responses  
Tumour 
protection 
Humoral 
responses 
 
pWT117-139 in CFA + NA + 
(Gaiger, Reese et 
al. 2000) 
LPS-activated spleen cells 
pulsed with pWT126-134 
+ + NA 
(Oka, Udaka et 
al. 2000) 
WT1 DNA plasmid + + NA 
(Tsuboi, Oka et 
al. 2000) 
pWT126-134 +BCG-CWS + + NA 
(Nakajima, 
Kawasaki et al. 
2004) 
WT1126-134 or WT1330-337 in 
IFA loaded DCs 
- - NA 
(Ramirez, Ghani 
et al. 2007) 
WT1-TCR gene therapy + + NA 
(Xue, Gao et al. 
2005) 
WT1122-140, WT1328-349, 
WT1423-441. 
+ NA + 
(May, Dao et al. 
2007) 
WT1 DNA plasmid  
(encoding epitope WT137-45) 
+ - + 
(Chaise, Buchan 
et al. 2008) 
Abbreviations: CFA: Complete Freund's adjuvant; NA: not available; BCG-CWS: 
Mycobacterium bovis bacillus Calmette-Guerin cell wall skeleton;  
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Table 11.  Summary of published clinical studies involving WT1-related cancer 
immunotherapy 
Vaccination strategy 
Patient No. & 
type of cancer 
Responses References 
Natural, or modified WT1235-
243 peptide emulsified with 
Montanide ISA51 adjuvant 
(Phase I) 
20 (breast or 
lung cancer, 
MDS, or AML) 
12/20 (reduction 
in leukaemic 
blasts or tumour 
sizes/markers) 
(Oka, Tsuboi 
et al. 2004) 
WT1235-243 peptide 
emulsified with Montanide 
ISA51 adjuvant 
2 (lung 
cancers) 
1 (tumour marker 
dropped and 
transient reduced 
tumour size) 
(Tsuboi, Oka 
et al. 2004) 
WT1126-134 with KLH and 
GM-CSF (Pilot) 
1 (relapsed 
AML) 
1 (CR>12 
months) 
(Mailander, 
Scheibenbog
en et al. 
2004) 
Modified WT1235-243 peptide 
emulsified in Montanide 
ISA51 adjuvant (Phase I/II) 
10 (solid 
tumours) 
1 PR, 5 SD 
(Morita, Oka 
et al. 2006) 
Modified WT1235-243 peptide 
emulsified in adjuvant 
Montanide 
3 (RCC) 2 SD 
(Iiyama, 
Udaka et al. 
2007) 
WT1235-243 peptide 
emulsified with Montanide 
ISA51 adjuvant. 
1 (relapsed 
MM) 
SD 
(Tsuboi, Oka 
et al. 2007)  
WT1126-134 and PR1169-177 in 
adjuvant Montanide  
(Phase I) 
8 (AML, CML 
and MDS in 
remission) 
Safety profiles 
and CD8+ 
responses 
(Rezvani, 
Yong et al. 
2008) 
Abbreviations: MDS: myelodysplastic syndrome; AML: acute myeloid leukaemia; RCC: renal cell 
carcinoma; PR: partial response; SD: stable disease; CR: complete remission; KLH: keyhole 
limpet hemocyanin; MM: multiple myeloma. 
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7.9 MY PROJECT IN THE FIELD OF WT1 IMMUNOTHERAPY 
 
The identification of TSA recognised by CTL has formed the basis for the design of T 
cell-based immunotherapeutic cancer vaccines. A growing number of phase I and II 
clinical trials, which are mainly targeted at melanoma antigens, have been reported 
over the last decade and are still in development. WT1 is a good TSA for cancer 
immunotherapy as there is accumulating evidence that WT1 is overexpressed in 
most leukaemias and various epithelial solid tumours and poorly expressed in normal 
tissues. Thus, several groups have identified the potent immunogenic peptides of 
WT1 for HLA-A2 and HLA-A24. They could elicit efficient CTLs against WT1-positive 
tumour cells in vitro (Ohminami, Yasukawa et al. 2000; Azuma, Makita et al. 2002; 
Bellantuono, Gao et al. 2002; Makita, Hiraki et al. 2002). In particular, the peptide 
WT1235-243 with modification of one amino acid has been applied in phase I/II clinical 
trials with promising results (Table 2) (Oka, Tsuboi et al. 2004; Morita, Oka et al. 
2006). However, this immunogenic epitope can only be applied in an HLA-restricted 
manner (MHC-A*2402). In Gao’s study (Gao, Bellantuono et al. 2000), only the WT1-
stimulated allo-HLA-restricted CTL lines can selectively eliminate CD34+ leukaemic 
cells. The limitations of traditional peptide vaccines are that the antigenic epitope 
needs to be identified and it may vary among different subjects with different 
karyotypes. In this regard, our approach that delivers the entire antigenic protein 
potentially provides a more generally-applicable strategy. 
Among the previous publications on WT1 CTL epitopes, pWT126 and pWT235 
have been studied for HLA-A*0201-positive patients. Not only are both peptide 
sequences identical in humans and mice, but also the vaccination of these peptides 
can effectively elicit specific CTLs (Oka, Udaka et al. 2000) and caused tumour 
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regression or disease remission in clinical studies (Mailander, Scheibenbogen et al. 
2004; Oka, Tsuboi et al. 2004). In addition, pWT126-specific CTLs could be 
expanded from tumour-draining lymph nodes in breast cancer patients and acted as 
effector cells (Gillmore, Xue et al. 2006). In agreement with Gaiger et al’s study 
(Gaiger, Reese et al. 2000), only vaccine containing one 9-mer peptide, pWT130, 
was able to elicit specific CTL capable of lysing cancer cells expressing WT1, 
demonstrating that pWT130 is a naturally processed WT1 epitope for B6 mice. In 
contrast to our data, Gaiger et al reported a lack of anti-tumour activity upon pWT130-
138 vaccination (Gaiger, Reese et al. 2000), highlighting the importance of the 
bacteria and the LLO as adjuvants.               
My project, aiming at the characterisation of the main antigenic motif involved in 
E. coli-LLO/WT1-mediated anti-tumour effect demonstrated the key role of the 9 
mers motif NAPYLPSCL (pWT130-138). Although my observation pointed to a specific 
epitope, pWT130, I did not exclude the possibility of other B6 CTL peptides. In 
another report by Kobayashi et al (Kobayashi, Nagato et al. 2006), pWT124-138 and 
pWT247-261, were shown to induce peptide-specific HTL, which were restricted by 
frequently-expressed HLA class II alleles (HLA-DR53). The CTL peptide we identified, 
pWT 130-138, is included in one of their proposed WT1 HTL epitopes. Therefore, it 
might partly explain why E. coli LLO/WT1 vaccination in our animal study can elicit 
effective cellular and humoral immune responses and also, in one CTL assay, we 
observed a moderate CTL killing in pWT423-stimulated cells (Figure 27). In this 
context, T cells responding to the helper T-cell epitopes provided further help for 
eliciting CTL responses and eradicating tumour cells. However, we could not prove 
its HTL stimulation in a CD4 subset proliferation assay. 
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7.10 POTENTIAL ADJUVANT ROLE OF E. COLI-LLO  
 
The role of bacteria as a vector or an adjuvant for cancer immunotherapy has been 
extensively discussed  (Loessner and Weiss 2004; Epaulard, Toussaint et al. 2006; 
Palffy, Gardlik et al. 2006; Singh and Paterson 2006; Vassaux, Nitcheu et al. 2006). 
In many cases, bacteria express the tumour antigen, target antigen-presenting cells 
and the adjuvant effect is provided by pathogen-associated molecular patterns 
(PAMPs). Likewise, the E. coli-LLO bacteria were used as a vehicle which expresses 
the target antigen and is delivered to the host. I have demonstrated that in the 
absence of an antigen, E. coli-LLO immunisation could lead to loss of suppression of 
Treg (Figures 15 and 20). Having determined the main antigenic motif involved in E. 
coli-LLO/WT1 antitumour activity, the next step was to assess whether this activity 
could be mimicked by injection of the fixed bacteria expressing LLO and the peptide 
pWT130-138. Vaccination, followed by challenge with WT1-expressing cells, 
demonstrated that injections of the peptide and the fixed E. coli-LLO were sufficient 
to obtain a full-protection against MBL2-WT1 cells (Figure 58). In treatment protocols, 
injection of E. coli-LLO and pWT130-138 resulted in a reduction in tumour growth rate 
comparable to that obtained with E. coli-LLO/WT1 but no overall statistically-
significant effect on survival of the animals (Figure 59), while treatment with E. coli- 
LLO/WT1 resulted in a 50% survival of the animals. Considering the superior 
adjuvant effect obtained upon E. coli-LLO injection and the lack of apparent toxicity 
observed in the mouse model presented here, we advocate the utilisation of either 
fixed E. coli-LLO in conjunction with WT1 antigenic peptides relevant to the HLA 
haplotype of the patients targeted or fixed E. coli-LLO/WT1 in immunotherapy against 
haematological malignancies. Moreover, since a single peptide with bacterial vaccine 
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did have a significant effect in tumour protection but not as good as E. coli-LLO 
expressing full antigen, a mixed series of relevant HLA-restricted HTL and CTL 
epitopes in conjunction with E. coli-LLO vaccination might produce a better anti-
tumour response. The results obtained in this project will facilitate the translation of 
this work to human studies by combining antigenic motifs relevant to specific human 
HLA haplotypes with the adjuvant effects of E. coli-LLO. 
 
7.11 THE CHALLENGES OF THERAPEUTIC VACCINE 
 
In many previous pre-clinical studies of cancer vaccines, anti-tumour vaccines are 
effective in preventing a subsequent tumour challenge in animals using many 
different fast-growing and aggressive mouse tumours. Vaccines being tested in these 
models consisted of live, irradiated or genetically modified tumour cells, dendritic 
cells, proteins, peptides or naked DNA. Each of these vaccine preparations can be 
given alone or combined with cytokines and co-stimulatory factors. In mice, effective 
immunity is often elicited and a successful pre-immunisation against almost any kind 
of tumour seems to be feasible. Previous experiments involving model antigen in E. 
coli-LLO/OVA vaccine have shown a significant anti-tumour effect following B16-OVA 
challenge in either therapeutic or preventive setting. In real antigen models, WT1-
expressing E. coli-LLO also can cure 50% of tumour-harboured animals and lead to 
increased long-term survival. However, in the experimental model, therapeutic 
vaccines were administered shortly after tumour implantation, that is, the animals 
were not an authentic model of immuno-compromised state. The theory of 
immunosurveillance suggests three phases in the evolution of a tumour, in relation to 
the immune system: elimination, whereby the immune system is capable of detecting 
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and eliminating the developing tumour; equilibrium, during which tumour cells 
maintain a dynamic equilibrium with the immune system and form new variants; and 
escape, when variant tumour cells successfully evade the immune response and 
grow into a clinically detectable tumour. This theory suggests that most tumours have 
evolved the ability to evade the immune system by the time they become clinically 
detectable (Dunn, Old et al. 2004). Implantable murine tumours may not be an 
adequate model for human cancer because the oncogenic events that drive the 
cancers and the relation between the cancer cells and the tumour milieu may not be 
the same as in spontaneously-arising tumours. The use of human tumour xenografts 
requires implantation into severe immunodeficient mice, obviously devoid of an 
immune system. Regeneration of a human immune system in these mice is 
technically challenging, and current approaches may not provide a fully functional 
immune response to test immune sensitisation approaches. In this context, one of 
the limitations of the implanted tumour model is that, a lethal dose of tumour cells is 
injected. The pathophysiologic situation is different, with a few cells evading 
immunosurveillance and creating a tumour.  
In cancer patients, we can expect that the efficiency of induction of antigen-specific 
T-cells will be reduced, mainly due to a global reduction of the T-cell repertoire as a 
consequence of tumour growth, the expansion of regulatory cells, and/or following 
cytotoxic chemotherapy. They may diminish the frequency or reactivity of tumour-
specific T cells. Results from testing the anti-tumour effect in existing tumour models 
are critical for the rationale in moving forward to clinical trials in cancer patients, but 
the effect might be suboptimal. Other combined strategies, such as ex-vivo 
expansion or adoptive T cell therapy, may be required when applied to cancer 
patients. Since experimental data suggest that vaccination is more likely to be 
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effective on small tumour burden, such as a minimal residual disease after 
conventional treatments, or tumours at an early stage of disease, better selection of 
patients will allow more reliable clinical results to be obtained (Bocchia, Bronte et al. 
2000). 
Another critical area of focus is the immunologic monitoring of patients. To date, there 
has been a lack of consensus on minimally-required assays, and standard operating 
procedures for assays in clinical trials (Keilholz, Weber et al. 2002); this has limited 
our ability to compare the results of trials, and to discover the basis of clinical benefit 
in the small fraction of patients who appear to be successfully vaccinated. Despite 
past disappointments, novel immunotherapeutic approaches to overcome tumour-
induced immune suppression are generating results that warrant renewed 
enthusiasm and have the potential to significantly alter the outcome of advanced 
cancer.  
 
7.12 DURABILITY OF MEMORY CTLS 
 
Most experiments described here were conducted in tumour challenge close to 
vaccinations. Another important point to be explored is the effect of a gap between 
vaccination and challenge. Induction of efficient long-term immune memory is the aim 
of all vaccination protocols. The factors required to maintain memory cell populations 
have been controversial. In mice, memory T cell survival does not require the 
persistence of cognate Ag and this notion may be supported in patients infected with 
HIV (Ogg, Jin et al. 1998). In contrast, persistent infection of mice with lymphocytic 
choriomeningitis virus (LCMV) resulted in selective deletion or anergy of high avidity 
memory CTL. Administration of LCMV vaccines successfully induced lytic MHC-
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restricted CTL in the persistently virus-infected mice; however, these CTL were of 
low avidity and could not clear the viral infection (Hou, Hyland et al. 1994).  
    The effector CD8+ T cells induced by CTL epitope peptides do not last more than 
about 3 weeks after induction and no functional memory CD8+ T cells are generated 
(Janssen, Lemmens et al. 2003; Kaech and Ahmed 2003). It is held that 
simultaneous induction of CD4+ T cells by incorporation of peptides containing T-
helper epitopes in the vaccine at the time of primary vaccination is necessary for the 
induction of long-lived functional memory CD8+ T cells (HTL-dependent) (Agnellini, 
Wiesel et al. 2008). The effect of inducing durable memory-CTL by E. coli-LLO/WT1 
vaccination or peptide with E. coli-LLO also needs to be documented before clinical 
application in cancer patients.      
 
7.13 AUTO-IMMUNE REACTION RELATED TO BREAKING SELF-TOLERANCE 
 
Immunotherapy aims to harness the immune system to impact the treatment of a 
wide variety of diseases. However, for any specific therapy to be successful, it is 
critical that it directs a specific immune attack to the disease while protecting the host 
from aggressive autoimmunity. This selectivity is particularly challenging in the case 
of cancer, where tumour growth is driven by mutations or abnormal expression of 
normal cellular proteins. To the host immune system, these “tumour-associated 
antigens” are likely to be recognised as an extension of self, allowing tumour 
protection via active immune tolerance. On the contrary, serologic and clinical 
manifestations of autoimmunity might occur if the immunotherapy is effective against 
those tumour antigens. For example, the appearance of autoantibodies and vitiligo is 
usually associated with improved survival in melanoma patients following interferon, 
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peptide vaccine, or Treg depletion treatment (Ribas, Camacho et al. 2005; Gogas, 
Ioannovich et al. 2006; Slingluff, Petroni et al. 2008).  
The WT1 gene is physiologically expressed in some organs such as kidney, 
spleen and bone marrow. Previous experimental evidence demonstrated that WT1-
specific CTLs kill WT1-expressing leukaemic cells, but spare normal haematopoietic 
cells (Gao, Bellantuono et al. 2000). In mice immunised with MHC class I-restricted 
WT1 peptides or WT1 cDNA, the WT1-specific CTLs induced killing of WT1-
expressing tumour cells, but no evidence of damage to normal tissue was observed 
(Tsuboi, Oka et al. 2000; Morita, Oka et al. 2006).  
    There are at least four possible mechanisms by which WT1-specific CTLs can 
ignore physiologically WT1-expressing normal cells. First, WT1 expression levels in 
normal cells are lower than those in tumour cells. However, this possibility is unlikely 
because WT1 expression levels in CD34+ normal haematopoietic progenitor cells are 
similar to those in leukaemic cells at the single-cell level. Second, expression of MHC 
class I molecules may be lower in normal cells than in tumour cells. Third, in WT1-
expressing normal cells, WT1 peptides may not be presented on MHC class I 
molecules, or the presentation of WT1 peptides onto the molecules may be weak. 
The poor presentation of WT1 peptides could be ascribed to differences between 
normal and transformed cells in the processing of WT1 proteins in proteosomes or in 
the transport of the processed WT1 peptides onto the cell surface. Fourth, compared 
to WT1-expressing tumour cells, WT1-expressing normal cells do not, or weakly, 
express cell surface costimulatory molecules needed for recognition and/or killing by 
WT1-specific CTLs.  
    To sum up, even though we did not observe clinically overt auto-immunity in 
kidney tissues (Dr. J Nitcheu-Tefit, personal communication) in E. coli-LLO/WT1-
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immunised mice, it is impossible to exclude long-term toxicity of the approach. This 
issue should be addressed when moving into clinical application.  
 
7.14 FUTURE WORK 
 
7.14.1 Clinical Application of E. coli-LLO/WT1 
 
In this thesis, I have clearly demonstrated that pWT130-138 was consistently the 
immuno-dominant epitope to stimulate lymphocyte proliferation in vitro and induce 
vigorous specific CTL responses. However, combination of pWT130-138 with other 
HTL or CTL epitopes may increase this efficacy. Another application of the E. coli-
LLO adjuvant properties may be their combination with tumour lysates. 
    My subspecialty is clinical haematology and oncology and most of my patients 
diagnosed as leukaemia and lymphoma. A certain number of these patients with 
WT1 over-expression in their tumours will be candidates for WT1 immunotherapy. 
Even though cytotoxic chemotherapy and stem cell transplantation can cure a large 
population of patients, some remain resistant to conventional treatments. Therefore, I 
would be keen to extend my preclinical work to the clinic. When the bacteria express 
a nearly full-length antigen, the concern of HLA-restriction can be eliminated. An 
important step is to produce GMP-grade, fixed-bacteria for human application and to 
start a phase I clinical trial to determine the toxicity and maximal tolerated dose in 
humans. It is assumed that the toxicity will be minimal by subcutaneous immunisation 
according to previous human studies involving intravenous injection of Salmonella 
vaccine (Toso, Gill et al. 2002). In addition to the clinical toxicity profiles, immunologic 
and tumour responses will be observed in the clinical trial, of particular importance 
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will be the effect of E. coli-LLO vaccination on Treg function. The feasibility of 
combination strategies with bacterial vaccines may be tested in the long run.  
 
7.14.2 Optimisation of immunotherapy  
 
Cancer vaccines are often successful at generating elevated numbers of tumour-
specific CTLs in peripheral blood; however, these CTLs are usually unable to 
eliminate tumours even after effective vaccination. Prolonged antigen stimulation 
might induce deletion of memory CTLs and tolerance compared to short antigen 
exposure (den Boer, Diehl et al. 2001). Utilisation of adjuvants may serve to stimulate 
a local immune response leading to recruitment of APCs, but the delivered antigen 
might be spread out of depot systemically, thus reducing the efficacy of vaccination. 
In this respect, it is important to find a balance between effective immune response 
and high yield with long-lasting CTL memory. 
    Recent evidences suggested that a prime-boost protocol involving sequential 
administration of different vaccination strategies was therapeutically effective in 
rejecting tumour cells in vivo  (Sedegah, Weiss et al. 2000; Meng, Butterfield et al. 
2001; Wang, Wang et al. 2005). In the study by Wang et al, priming with plasmid 
DNA and boosting with antigen-expressing adenovirus induced higher levels of 
cellular and humoral immunity than either plasmid or adenovirus vaccination alone 
(Wang, Wang et al. 2005). Since the bacterial vaccine in our study can elicit vigorous 
CTL responses, we may try to prime first with bacterial vaccine and boost by other 
strategies, such as plasmid DNA, peptides, or tumour lysate with/without E. coli-LLO 
adjuvant, to maintain the viability of specific CTLs. However, a sustained memory 
CTLs with effective tumour killing should outweigh the drawback of immune tolerance 
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from prolonged antigen stimulation. In addition, the local suppressive factors within 
the tumour microenvironment should be considered even if substantial maintenance 
of effector memory cells can be achieved.  
 
7.14.3 Listeriolysin-O-mediated functional change of Treg 
 
Evidence from our previous experiments suggested that LLO did impact on the 
suppressive function of Treg. The data from mRNA expression profiling of Treg cells, 
regarding the differentially-regulated genes encoding proteins mediating the 
functional change of Treg cells, provide valuable information. These data have been 
validated by RT-PCR, and I was able to identify several genes of chemokine/cytokine, 
growth factors and receptors associated with non-functional Treg. The next step will 
be to manipulate those genes in vitro to determine the effect on Treg function.  
Several additional issues still need to be further clarified: (1) Is LLO the effect on 
Treg cells dose-dependent, (2) does LLO itself triggers the response or is LLO 
needed simply to allow for cytosolic localisation of bacterial product, (3) the 
interaction between bacterial product and expression of LLO within the cytosol, (4) 
the signalling pathway of LLO in the cytosolic compartment. According to the study 
by Mandal and Lee (Mandal and Lee 2002; Stier, Mandal et al. 2005), effectively 
priming cellular immunity with a robust CTL response could be achieved in the LLO-
liposome system delivering OVA antigen. To elucidate the aforementioned issues, a 
precisely-controlled LLO concentration and intra-cytosolic delivery of LLO can be 
achieved in this system. In addition, the signalling pathway of LLO in cytosol can be 
further studied in the absence of co-stimulatory effect from digested bacterial product, 
PAMPs, or co-expressed antigen.  
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    Since the LLO-expressing gene, hly, was “borrowed” from Listeria monocytogenes, 
the immune responses stimulated by E. coli-LLO/OVA and Lm-LLO/OVA vaccination 
were similar, but not exactly the same (Grosenbach, Barrientos et al. 2001) (D'Orazio, 
Troese et al. 2006). Cytosolic LLO is directly responsible for triggering an early IFN-γ 
response in both vaccine strategies although it is not yet clear whether LLO plays a 
direct role in triggering a signal cascade that leads to cytokine production or whether 
it is required simply to release other bacterial product(s) into the host cell cytosol. To 
investigate the detailed immune mechanisms of the LLO effect, the use of L. 
monocytogenes or liposome-encapsulated LLO might be considered. 
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CONCLUDING REMARKS 
 
Efforts to harness the immune system for cancer therapy have tremendous potential, 
but immunotherapy faces daunting challenges. To be successful, immunotherapy 
must overcome a variety of obstacles, including tumour-induced immune suppression. 
As more and more antigens are identified for various kinds of cancer, bacterial 
vectors will offer a shuttle to introduce the newly identified antigens to the immune 
system. Furthermore, it should be possible to coordinately express more then one 
antigen at a time (i.e., a panel of disease-specific antigens) to mount a complete 
immune response against a particular disease in one particular vaccination. Although 
the experiences from LLO expressed in bacterial vaccine have greatly improved the 
antigen delivery and intracellular processing, the detailed mechanisms involved in 
LLO-mediated modification of the immune response remain to be characterised. Also, 
the dosage, route of vaccination, and optimal prime/boost strategy in bacterial 
vaccine therapy still need to be further defined. 
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